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Abstract 
Whilst cough is a defensive reflex, in respiratory diseases such as asthma and chronic 
obstructive pulmonary disease (COPD) the cough reflex may become exaggerated and 
unproductive, leading to presentation of chronic cough as a troublesome symptom. 
Chronic cough is the most common reason that patients seek ambulatory care in the UK, 
and cough medications are one of the largest segments of the global over-the-counter 
drugs market, yet there are no cough medications (prescription or OTC) available that 
are both efficacious AND safe, indicating a large unmet clinical need.  
 
β-adrenergic receptor (β-AR) agonists, methylxanthines (theophylline) and fatty acid 
amide hydrogenase inhibitors (FAAHi) are peripherally acting drugs with a proven safety 
profile in humans for other uses, but are not currently recognised as anti-tussive 
medications. This thesis aimed to examine whether these drugs possess anti-tussive 
activity, and if so, the mechanisms by which they inhibit cough.  
 
These drugs were all effective at blocking the in vivo cough response to tussive stimuli in 
naïve guinea pigs, and in addition β-AR agonists and theophylline inhibited tussive 
stimulus evoked cough in guinea pigs previously exposed to cigarette-smoke, which 
display a clinically relevant enhanced cough phenotype. In vitro and in vivo assays of 
guinea pig vagus nerve/neuron activation were used to show that these compounds 
inhibit depolarisation of airway-innervating peripheral sensory nerves. Pharmacological 
and genetic tools were used to investigate the receptors and signalling pathways 
activated by these drugs. Whilst β-AR agonists, theophylline and FAAHi had different 
mechanisms of action, a common component was that all three classes of compound act 
on various potassium channels, thereby reducing the excitability of sensory neurons.  
 
This work suggests that drugs that inhibit peripheral sensory nerve activity have the 
potential to be efficacious as anti-tussives. Specifically the compounds tested have 
improved clinical side-effect profiles over currently used anti-tussives, and therefore have 
potential as therapies for chronic cough. 
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1.1 The physiology of the cough reflex 
Cough is a phenomenon that all humans will be familiar with, through personal 
experience during their lifetime. As with most everyday and unconscious bodily functions 
that are normally taken for granted, a cough is actually a complex and precisely 
coordinated manoeuvre. The physical portion of cough begins with a sudden contraction 
of multiple thoracic muscles, causing compression of the lungs (Leith et al., 2011). During 
the initial compression of the lungs, the glottis remains closed, trapping air within the 
airways. The volume of the airways therefore decreases, whilst the amount of air (gas) 
within that volume remains the same, resulting in an increase in intra-luminal air pressure 
(Ross et al., 1955). Subsequent opening of the glottis allows release of this pressure, 
which occurs as a rapid and explosive expulsion of (volume) air from the airways at 
speeds of up to 30mph (Ross et al., 1955). The expulsive release of this pressurised air 
at high speeds causes the characteristic sound that humans can readily discern as a 
cough through lifelong experience (Morice et al., 2007b; Smith, 2010).  
 
This complicated manoeuvre has evolved as a defense in order to forcefully expel, via 
the explosive release of air, materials that may occlude the airways and impair breathing 
or cause complete asphyxiation (Leith et al., 2011). Such ‘materials’ can include excess 
endogenous matter (e.g. sputum) as well as foreign bodies or irritants (e.g. inhaled 
foodstuffs or noxious gases). Whilst the physical portion of cough begins with muscle 
contraction, defensive (or ‘involuntary’) cough really begins with detection of an 
appropriate stimulus in the airways. Thus defensive cough is best described as a reflex 
arc, possessing three components; sensing of a ‘cough stimulus’ by airway afferent 
nerves (peripheral sensation), processing of afferent input by central nervous system 
(CNS processing), & innervation of thoracic muscles by efferent neurons (motor 
innervation) (Fig. 1.1). 
 
1.1.1 Peripheral Sensation 
Anatomy of airway sensory neurons  
The defensive cough reflex begins with a tussive stimulus acting on the termini of afferent 
nerves which protrude into various levels of the airway smooth muscle and epithelium. 
The majority of the afferent (or sensory) nerves that innervate the airways have cell 
bodies that are housed either within the jugular (superior vagal) or nodose (inferior vagal) 
ganglia, which are located slightly caudally to the jugular foramen. Airway sensory nerves 
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Figure 1.1 Diagram of the cough reflex arc  
Illustration of the relative locations of peripheral sensory nerves and soma (dark grey), 
nucleus tractus solitarii (red) and efferent nerves (blue) to central nervous system, lungs, 
trachea, diaphragm, and intercostal muscles. N.B. in the interests of clarity only a few 
afferent and efferent nerve endings are depicted.  
 
are pseudo-unipolar in their morphology; the spheroidal cell body extends a single short 
process, which is then bifurcated into peripherally and centrally projecting axonal 
processes (Undem & Weinreich, 2005) (Fig.1.2). Once the axonal processes of these 
nerves leave the ganglia they form part of the vagus nerve. It should be noted that the 
vagus nerve is a paired nerve – that is to say that an individual possesses two vagus 
nerves, including two sets of nodose and jugular ganglia, positioned symmetrically along 
the anterior-posterior axis (Fig. 1.1). The vagus nerve is the longest cranial nerve 
(number 10), containing the axonal processes of motor and sensory nerves innervating 
many mid-line organs and other tissues, as well as those innervating the airways 
(Standring, 2008).  
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Figure 1.2 Anatomy of airway afferent vagal neuron 
Illustration of the anatomy and morphology of an airway-terminating afferent neuron. The 
portions of the nerve located within the airways, within the vagus nerve, within the vagal 
(jugular or nodose) ganglia and the nucleus tractus solitarii (NTS) are indicated. N.B. 
Schwann cells (which collectively form the myelin sheath) and nodes of Ranvier are 
present only on myelinated neurons. 
 
Caudally to the jugular and nodose ganglia, the vagus nerve runs parallel to the trachea, 
inside the carotid sheath, along with the carotid artery and jugular vein. Posterior to the 
trachea, the vagus nerve continues down into the abdomen. Along its length, nerve fibres 
branch off laterally from the vagus nerve to innervate nearby organs and tissues, 
including the trachea, bronchi and lungs. Rostral to the jugular and nodose ganglia, the 
vagus nerve enters the skull though the jugular foramen, and terminates in the solitary 
tract (tractus solitarius). The solitary tract is a compact bundle of axonal processes 
(including vagal neurons), and is surrounded by the nucleus of the solitary tract (nucleus 
tractus solitarii, or NTS), which itself is an embedded posterolateral portion of the medulla 
oblongata. The sensory and motor neurons in the solitary tract synapse (interface) with 
the neurons of the NTS. This synapse is the point at which electrically coded signals 
conducted by airway-terminating sensory neurons are passed from the peripheral 
nervous system to the central nervous system.  
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Transducing tussive stimuli into electrical signals  
In the case of airway-terminating afferent neurons, electrical signals are generated by the 
activation of receptors on the caudal termini protruding into the airway tissues, at the 
caudally opposite end of the axonal processes to the NTS. Stimuli that activate airway-
terminating sensory nerves can be chemical (e.g. inhaled noxious gas) or 
physical/mechanical (e.g. inhaled foodstuff) in nature, with different stimuli acting on 
populations of afferent nerve endings. In order to transduce the various types of stimuli 
into electrical impulses, many different types of specialised receptor are present on the 
termini of airway sensory nerves. These nerves therefore can be broadly categorised into 
mechano-sensitive and chemo-sensitive neurons, although there is some overlap 
between these two categories. As such, airway afferent nerves are classified by not just 
their responsiveness to different types of stimulus, but also conduction velocity, location 
of termini within the airway lumen, anatomy, and also developmental origin of neuronal 
soma (discussed in greater detail in Introduction 1.2).  
 
Generator and Action Potentials 
Activation of the relevant receptor(s) by an appropriate stimulus leads to a localised 
membrane depolarisation at the nerve terminus, known as a generator potential. The 
generator potential is an analogue signal, as the magnitude of depolarisation is positively 
correlated with the ‘strength’ of the stimulus – i.e. the greater the number of receptors 
and potency of receptor activation, the greater the generator potential. If the generator 
potential reaches a critical threshold, an action potential (AP) is initiated. The magnitude 
of an AP is fixed, and not related to the ‘strength’ of the stimulus (i.e. number of receptors 
activated), and therefore the conversion of the local generator potential to an AP can be 
considered the conversion of an analogue into a digital signal. The critical threshold for 
the generation of an AP is the gating voltage for voltage-gated sodium channels (VGSCs) 
in the plasma membrane (Fig. 1.3). When the voltage of the generator potential 
increases sufficiently, the pore domain of VGSCs opens, enabling positively charged 
sodium ions (Na+) to move into the cell along their electrochemical gradient, causing 
greater depolarisation of the membrane. This further activates proximal VGSCs, which 
results in a spreading wave of localised depolarisation. The depolarisation spreads along 
the axonal membrane of the neuron as additional VGSCs open in response to the 
depolarisation. Whilst the opening of VGSCs allows the influx of sodium ions, opening of 
the channel causes it to self-inactivate shortly after opening, via a mechanism known as 
“ball and chain” inactivation, which has three main stages (as illustrated in Figure 1.3).   
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Figure 1.3 Action potential wave & voltage-gated sodium channel states 
[A] Local axon membrane voltage over time, during an action potential. Numbers in 
circles relate to panel B. [B] Idealised cartoon of VGSC channel opening and mechanism 
of “ball-and-chain” inactivation. At resting potential (1), the central pore of the VGSC is 
closed and impermeable to sodium ions (Na+), and a peptide motif (ball) resides in the 
cytoplasmic compartment as part of the cytoplasmic peptide tail (chain) of the VGSC 
protein. As the channel pore opens (2) due to increased voltage, sodium ions move along 
their electrochemical gradient into the neuron, and the peptide motif begins to move to a 
docking domain in the internal pore that is exposed in the open VGSC configuration. 
Binding of the peptide motif (3) blocks the opened pore, preventing further Na+. 
Restoration of the membrane potential (4) by potassium ion efflux (not shown) causes 
closing of the pore domain, undocking of the peptide motif, and restoration of the VGSC 
to a resting state.   
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In essence, opening of the channels by an increase in voltage allows the influx of sodium 
ions for a short period before the channel then becomes physically inactivated in a 
voltage-insensitive manner. The result is that the influx of sodium ions through VGSCs in 
their open and activated period causes a local depolarisation great enough to induce 
nearby additional VGSCs to open before the original VGSCs are inactivated. A 
consequence of the fast inactivation of the VGSCs is that the membrane depolarisation 
can only spread in one direction, as the voltage-independent inactivation of VGSCs does 
not allow further influx of sodium ions. The spread of membrane depolarisation then 
continues along the axonal membrane until it reaches the synaptic terminal of the neuron 
in the NTS. Behind the wave of opening VGSCs, the membrane potential reaches its 
peak (positive) amplitude. As the membrane potential approaches this peak amplitude, 
the potassium permeability of the axonal membrane increases, increasing the efflux of 
potassium ions (K+) from the cell, slowing the rate of depolarisation. In addition, the 
positive membrane potential begins to open voltage-gated potassium channels (VGPCs). 
VGPCs operate in a similar but opposing manner to VGSCs, having an inverse 
relationship to the membrane voltage, and allowing the rapid diffusion of potassium ions 
out of the cell (along their electrochemical gradient) through the opened pore domain. As 
the peak amplitude of the AP is approached, the efflux of potassium ions slows the 
depolarisation caused by the influx of sodium ions. As the VGSCs become inactivated, 
the efflux of potassium ions continues, rapidly repolarising the axon to restore the original 
membrane potential. However, the inactivation of VGPCs is slower than that of VGSCs, 
and due to this property, the cell membrane becomes slightly hyperpolarised as 
potassium ions continue to efflux along their electrochemical gradient. The resting 
potential of the membrane is then actively restored through the activity of Na+/K+-trans-
membrane transporter (requiring the breakdown of ATP). 
 
As the membrane repolarises, the inactivation of sodium channels is reversed as the 
pore of the VGSC returns to its resting (closed) state, obscuring the binding domain for 
the inactivating peptide motif, causing release of the motif and restoration of the ‘resting’ 
state of the VGSC. When a sufficient number of channels at the nerve terminus have 
returned to a closed but active state, another AP can be initiated. Until the resting state of 
the VGSCs has been restored, no new AP can be initiated, and this period of time is 
referred to as the absolute refractory period. However, following the restoration of 
VGSCs to a resting state, the potential for the initiation of a new AP is reduced due to the 
hyperpolarisation of the membrane. In this relative refractory period, a new AP can be 
initiated, but requires a greater generator potential. Therefore, a larger and persistent 
generator potential causes an increased frequency of AP firing. In this way, the analogue 
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input, or ‘strength’ of stimulus, is encoded as a digital signal, i.e. the frequency of AP 
firing.  
It should be noted that if the generator potential is not of sufficient magnitude, the 
membrane potential will be gradually restored to its resting voltage, and no ‘information’ 
will be sent from the nerve terminus.  
 
The above description describes the spread of an AP along the axon of an unmyelinated 
nerve fibre. However, populations of airway afferent nerve fibre may also be coated with 
a myelin sheath, formed by Schwann cells wrapping around the axon (Fig. 1.2). These 
sheaths allow an AP to be conducted at much greater speeds along the axon. Schwann 
cells provide a highly insulated sheath, which inhibits the exchange of ions along those 
portions of the nerve. At portions of the axon however, there are gaps of approximately 
1µm, known as the nodes of Ranvier, where there is a great density of the ion channels 
and pumps involved in AP propogation. An AP ‘jumps’ from node to node in a process of 
saltatory conduction that is enabled by insulating effect of the myelin sheath, which 
reduces dissipation of the electrical signal. Saltatory conduction occurs at much greater 
speeds than the spread of activating Na+ channels, and therefore myelinated nerve 
axons have greater velocity of AP propogation to the central terminals.  
 
Once the AP reaches the central terminus of the peripheral nervous system, synaptic 
vesicles containing neurotransmitter chemicals migrate and fuse with the membrane. 
Vesicle fusion results in release into and diffusion across the synaptic cleft of the 
neurotransmitters, which then activate receptors on the termini of second order neurons 
of the CNS. 
 
1.1.2 CNS processing – input, ‘urge-to-cough’, and output signals 
The circuits and mechanisms by which airway afferent input signals are integrated and 
organised in the CNS to form the cough response are complex, and are not fully 
elucidated (Fong et al., 2004). It is generally agreed that the afferent input signals which 
cause defensive cough are input to second order neurons within the NTS (Widdicombe & 
Undem, 2002). This comes from evidence that neurotransmitter antagonists injected into 
a discrete site of the NTS can inhibit the cough response (Canning, 2009).  
 
A model of the brainstem centres that act in concert to integrate airway afferent input and 
form motor cough responses has been proposed by Shannon et al. (2004). The input 
signal from vagal airway afferent neurons is passed to relevant second order NTS 
neurons, which relay the signal into the Bötzinger-Ventral Respiratory Group (Böt-VRG), 
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a core network of neural centres that processes input from airway afferents. Importantly 
this centre receives input from both afferent neurons that regulate cough, but also those 
known to regulate breathing patterns (see Introduction 1.2). In addition to the Böt-VRG 
network, the Pontine Respiratory Group (PRG), has been implicated with an essential 
role in the formation of a cough reflex, although the nature of interaction/regulation of the 
Böt-VRG and PRG networks is not clear. Neurons from these core neurons synapse onto 
respiratory bulbo-spinal pre-motor neurons (I-Aug and E-Aug).  
 
However, one interesting feature of cough is that there is a level of both unconscious and 
conscious control over this reflex. The afferent input, or sensation, of a need to cough 
can be consciously suppressed, at least to some extent. That a complete cough 
movement can be consciously mimicked in the absence of any urge-to-cough testifies to 
the conscious control over the cough reflex. However, this conscious control is not 
complete, as the conscious control over the cough reflex is not absolute.   
 
1.1.3 Motor innervation of cough 
The signal to cough encoded from the NTS is patterned from the respiratory bulbo-spinal 
pre-motor neurons (I-Aug and E-Aug) onto inspiratory and expiratory laryngeal motor 
neurons, which have soma within the thoracic and lumbar dorsal root ganglia (Bongianni 
et al., 1998; Giraudin et al., 2008). Upon excitation from pre-motor neurons, APs are 
generated and travel to the peripheral termini of these motor neurons, which are located 
within intercostal, diaphragm, abdominal and glotteal muscles (Undem & Weinreich, 
2005; Giraudin et al., 2008). Chronologically and anatomically coordinated activation of 
these neurons by the core networks in the CNS causes contraction of the inspiratory 
muscle groups following by expiratory muscle groups, in a manner to form a coherent 
cough reflex (Bongianni et al., 1998).  
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1.2 Airway afferent sensory nerves  
Afferent nerves innervating the airways collectively form part of a neural network, 
conveying relevant information to the CNS, where it is used to regulate breathing 
patterns, airway autonomic tone, and cough. A wide variety of conditions and 
pharmacological ligands at the nerve termini can activate or modulate the activity of 
afferent neurons. For example, stimuli that induce cough include mechanical stimulation 
(punctate touch, distension) (Canning, 2004), mucus (Basser et al., 1989), irritants 
including cigarette smoke, dust and chemical fumes/noxious gasses (Lee et al., 2007; 
Belvisi et al., 2011), inflammatory mediators including PGE2 and bradykinin (Kawakami et 
al., 1973; Choudry et al., 1989; Maher et al., 2009; Grace et al., 2012), and changes in 
luminal osmolarity (Lowry et al., 1988; Koskela et al., 2005), pH, and changes in 
temperature (McGarvey et al., 1998; Wong et al., 1999). This wide variety of stimuli 
activates one or more of a range of specific receptors expressed on the surface of airway 
terminating neurons. Activation of these receptors, which may be ligand-gated ion 
channels, or metabotropic receptors that indirectly activate ion channels, causes the 
influx of cations necessary to induce action potentials.  
 
Specific categories of nerve fibre type have been described based on information from 
multiple studies collating functional and anatomical information about individual neurons. 
This categorisation delineates subtypes of airway afferent according to their 
responsiveness to specific stimuli, the location of termini within the airway structures, the 
location of neuronal soma, and axonal conduction velocity. This work has been greatly 
advanced through the pioneering of techniques such as single-fibre nerve recording, 
which can be used to record action potential firing in a single nerve fibre, both in vivo, 
and also in ex vivo lung/trachea/vagal nerve preparations (Coleridge & Coleridge, 1984).  
Delineation of airway afferents into these categories must be interpreted with a degree of 
caution, as the data about these various types of fibre has often been obtained in multiple 
species, using a variety of both in vivo and in vitro techniques. In particular, most studies 
of airway afferent fibre responsiveness have been conducted in multiple non-human 
species (mostly guinea pig, rat, cat and rabbit) (Coleridge & Coleridge, 1984). A 
summary of the nerve fibre categories and attributes is given in Table 1.1, and their role 
in the cough reflex and other airway functions is discussed in more detail below. 
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Slowly adapting stretch receptors 
Slowly adapting stretch receptors (SARs) have myelinated axons, and therefore conduct 
APs at comparatively fast velocities of approximately 18m.s-1 (Canning et al., 2006). 
These fibres are involved in the regulation of tidal breathing patterns; during inspiration 
and exhalation, as the smooth muscle begins to approach maximum tidal distension or 
compression, SARs begin to fire (Schelegle & Green, 2001). At either extreme, a burst of 
prolonged AP firing is observed, which inputs to the correct second-order neurons in the 
CNS to inhibit further inhalation or exhalation, as determined by the type of input stimulus 
(hyper- or hypo-inflation) (Schelegle & Green, 2001). When stimulated by a sustained 
mechanical deformation, these fibres are slower to ‘adapt’ to the new mechanical 
conformation of their receptors, and therefore firing in response to hyper- or hypo-
inflation is prolonged compared to other types of mechano-transducing fibre (Coleridge & 
Coleridge, 1984). The receptors mediating mechano-transduction in airway afferents are 
currently unknown; as Taylor-Clark et al. (2006) state, “The ‘physical hypothesis’ for 
mechanical nerve activation is that mechanical stimulation physically alters a mechano-
gating protein leading to the opening of a cation channel in the terminal membrane.”  
 
SAR termini are found within the smooth muscle layer of the trachea, bronchi, 
bronchioles and smaller diameter airways – essentially within any airway structure that 
possesses smooth muscle (Bartlett et al., 1976). Whilst SARs do not respond directly to 
stimuli that provoke cough, this does not preclude the possibility that SAR input to the 
CNS may indirectly modulate cough by affecting how the CNS responds to stimuli from 
other airway afferent fibres firing in response to a cough stimulus (Canning, 2006a; 
Canning & Mori, 2011).   
 
Rapidly adapting stretch receptors 
Rapidly adapting receptors (RARs) possess myelinated axons, and therefore have fast-
conducting action potentials, in the range of 14-23m.s-1 (Fox et al., 1993; Riccio et al., 
1996). RARs are activated by mechanical stimuli including hypo- and hyper-inflation of 
the lung, and also by punctate touch, but are relatively insensitive to chemical stimuli 
(Bergren & Sampson, 1982; Pack & DeLaney, 1983; Ho et al., 2001; Widdicombe, 2003). 
By contrast to SARs, RARs nomenclature relates to their rapid adaption (cessation of AP 
generation) in the presence of persistent stimulation. Whereas SARs are thought to play 
a greater role in tidal breathing, activation of RARs can elicit cough responses. Whilst 
RARs are generally considered to be insensitive to chemical pro-tussive stimuli such as 
capsaicin and bradykinin, they may be activated by these stimuli indirectly via the mucus 
production and bronchoconstriction induced by these stimuli (Widdicombe, 2003).  
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RARs mostly originate in the nodose ganglia, and protrude sub-epithelial termini that are 
found throughout the airways, but are particularly abundant in the larger structures of the 
upper airways (Mortola et al., 1975; Sant'Ambrogio et al., 1978; Canning, 2004; Nasra & 
Belvisi, 2009). Given their exquisite sensitivity to even light punctate touch it has been 
suggested that their primary role is therefore in evoking defensive cough to clear 
obstructive matter and maintain airflow (Nasra & Belvisi, 2009).  
 
‘Cough’ receptors 
The suggestion of a specific ‘cough receptor’ type of airway afferent fibre was suggested 
by Canning et al. (2004) to describe “a subpopulation of myelinated, capsaicin-insensitive 
polymodal afferent neurones that are not readily classified as either rapidly or slowly 
adapting receptors [and] are primarily responsible for regulating cough evoked from the 
trachea or larynx”. These fibres have similar characteristics to RARs, including 
myelination of axons and cell bodies originating from the nodose ganglia. The conduction 
velocity of cough receptors is however slower from RARs, mostly in the range of 
approximately 4-6m.s-1 as opposed to 14-23m.s-1. In addition, whilst these fibres are, like 
RARs, mechanically activated in that they are exquisitely sensitive to light punctate 
touch, they are by contrast unresponsive to stretch of the airway structures (i.e. changes 
in pulmonary volume and bronchoconstriction). They are also unresponsive to certain 
chemical stimuli such as capsaicin and bradykinin, similarly to RARs. However in 
contrast to RARs the cough receptors are responsive to other chemical stimuli such as 
CA and changes in pH (Canning, 2004; Mazzone, 2004).  
 
Currently the identification and characterisation of ‘cough receptors’ has been carried out 
exclusively in the anaesthetised guinea pig, and the existence of these fibre types, and 
their relevance to the cough reflex in other species, including humans, is unclear 
(Canning, 2004; Mazzone, 2004)  
 
C-fibres 
C-fibres possess non-myelinated axons, and are the slowest conducting nerve fibre type 
innervating the airways, conducting APs at a velocity of under 1m.s-1 (Fox et al., 1993; 
Riccio et al., 1996; Mazzone, 2004). C-fibres originate in both the nodose and jugular 
ganglia, and protrude termini to sites in both intra- and extra-pulmonary airways. They 
are activated predominantly by chemical stimuli, including capsaicin, bradykinin, PGE2 
and CA, but are also mildly sensitive to stimulation by punctate touch, although are not 
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activated by changes in pulmonary volume or bronchoconstriction (Coleridge & 
Coleridge, 1984; Mohammed et al., 1993; Riccio et al., 1996; Lee & Pisarri, 2001; 
Undem, 2004). As C-fibres are unresponsive to changes in airway pressure and 
bronchoconstriction, the activation of these fibres by chemical stimuli is via a direct effect 
on these nerves rather than indirect result of bronchoconstriction (Coleridge & Coleridge, 
1984; Undem, 2004). In addition, a subset of C-fibres are activated by a multitude of 
inhaled irritants (cigarette smoke, air pollution), aromatic compounds in food and perfume 
(mustard oil, wasabi, cinnamon) and endogenous inflammatory mediators (PGE2, 
bradykinin) (Bessac & Jordt, 2008; Nassenstein et al., 2008; Taylor-Clark et al., 2008; 
Grace et al., 2012).  
 
Whilst all C-fibres are unmyelinated and respond to capsaicin and other chemical stimuli, 
there are two distinct populations of C-fibre, termed ‘pulmonary’ and ‘bronchial’ C-fibres, 
which respectively innervate the intra- and extra-pulmonary airways and possess unique 
phenotypes (Coleridge & Coleridge, 1984; Springall et al., 1987; Kummer et al., 1992; 
Undem, 2004): Bronchial C-fibres originate in the jugular ganglia, primarily innervate the 
larger conducting (extra-pulmonary) airways, and are mostly not stimulated by ATP, and 
express neurokinins such as substance P (SP) and calcitonin gene-related peptide 
(CGRP). By contrast, pulmonary C-fibres originate in the nodose ganglia, primarily 
innervate the lower (pulmonary) airways, are stimulated by ATP, and mostly do not 
express substance P or CGRP.  
 
Stimuli that cause C-fibre firing in anaesthetised animals also evoke cough in conscious 
animals (and humans). However, cough evoked by C-fibre activation is abolished in 
anaesthetised animals. This means that it is not possible to directly demonstrate that 
activation of bronchial or pulmonary–terminating fibres evoke cough. It is thought that, as 
mechanically-evoked cough is stimulated by nerve fibres with receptive fields in the 
upper airways, that bronchial C-fibres are most likely to cause cough (Undem et al., 
2002). In concordance with this hypothesis, it has been shown that activation of 
pulmonary C-fibres may inhibit cough in anaesthetised animals (Widdicombe, 1995; 
Widdicombe & Undem, 2002). Pulmonary C-fibre stimulation promotes the reflexes of 
apnoea, shallow/rapid breathing, and bradycardia (Coleridge & Coleridge, 1984). It is 
therefore thought that the afferent input by pulmonary C-fibres that act to modify the 
breathing pattern opposes afferent inputs that would normally evoke cough, at the level 
of the CNS, resulting in inhibition of the cough response (Tatar et al., 1994; Karlsson & 
Fuller, 1999).   
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In addition to a possible role in evoking cough, activation of bronchial C-fibres can cause 
local axonal reflexes, causing release of neuropeptides such as CGRP, SP, and 
Neurokinin A (NKA) from C-fibres at both peripheral and central termini (Barnes, 1986; 
1995). It has been shown in animal models that peripheral release of neuropeptides can 
contribute to inflammatory processes in the lung, causing bronchoconstriction, mucus 
production and oedema (Nasra & Belvisi, 2009). In addition, neuropeptides may act in a 
paracrine fashion on both peripheral and central nerve termini to alter the expression of 
receptors on sensory nerves and second order neurons in the NTS to potentiate the 
responsiveness to future chemical cough stimuli (Fischer et al., 1996; Undem et al., 
1999; Myers et al., 2002; Bonham et al., 2006; Sekizawa et al., 2008; Lieu & Undem, 
2011; El-Hashim et al., 2013). 
 
Additionally, a small number of airway C-fibres have cell bodies residing in thoracic 
dorsal root ganglia (DRG), although what input these fibres contribute to the cough reflex 
is unclear, as bilateral vagotomy abolishes the cough response to capsaicin (Coleridge & 
Coleridge, 1984; Nasra & Belvisi, 2009).  
 
Aδ nociceptors 
Aδ-nociceptors are a population of airway afferents that originate in the jugular ganglia, 
protruding myelinated axons that conduct APs at velocities of 4-6m.s-1, from termini 
located in both the intra-and extra-pulmonary airways (Canning et al., 2006). Aδ-
nociceptors express the ligand-gated Transient Receptor Potential Vanniloid type 1 
(TRPV1) ion channel, and so are chemically sensitive to agents such as capsaicin, 
bradykinin and PGE2, but differ from C-fibres in that they do not express substance P or 
tachykinins (Riccio et al., 1996; Kajekar et al., 1999; Yu, 2005). Additionally these fibres 
possess low responsiveness to mechanical stimulation.   
 
Nerve fibre types involved in the cough reflex 
The use of single fibre recording techniques, both in vitro and in vivo (in anaesthetised 
animals), has allowed researchers to determine which fibre types are activated by 
particular stimuli. However this information does not necessarily translate to cough; or 
rather, afferent nerve firing does not necessarily equate to generation of a cough 
response. For example, the tussive stimulus capsaicin evokes C-fibre firing in 
anaesthetised animals, but anaesthesia abolishes capsaicin-evoked cough. This 
highlights the complex neural integration of inputs from multiple nerve fibres that is 
regulated at both conscious and unconscious levels of the CNS. Furthermore, it 
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highlights the difficulties in making conclusions about which fibres mediate cough in 
conscious animals from single fibre studies in anaesthetised animals. Therefore, whilst 
there are many similarities in the stimuli that can evoke cough in animal models and 
humans, it remains unclear whether the characteristics of nerve fibre sub-types as 
determined in animal models are the same as those of human airway afferent nerves.  
 
However, current dogma suggests cough evoked by chemical stimuli, such as capsaicin 
and bradykinin, is evoked primarily by bronchial C-fibres, with some possible contribution 
from RARs and/or cough receptors, whereas cough evoked by mechanical stimuli such 
as bronchoconstriction and mucus is mediated primarily by cough receptors and/or extra-
pulmonary RARs (Canning, 2009; 2011). However this summary undoubtedly greatly 
oversimplifies the processes involved in evoking cough, as there is evidence that all 
fibres which innervate the airways may be involved in the regulation of cough at some 
level, via integration of their respective signals in the CNS (Mazzone, 2005; Canning, 
2011). What is more, the phenotype of airway afferent nerves may change under certain 
conditions (see Introduction 1.3.4), such as those found in respiratory infections and 
diseases, leading to a dysfunction of the normal cough reflex. 
 
1.3 Chronic cough; burden, causes and mechanisms  
31 
1.3 Chronic cough; burden, causes and mechanisms 
1.3.1 Problematic cough – incidence and health burden 
A European Respiratory Community Health survey (Cerveri et al., 2003) suggests that as 
much as 12% of the general population may suffer from excessive, or problematic, 
cough. In addition cough is one of the most common complaints for which patients seek 
medical care (Schappert & Rechtsteiner, 2011). Short-term problematic cough is a 
frequent symptom of influenza infection, but cough may also present as a problematic 
and persistent symptom common to many respiratory diseases (Irwin et al., 2006). 
 
Under normal physiological conditions in healthy individuals, cough is an essential 
defensive reflex that is initiated by relevant and appropriate stimuli acting on sensory 
nerves in the airways. An occasional cough is therefore a necessary function to maintain 
normal airflow to the airways. However, in certain conditions, excessive cough can 
become a problematic and distressing symptom. In these situations, the cough reflex 
becomes hyperresponsive, with coughs being evoked by normally innocuous stimuli, 
leading to unproductive bouts of coughing that cannot be consciously suppressed 
(Pratter, 2006b). Frequently the impact that such coughing can have on patients quality 
of life may be underestimated, however it should be borne in mind that coughing can vary 
from a relatively gentle ‘clearing of the throat’ to a vigorous and explosive ‘line of last 
defense’ mechanic (Irwin, 2006a). It is reported that during vigorous coughing, 
intratracheal expiratory velocities of up to 500 miles per hour, or about 5/7 the speed of 
sound, and high intrathoracic pressures of up to 300 mmHg may be reached (Irwin, 
2006c). Whilst in a defensive cough, for example to expel an inhaled foreign object, this 
explosive release of air is highly effective and desirable, on a recurring basis this 
manoeuvre can cause a variety of adverse effects, both physical and psycho-social 
(Irwin, 2006c). The physical adverse effects include a long list of symptoms affecting 
multiple bodily systems including cardiovascular, gastrointestinal, genitourinary and 
respiratory (Irwin, 2006c). These effects can be serious and immediate medical 
concerns, including brady/tachyarrythmia (Omori et al., 1984; Reisin et al., 1994), 
diaphragmatic rupture (George et al., 2000) and loss of consciousness/cough syncope 
(Mccann & Bruce, 1949; Kerr & Derbes, 1953; Skolnick & Dines, 1969). Patients with 
long-term excessive cough may also suffer ongoing psychosocial issues, such as self-
consciousness at inability to voluntarily control cough and at apparent symptoms that 
may include excessive sweating, cough syncope and urinary incontinence (among 
others) (Irwin & Curley, 1991; French, 1998; French et al., 2002). Such symptoms may 
significantly reduce the patients quality of life and lead to social withdrawal (French, 
1998).  
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In order to assess both the impact of chronic cough on patients lives, and also to better 
understand the nature of how the cough reflex is altered in chronic coughers, a range of 
methodologies to assess cough in the clinic have been devised. 
 
1.3.2 Assessment of cough in the clinic  
Study design in the clinical evaluation of cough can vary widely, depending on the 
hypothesis under examination. However in the main the methodology employed can be 
described as belonging to one of 3 main categories; cough questionnaires, ambulatory 
cough measurements, and cough reflex sensitivity testing. 
 
Cough questionnaires  
Cough questionnaires are retrospective subjective analyses that seek to assess the 
severity and/or impact of cough on patients’ lives. The Leicester Cough Questionnaire 
(LCQ) (Birring et al., 2003), the Cough-specific Quality of Life Questionnaire (CQLQ) 
(French et al., 2002), and the Chronic Cough Impact Questionnaire (CCIQ) (Baiardini et 
al., 2005) are validated cough-specific questionnaires that have been designed with the 
aim of evaluating the impact of chronic cough on patients’ quality of life.  
 
The LCQ contains 19 items that examine the physical, psychological and social impacts 
of cough. Each question is rated on a 7-point Likert* scale, and a low LCQ score 
indicates poorer quality of life. The CQLQ contains 28 items that examine how cough 
impacts on patients in terms of physical complaints, psychosocial issues, emotional well-
being, health anxieties, and functional abilities.  These questions are rated on a 4-point 
Likert* scale, and a high CQLQ score represents poorer quality of life. The CCIQ 
contains 25 items that examine the practical, emotional, social and physical aspects of 
the impact of cough on patients. These questions are rated on a 5-point Likert*∗ scale, 
and a high CCIQ score represents poorer quality of life.  
 
The CCIQ is the least validated of the three questionnaires, having been validated in a 
heterogeneous sample of patients with chronic cough associated with asthma, 
gastroesophageal reflux disease (GERD), post-nasal drip syndrome (PNDS) and chronic 
                                                   
∗* ’Likert scale’ refers to a format for quantifying qualitative data, by generating a score 
from a collection of responses that are scored along a range (Guttman, 1944).  
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obstructive pulmonary disease (COPD), that was also a mix of smoking status (current, 
ex-, never) (Baiardini et al., 2005). The LCQ and the CQLQ were validated using patients 
with unexplained chronic cough (French et al., 2002; Birring et al., 2003; 2006; Kelsall et 
al., 2008), showing a decrease in quality of life of these patients. Similarly, patients with 
chronic cough associated with cystic fibrosis, asthma, and COPD were also found to 
have low quality of life scores (Smith et al., 2006; Marsden et al., 2008; Polley et al., 
2008; Fathi et al., 2009; Field et al., 2009). Additionally, the LCQ and the CQLQ have 
been directly compared in groups of patients with asthma, COPD or chronic cough, and 
overall were found to correlate in their assessment of the impact of cough on patients 
quality of life (Kalpaklioglu et al., 2005; Polley et al., 2008).  
 
Ambulatory cough counting  
Ambulatory cough counting is an objective measure that seeks to quantify cough in terms 
of numbers, duration, and frequency during a patients ‘normal’ routine. Ideally, a patient 
would wear a recording device and microphone, which would record cough sounds made 
by the subject as they go about their normal daily routine. The recording system would 
receive input from an open field or contact type microphone, possibly supplemented with 
additional hardware, for example accelorometers or bands to measure chest 
compression. The recording would then be analysed by an algorithm designed to isolate 
cough sounds made by the subject from background noise to accurately quantify cough 
number, duration and frequency. Unfortunately such an idealised system has yet to be 
fully realised (Smith, 2010). Probably the main difficulty has been in the design of 
software which can accurately discern cough from background noises (Smith, 2010). In 
terms of recording hardware, advances in commercially available audio equipment (eg. 
MP3 players) have made possible portable and unobtrusive microphone/recording 
devices that can be worn by patients and make recordings over extended periods of time. 
There are multiple such systems in development, each with various types of hardware 
and custom software for recording analysis, which have been recently reviewed by Smith 
(2010). Generally these systems may have good correlation with manual counting over 
shorter periods of time, for instance 1 hour (Barry et al., 2006; Paul et al., 2006; Birring et 
al., 2008). But currently these systems are either unable to record for longer periods of 
time, or suffer from decreased correlation with manual counting as time increases. 
Problems with software analysis include difficulties with differentiating between cough 
sounds and background noises and speech. Other systems currently in development, 
which utilise sensors such as a contact microphone or chest compression band, promise 
improved accuracy over longer recordings, although these systems remain to be 
validated in larger scale studies (Smith, 2010; Vizel et al., 2010).  
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Cough reflex sensitivity testing  
Assessment of cough reflex sensitivity is an objective measure of cough evoked by 
inhaled stimuli. This technique is a laboratory research/diagnostic tool, and differs from 
cough questionnaires and ambulatory cough counting, as it does not directly assess the 
impact or severity of spontaneous cough in ‘normal’ settings. The technique does 
however allow an empirical pharmacological assessment to be made. Subjects inhale a 
designated amount of a series of increasing concentrations of an aerosolised agent that 
evokes cough, and are instructed to cough freely. This instruction to cough freely is 
important, as it serves to remove the conscious decision not to cough (Morice et al., 
2007a), resulting in the technique being closer to a measure of the afferent input that 
causes the  ‘urge-to-cough’ (Davenport, 2008).  
 
Results from cough reflex sensitivity assessments are usually presented as log[C2] and 
log[C5] values, or rather, as the concentrations of tussive stimulus required to evoke 2 or 
5 coughs (respectively) from the subject (Morice et al., 2007a). C2 and C5 values can 
either be interpolated from a concentration-response curve, or determined by selecting 
the lowest concentration of the tussive agent to evoke the required number of coughs 
(Morice et al., 2007a). These values can be compared between individuals (i.e. healthy 
vs chronic cough patients with different underlying disorders), or within the same 
individual pre- and post-treatment. C2 and C5 measurements within individuals have been 
found to be reproducible at periods of up to 6 months, demonstrating the reliability of this 
technique for clinical trials of anti-tussives or interventions aimed at treating chronic 
cough (Dicpinigaitis, 2003).  
 
Patients reporting with chronic cough have generally been demonstrated to have a 
lowered cough threshold (indicating increased sensitivity) to tussive stimuli, such as 
capsaicin and CA. This includes chronic cough patients with COPD, asthma, and GERD 
as underlying respiratory conditions, and also has been observed in patients with 
unexplained (idiopathic) chronic cough (Choudry & Fuller, 1992; Ferrari et al., 1995; 
Wong & Morice, 1999; Doherty et al., 2000). 
 
Comparison of QoL, ambulatory recording and cough reflex measures  
The choice of clinical methodology for assessment of cough will depend on the 
hypothesis a researcher wishes to test, and in this regard, subjective and objective 
measures of cough each offer different advantages. For example, quality of life studies 
provide a quantitative examination of the impact of cough on patients’ lives. It may be 
argued that this is the most important statistic to determine; as lowered quality of life is 
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the reason patients’ seek medical care. However subjective measures provide 
information about the patients perception of the impact of cough, they do not provide 
information on how the cough reflex is altered in disease, nor on how cough therapies 
work. By contrast, ambulatory cough measurements hold much promise for the future to 
provide objective measures of the severity of cough, and empirical data on recovery 
following treatments. However the available hardware/software must be able to monitor 
cough over longer periods (24h+) of time, and larger studies with such systems are still 
required to further validate this technique (Irwin, 2006a; Smith, 2010). Cough reflex 
sensitivity testing is a validated technique that is particularly useful in the initial 
assessment of anti-tussive therapy in the clinic, due to the controlled conditions of the 
assessment, reproducibility of measurements over time, and the empirical pharmacology 
of the data produced (Dicpinigaitis, 2003; Irwin, 2006a; Morice et al., 2007a). In addition, 
the use of different pharmalogical stimuli to evoke cough enables probing of the 
mechanisms by which the cough reflex is altered, and also may be relevant to 
understanding the mechanisms by which potential anti-tussives have their action (Irwin, 
2006a; Smith, 2010).  
 
To date, data on comparisons of the utility and concordance of the various techniques for 
assessing chronic cough (and its impact) are limited, with only a few studies directly 
comparing the different methodologies. The earliest such comparative study was carried 
out by Birring et al. (2006), whom compared cough frequency (recorded over 6h, 
manually counted) to cough reflex sensitivity to capsaicin and to quality of life (assessed 
by LCQ) in 20 “chronic coughers”. The authors observed that cough frequency correlated 
with a lowered quality of life (as determined by LCQ), but unexpectedly also correlated 
with increased C2 and C5 to capsaicin; implying that sensitivity to capsaicin decreases as 
cough frequency increases. There are however, some issues with the methodology/study 
design that may explain this counter-intuitive result: the population selected was highly 
heterogeneous, including a small number (20) of patients with a variety of causes of 
cough (cough variant asthma, eosinophilic bronchitis, GERD, post-viral, unexplained, 
beonchiectasis, chronic bronchitis and COPD, n=1-5 per group). In addition, the 
population included subjects with cough duration of >3 weeks as ‘chronic’ coughers, only 
8 subjects had cough reflex sensitivity assessed, and ambulatory measurements were 
taken for only 6h. Together these issues make it difficult to interpret this data, especially 
when compared to similar comparative studies that have utilized longer (24h) ambulatory 
recordings, have a better-defined chronic cough subject population, and larger numbers 
of subjects. Generally, 24h ambulatory cough recordings have found that frequency of 
cough inversely correlates with log[C2] and/or log[C5] values (to citric acid) in asthmatics 
(non-selected for cough) (Marsden et al., 2008), in COPD patients with chronic cough 
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(Smith et al., 2006), and also in a larger population of chronic coughers albeit with 
various causes (Decalmer et al., 2007). Also in these studies – as well as a study by 
Kelsall et al. (2008) – increased cough frequency was moderately well associated with 
decreased quality of life (assessed by LCQ), and also with symptom scoring (via 
questionnaire or visual analogue scoring).  
 
Taken together these studies seem to indicate that objective measures of cough 
generally agree with subjective measurements of cough. The choice of study design may 
therefore be tailored on the type of hypothesis under examination. For example, cough 
reflex sensitivity testing may be better suited to initial clinical trials examining the efficacy 
of therapies for cough, whereas ambulatory cough counting and symptom scoring may 
require larger populations.  
 
1.3.3 Causes of chronic cough 
Cough is one of the most common symptoms for which patients seek medical care 
(Schappert & Rechtsteiner, 2011). The American College of Chest Physicians (ACCP) 
guidelines on the diagnosis and management of cough give a diagnostic workflow to 
identify the cause(s) of cough, based on the reported duration of cough symptoms. Firstly 
a patient history and medical examination will be undertaken. The duration of symptoms 
is therefore divided into 3 categories, with cough of less than 3 weeks termed ‘acute 
cough’, cough lasting between 3-8 weeks ‘sub-chronic cough’, and cough persisting 
longer than 8 weeks is referred to as ‘chronic cough’. There are a variety of possible 
causes of cough, or rather, disease states that are associated with problematic cough. 
Upon identification of a possible cause, treatments will generally be directed at treating 
the underlying condition.   
 
The most common cause of acute and sub-chronic cough are respiratory infections, 
particularly viral infections (common cold) (Irwin et al., 1990). Typically post-viral cough 
resolves itself shortly after clearance of the infection without requiring additional 
treatment, but may persist for several weeks following clearance of other symptoms 
(Irwin et al., 2006). For this persistent cough, treatments may be attempted, however 
there is limited evidence that current cough therapies have efficacy in this patient 
population (Pratter, 2006a). Cough can also be a symptom of other types of respiratory 
infection, including pneumonia and Bordatella Pertussis (‘whooping cough’). In these 
cases, the infection itself will be considered more hazardous to patient health, and 
treatments will therefore be aimed at treating the infection first and foremost.  
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Whilst acute and sub-chronic cough are frequently caused by short-term infection of the 
upper respiratory tract, which resolves upon resolution of the underlying condition, long-
term unresolved coughing can be a symptom of a range of conditions, including lung 
cancer, PNDS, GERD, COPD and asthma (Irwin et al., 2006). Normal clinical strategy for 
the treatment of cough associated with a respiratory infection or disease would be to treat 
the underlying condition associated with the onset of chronic cough (Irwin et al., 2006). 
However, successful treatment of the underlying condition is not always possible, and in 
these cases, and where the cause of cough cannot be defined, this is not a viable clinical 
strategy for the treatment of cough. This includes, for example, patients with inoperable 
lung tumours, and also patients with chronic respiratory diseases that are associated with 
chronic cough, such as asthma and COPD, where treatments do not completely reverse 
the disease conditions, and cough continues to be a distressing symptom.  
 
COPD  
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent and debilitating 
respiratory disease, primarily of the airways. It is a leading cause of death and disability 
worldwide, and disease incidence is predicted to continue increasing, such that COPD is 
predicted to be the third leading cause of death by 2020 (Vestbo et al., 2013). COPD is 
characterised by irreversible and progressive reduction of airflow, measured as a decline 
in lung function through spirometry (Barnes & Stockley, 2005; Rabe et al., 2007; Paredi 
et al., 2010). Current treatments provide essentially only moderate symptomatic relief 
and do not halt progression of the disease. The airflow limitation in COPD is 
accompanied by an abnormal inflammatory response to noxious inhaled particulates or 
gases, for example tobacco smoke, which is thought to be one of the primary causative 
agents for the initiation of COPD (Barnes & Stockley, 2005; Rabe et al., 2007; Salvi & 
Barnes, 2009). Typically such exposures must take place over a long duration before the 
symptoms of COPD appear – hence most diagnoses of COPD are made when patients 
are in middle age.  
 
Chronic cough is often one of the first complaints that patients present with prior to a 
diagnosis of COPD: such that the recent GOLD strategy for diagnosis, management and 
treatment of COPD notes that patients presenting with chronic cough accompanied by a 
decline in actual compared to predicted spirometry values should be considered for a 
diagnosis of COPD (Vestbo et al., 2013). Indeed, cough was found to be the most 
commonly experienced symptom, as reported by 70% of 3265 COPD sufferers 
interviewed, occurring daily in 46% of the same population (Rennard et al., 2002).  
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One of the primary characteristics of COPD is an abnormal inflammation of the airways 
that is unresponsive to standard anti-inflammatories, including the gold-standard 
treatment of corticosteroids (Barnes, 2013). It is thought that chronic exposure to noxious 
gases/particles drives inflammation in the lungs (Decramer et al., 2012). Cigarette smoke 
(CS), for example, stimulates multiple pulmonary immune cells (in particular 
macrophages, but also neutrophils, and CD4+ Th1 and CD8+ Tc lymphocytes) to release 
many inflammatory mediators, which recruits further inflammatory cells (in particular 
neutrophils, but also macrophages and CD4+ Th1 and CD8+ Tc lymphocytes) to the 
airways (Barnes, 2008). It is thought that this positive feedback loop, along with repeated 
stimulation provided by chronic CS-exposures, drives a persistent and progressive 
inflammation. This inflammation, along with exposure to the damaging components of 
CS, causes destruction of the alveolar structure, and enhances mucus production (via 
goblet cell hyperplasia and hypertrophy) and fibrosis, resulting in reduction in the surface 
area for gas exchange, reduced elastic recoil, and increased airflow obstruction (Hogg et 
al., 2004; Barnes, 2008; Lai & Rogers, 2010). The exact proportion of these structural 
changes may vary between patients, as COPD is an umbrella term that covers several 
inter-related lung diseases, including chronic bronchitis, small airways disease (SAD) and 
emphysema (Barnes, 2004a; Sturton et al., 2008). Whatever the proportion in an 
individual patient, these structural changes contribute to the reduction in airflow, as 
assessed by spirometry. 
 
The mechanism by which cough becomes problematic in COPD is unclear. There is 
some evidence, however, that components of both the inflammatory response and CS 
exposure may cause modulation of the cough reflex, both at the level of sensory 
innervation and the CNS (expanded on in Section 1.3.4). Normal clinical strategy for the 
treatment of cough associated with respiratory disease would be to treat the underlying 
condition associated with the onset of chronic cough (Irwin et al., 2006). However, due to 
the ineffectiveness of anti-inflammatories for COPD and the progressive nature of the 
disease, this is not a viable strategy for the treatment of cough in COPD.   
 
Asthma 
Defining asthma is somewhat difficult, as there is no single definitive genetic or 
environmental cause or trigger for development of this disease (Hargreave & Nair, 2009). 
However, broadly speaking, asthma is a chronic inflammatory disease of the airways, 
characterised by sudden but transient decreases in airflow associated with dyspnea, 
cough and wheeze, which are generally fully reversible by bronchodilator treatment. It 
has been estimated that 300 million people worldwide may suffer from asthma, with the 
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highest incidences in the Americas, Europe, and Australia of 5-10% of the population 
(Masoli et al., 2004).  
 
Sudden bronchospasm of airway smooth muscle in asthmatics (‘asthma attack’) causes 
breathlessness and wheeze. Bronchospasm may be triggered by many stimuli, which in 
normal subjects would be innocuous, including dust and other allergens, pollen, air 
pollution, exercise, and cold air (Eder et al., 2006). This airway hyperresponsiveness is 
driven either by chronic airway inflammation and/or structural changes to the airways 
induced by this inflammation (Lommatzsch, 2012). Whilst the chronic inflammation in 
asthma also involves an abnormal activation of multiple immune cells, it is different from 
the inflammation observed in COPD, in that it is mostly suppressed by anti-inflammatory 
therapy, and involves different cell types, including CD4+ Th2 cells, mast cells, and 
eosinophils (Barnes, 2008).  
 
Asthma is one of the most frequent causes of chronic cough, and almost all asthma 
patients report cough as a symptom, with many reporting persistent and problematic 
cough (Niimi, 2011). Indeed, so common is the association that the ACCP guidelines 
recommend that in non-smoking patients presenting with chronic cough, and in the 
absence of other causative diagnoses, asthma should always be considered as a cause 
(Dicpinigaitis, 2006). It is further recommended that chronic cough patients be trialed on 
standard asthma therapeutics (inhaled bronchodilators and/or steroids), even in the 
absence of a diagnosis of asthma by decreased predicted % FEV1, methacholine 
inhalation challenge. Thus chronic cough patients whom do not display asthmatic 
symptoms but are successfully treated with asthma therapy are diagnosed with cough-
variant asthma (CVA) (Dicpinigaitis, 2006). Whilst CVA sufferers do not display the 
symptoms of classic asthma, a similar inflammatory phenotype and structural changes 
(fibrosis, airway thickening) are present in both conditions (Niimi et al., 2000; De Diego et 
al., 2005; Matsumoto et al., 2007).  
 
The exact mechanisms by which chronic cough develops on a background of asthma are 
unclear. Similarly to COPD, one of the hallmarks of asthma is chronic inflammation of the 
airways (Barnes, 2008), although in asthma this inflammation is generally well-controlled 
by the use of steroids, one of the mainstays of treatment (Dicpinigaitis, 2006). The 
successful treatment of the cough in all CVA patients (Pavord, 2004), and in the majority 
of chronic coughing asthmatics (Dicpinigaitis, 2006) with anti-inflammatories suggests a 
causative association between airway inflammation and modulation of the cough reflex. 
Severe asthmatics are a sub-group of asthma subjects whose symptoms are refractory to 
anti-inflammatory treatment with the gold-standard therapy of inhaled or oral steroids 
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(Pakhale et al., 2011), and chronic cough may continue to be a distressing symptom to 
these patients in particular, further strengthening the association between inflammation 
and chronic cough.   
 
Unexplained (idiopathic) chronic cough 
Formerly known as idiopathic chronic cough, the 2006 ACCP guidelines on the diagnosis 
and management of cough advises that chronic cough of indeterminate cause be 
referred to as ‘unexplained’ chronic cough (Irwin et al., 2006). This name change was 
selected to emphasise that unexplained cough is a ‘diagnosis of exclusion’, and thus is a 
label for chronic cough caused by any of a range of conditions that are not as yet 
implicated in causing cough (Pratter, 2006c).  
 
Chronic cough may be the only presenting symptom of multiple respiratory disorders, 
including asthma, eosinophilic bronchitis and GERD (Irwin et al., 1990; Lee et al., 2001). 
A difficulty with making a diagnosis of unexplained chronic cough is that physicians must 
carefully rule out these potential causes. Therefore, considering only data from more 
recent studies in several specialist cough clinics in the UK, US, Australia and Japan, 
Chung and Pavord (2008) estimate that unexplained chronic cough may account for 
between 7 and 46% of patients presenting with chronic cough. 
 
Similar to chronic cough in asthma and COPD, unexplained chronic cough patients 
describe bouts of coughing brought on by normally innocuous stimuli, such as exposure 
to perfumes or aerosols, sudden changes in temperature of inspired air, and during 
talking (McGarvey et al., 2009; Morice et al., 2011).  
 
It has been argued that many unexplained chronic cough patients may be better 
described as having ‘cough reflex hypersensitivity syndrome’ or ‘airway sensory 
hyperreactivity syndrome’ (Chung, 2011; Millqvist, 2011). This is due to the observation 
that unexplained chronic cough patients frequently have a lowered threshold to tussive 
stimuli such as capsaicin and CA in the absence of any causative factor (Chung, 2011; 
Millqvist, 2011). The mechanisms underlying the modulation of the cough reflex in 
unexplained chronic cough and/or cough hypersensitivity syndrome are unclear (Pratter, 
2006c; Chung, 2011; Millqvist, 2011). 
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1.3.4 Mechanisms underpinning chronic cough 
There are a number of potential mechanisms that may contribute to coughing in 
respiratory diseases, including excess airway mucus production, airway inflammation, 
and the inhalation of noxious particles/fumes (e.g. cigarette smoke) (Smith & Woodcock, 
2006).  
 
The accumulation of excess mucus in the small airways has been shown to correlate with 
disease progression in both COPD and asthma, as indicated by a decline in respiratory 
flow (FEV1) (Hogg et al., 2004; Hesselink et al., 2006). However, in both asthma and 
COPD subjects, measures of FEV1 do not correlate with cough reflex sensitivity to 
capsaicin (Doherty et al., 2000), suggesting that mucus production does not play a role in 
the modification of the chemical stimulus-evoked cough reflex. Whilst mucus production 
may not alter the cough reflex via modification of the sensitivity of airway afferents, 
excess mucus production is likely to evoke increased coughing via direct mechanical 
stimulation of airway afferents (Smith & Calverley, 2004). This cough is likely productive 
in the sense that it serves to loosen and remove excess secretions to maintain airflow, 
and as such may not be a sensible target for anti-tussive therapy.  
 
Levels of inflammatory mediators and cells are increased in chronic respiratory diseases 
associated with chronic cough, such as COPD and asthma (Bhowmik et al., 2000; 
Gompertz et al., 2001; Biernacki et al., 2003; Montuschi et al., 2003). Inflammatory 
mediators that are upregulated in these conditions, such as PGE2 and BK, have been 
demonstrated to evoke cough in humans, and in animal models can directly activate 
sensory nerves (Kawakami et al., 1973; Choudry et al., 1989; Grace et al., 2012). 
 
The inhalation of noxious particles and fumes, in particular cigarette smoke, have been 
linked with the development of chronic cough, with for example, current cigarette 
smoking being the leading risk factor associated with chronic cough in the general EU 
population (Cerveri et al., 2003). Inhalation of noxious particles and fumes, from 
occupational exposures, as well as cigarette smoking, can increase the level of airway 
inflammation seen in both asthma and COPD patients (Barnes, 2008). In addition, 
inhaled irritants such as CS have been shown to evoke cough in humans, and in animal 
models CS can directly via activate airway C-fibres and RARs (Lee et al., 1989; Kou & 
Lee, 1990; Lai & Kou, 1998; Bessac & Jordt, 2010). 
 
Airway inflammatory mediators have been shown to increase the production of oxidants 
by multiple airway cells. Noxious fumes such as cigarette smoke can also contain high 
levels of oxidizing agents, further increasing the oxidative stress in the airways (van der 
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Vaart, 2004). Increases in oxidative stress may be important in the development of 
chronic cough, as multiple oxidants, for example hypochlorite, hydrogen peroxide and 4-
hydroxynonenal, have been shown to directly activate airway-terminating C-fibres or 
vagal afferent neurons in guinea pigs (Bessac et al., 2008; Taylor-Clark et al., 2008). 
Additionally, 8-isoprostane, a marker of oxidative stress, has been shown to be 
associated with increased cough reflex sensitivity and lower quality of life scores 
(assessed by LCQ) in asthma patients (Koskela et al., 2012).  
 
It has been suggested that in chronic respiratory conditions, the general milieu of 
increased pro-tussive endogenous and exogenous chemical stimuli may play a role in 
directly evoking frequent cough. In particular, the Transient Receptor Potential Vanilloid 
type 1 (TRPV1) and TRP Ankyrin type 1 (TRPA1) channels have been implicated with a 
role in mediating the responsiveness of airway nerves to a range of stimuli. TRPV1 and 
TRPA1 belong to a superfamily of TRP channels, which are 6 transmembrane domain, 
non-selective, but Ca2+-preferring ion channels, with a pore region between the 5th and 
6th transmembrane regions (Clapham, 2005; Szallasi et al., 2007). TRPV1 is a ligand-
gated, cation permeable (Ca2+ preferring but also Na+) channel expressed on Aδ and C-
fibres, and is a key receptor mediating afferent chemosensitivity (Canning, 2009). 
Capsaicin is a direct and specific exogenous activator of TRPV1; therefore as the cough 
reflex threshold to capsaicin is decreased in asthma, COPD and unexplained chronic 
cough patients, TRPV1 has been implicated with a key role in these conditions (Choudry 
& Fuller, 1992; Wong & Morice, 1999; Doherty et al., 2000). TRPA1, another ligand-gated 
Ca2+ permeable channel, is also present on subsets of chemosensitive sensory neurons, 
and is also implicated with a role in chronic cough, as it is directly activated by reactive 
oxygen species (ROS) and cigarette smoke constituents, such as reactive aldehydes 
acrolein (Bessac & Jordt, 2010; Grace & Belvisi, 2011). Indirect activators (via 
metabotropic receptors) of TRPV1 and/or TRPA1 include mediators that are increased in 
inflammatory conditions, such as bradykinin, PGE2, leukotriene (LT) B4, and 
hydroxyeicosatetraenoic (HETE) and hydroperoxyeicosatetraenoic (HPETE) acids 
(Hwang et al., 2000; Carr & Undem, 2003; Clapham, 2003; Adcock, 2009; Maher et al., 
2009).  
 
However, in addition to direct activation, there are several lines of evidence supporting a 
role for indirect sensitisation of the cough reflex to subsequent pro-tussive stimuli. 
Generally these mechanisms may be sub-divided into modulation of receptors expressed 
on airway afferent nerves at either the peripheral or central nerve terminals.  
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Peripherally, it has been suggested that TRPV1 activity may be modulated, either via 
phosphorylation of an intracellular loop of the channels, or via a reduction in inhibition of 
TRPV1/TRPA1 by phosphatidylinositol 4,5-bisphosphate (PIP2) as a consequence of 
modified intracellular signaling pathways activated by e.g. inflammatory mediators (Ma & 
Quirion, 2007; Petrus et al., 2007; Zhang et al., 2008b; Adcock, 2009). However, whilst in 
vitro research has demonstrated that these mechanisms are feasible, direct evidence of 
the relevance of activation of these pathways in vivo are lacking. Another suggested 
mechanism of sensitisation is an upregulation in TRPV1 and/or TRPA1 expression in 
afferent sensory neurons, either in fibres expressing these receptors already (increasing 
sensitivity), or de novo expression in normally chemically insensitive afferent fibres 
(Undem et al., 1999; Myers et al., 2002; Zhang et al., 2008a; Lieu et al., 2012). In human 
subjects, increased densities of CGRP- and SP-positive nerves have been observed in 
the pulmonary epithelium of unexplained cough and CVA subjects (O'Connell et al., 
1995; Lee et al., 2003). Furthermore, Groneberg et al. (2004) have further found that an 
increased density of TRPV1-expressing nerves observed in chronic cough subjects 
correlates with a lowered cough reflex sensitivity to capsaicin. These findings suggest an 
increase in the numbers of chemosensitive nerves may be important in the development 
of chronic cough.   
 
Sensitisation of sensory afferent nerve may also occur at the central terminals. The 
release of neuropeptides in the ganglia and NTS may enhance the activity of and 
modulate the receptor expression of airway-terminating afferent fibres, as well as second 
order neurons in the NTS (Fischer et al., 1996; Bonham et al., 2006; Sekizawa et al., 
2008; Lieu & Undem, 2011; El-Hashim et al., 2013).  
 
The mechanisms by which cough reflex sensitivity is enhanced in chronic cough patients 
are not fully understood, but are likely to involve either an increased expression or activity 
of TRPV1 (and possibly TRPA1), probably driven by interactions between multiple 
mediators associated with airway inflammation (Fig. 1.4). 
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Figure 1.4 Schematic of cough activating and sensitising pathways 
Cough is initiated by activation of TRPV1/A1-expressing chemically-sensitive C-fibres (or 
possibly Aδ-nociceptors), or of mechanically-sensitive RARs/cough receptors. 
Components of cigarette smoke and air pollution, or exogenous inhaled chemicals such 
as capsaicin and acrolein can activate TRPV1 or TRPA1 and evoke cough via C-fibres 
directly. Additionally these stimuli, as well as allergens, can contribute to inflammatory 
processes, elevating the levels of mediators such as PGE2 and BK, which can directly 
activate TRPV1 and/or TRPA1, and also sensitise these receptors to further stimuli. 
Cough responses can also be modulated by the release of neuropeptides, which may 
enhance TRPV1/TRPA1 responses by modulating the activity and/or expression of these 
channels on C-fibres and RARs. Abbreviations: RAR; Rapidly Adapting Receptor, SP; 
Substance P, CGRP; Calcitonin Gene-related Peptide, TRPV1/A1; Transient Receptor 
Potential Vanniloid type1/Ankyrin type1, EP3; Prostaglandin E receptor type 3, B2; 
Bradykinin receptor type B2, PGE2; Prostaglandin E type 2, BK; Bradykinin. Figure 
adapted from Canning et al. (2004).  
1.4 Current cough therapeutics  
45 
1.4 Current cough therapeutics  
Pharmacological therapies aimed at treating chronic cough can be broken into three main 
categories based on their intended method/site of action, into drugs that treat an 
underlying component of disease (i.e. inflammation, mucus, reflux), drugs targeting the 
peripheral nervous system, and those that dampen the urge-to-cough by targeting the 
CNS.  
 
Drugs that successfully treat an underlying condition in subjects with chronic cough are 
often successful at restoring a normal cough reflex. For example, proton pump inhibitors, 
used to treat reflux, are said to have a high success rate in chronic cough patients with 
GERD (Irwin, 2006b). Additionally, for many asthmatic subjects, anti-inflammatories and 
bronchodilators often provide good control of chronic cough in line with other symptoms 
(Dicpinigaitis, 2006).  
 
However, where current therapies are ineffective, such as in COPD patients and severe 
asthmatics, or where the underlying condition cannot be identified (unexplained chronic 
cough), peripheral- or CNS-targeting therapies that directly inhibit cough are required.  
 
The most effective anti-tussive medications currently available are centrally-acting 
compounds, including drugs such as codeine, morphine and dextromethorphan, that act 
on receptor types including opioid (µ-, δ- & κ-opioid) and/or σ- receptors as agonists, and 
additionally dextromethorphan acts as an NMDA receptor antagonist (Bolser, 2006b). 
However, a recent paper by Smith et al. (2006) demonstrated that codeine had no 
significant benefit over placebo, as assessed by objective cough monitoring. 
Furthermore, another study by Paul et al. (2007) comparing dextromethorphan, 
diphenhydramine (anti-histamine/anti-tussive non-prescription cold medication) and 
honey to placebo found that honey provided the greatest symptomatic relief, as assessed 
by cough questionnaire (on a Likert scale). Whilst this study was conducted in children 
with upper respiratory tract infections rather than chronic cough patients (whom may 
therefore not have the same modified cough reflex sensitivity), that the most efficacious 
anti-tussive (dextromethorphan) was outperformed by honey highlights the lack of 
efficacy of current cough medications.  
 
Whilst there are currently no effective peripherally acting anti-tussive therapies available, 
targeting the PNS is attractive for two reasons. Firstly they generally are not associated 
with the same adverse effects observed with many CNS-targeting compounds, such as 
nausea, sedation and addictiveness (Bolser, 2006a). In addition, peripherally acting 
drugs may be more specific in their targeting, and hold potential to, for example, inhibit 
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the heightened sensitivity to chemical agents, whilst leaving the ‘normal’ defensive cough 
reflex to mechanical stimuli intact (Nasra & Belvisi, 2009). Interestingly, a recent small 
clinical trial of a novel compound that may fit into this class has been recently reported; 
Abdulqawi et al. (2013 – ERS abstract In Press) have demonstrated that an oral P2X3 
antagonist was successful at reducing cough rates and severity in unexplained chronic 
cough patients. P2X3 receptors, which are activated by ATP, are present on airway 
sensory nerves (Undem & Nassenstein, 2009). Currently however, the role that P2X3 
receptors play in regulating the cough reflex is unclear.  
 
A recent meta-analysis on the efficacy of all types of existing cough therapies concluded 
that, of all clinically-evaluated compounds, only centrally-acting opioid-based drugs and 
dextromethorphan have any significant anti-tussive effect (Yancy et al., 2013). However, 
codeine and dextromethorphan, whilst moderately effective, were associated with 
significant side-effects at therapeutic doses including sedation, nausea (including 
vomiting), drowsiness, and dizziness (Bolser, 2006b). No peripherally-acting cough 
therapies were found to be have any significant anti-tussive effect (Yancy et al., 2013). In 
fact, so low is the demonstrable level of efficacy of all types of non-prescription, or over-
the-counter (OTC) cough medications, compared to the low, but real risk of severe 
adverse effects, that these products for infants were withdrawn from the US market in 
October 2007 (Shehab et al., 2010; Vassilev et al., 2010).  
 
The market for OTC anti-tussive drugs has been estimated to be worth approximately 
US$3.6 billion in the US, and GB£100 million (Dicpinigaitis, 2011). Additionally, it is 
estimated that in the EU, as much as 12% of the general population may suffer from 
chronic cough (Cerveri et al., 2003). Considering that no existing anti-tussive has been 
demonstrated to be both effective and safe, it is apparent that there is a significant unmet 
clinical need for novel anti-tussives.  
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1.5 Outline of thesis  
1.5.1 Aims  
There are currently no available therapies for cough that are both effective and safe. 
Frequently the most effective therapies are unsafe due to their action in the CNS, 
whereas many peripherally acting therapies are safe but ineffective. There are therefore 
two potential routes to novel safe and effective cough therapies; either designing novel 
centrally acting anti-tussives that have improved safety profiles, or designing peripherally 
acting compounds that have improved efficacy. Due to the problems associated with 
safety in centrally acting drugs, and our lack of understanding of the CNS processes 
involved in mediating the cough reflex, this thesis will primarily focus on examining the 
efficacy of novel peripherally acting anti-tussive compounds.  
 
The drug development process can be long and costly, taking approximately a decade 
and incurring costs of US$1 billion for a new compound to go from discovery to clinical 
usage (DiMasi et al., 2003). This thesis therefore aims to examine the efficacy of two 
existing compounds, which are clinically approved for other uses, as well as a novel 
compound that is currently in the lead development stage of the drug discovery pipeline 
(Meyers et al., 2011). Where these compounds are found to be effective at inhibiting 
cough, their mechanism(s) of action will be examined. 
 
The classes of compound evaluated in this thesis for their anti-tussive potential are β-
adrenergic receptor agonists, methylxanthines and Fatty Acid Amide Hydrolase (FAAH) 
inhibitors. Various β2-adrenergic receptor agonists, and the methylxanthine compound 
theophylline have been prescribed for decades for the relief and treatment of the 
symptoms of asthma, as bronchodilators that act on airway smooth muscle to cause 
relaxation of constricted airways. By contrast, FAAH inhibitors are a novel class of 
compound, and currently are not clinically approved for use in patients.  
 
1.5.2 Strategy of Investigation 
The potential of each of the anti-tussive compounds will be examined using a range of in 
vivo and in vitro animal models of cough and sensory nerve activation: 
• The efficacy of the compounds will be examined using an in vivo guinea pig 
model of tussive stimuli-evoked cough. 
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• The peripheral action of the compounds on airway sensory afferent nerves will be 
examined using an in vivo model of single airway fibre firing, and/or an in vitro 
model of calcium influx into isolated airway-terminating afferent neurons. 
• The mechanism of action of the compounds will be examined using a range of 
relevant pharmacological tools in an in vitro preparation of vagus nerve tissue 
from guinea pigs, or knock-out mice, as appropriate. 
• Furthermore, key experiments with the isolated vagus nerve technique will be 
repeated using human tissue, in order to confirm that the compounds sensory 
nerve activity and mechanism of action is relevant to humans. 
• Finally, where possible, the efficacy of the compounds will be examined in a 
guinea pig CS-exposure model that displays enhanced cough and sensory nerve 
responses to tussive stimuli. This will hopefully provide a more realistic indication 
of the likely efficacy of these compounds in the clinic, where any potential anti-
tussive would be expected to inhibit an enhanced cough reflex.  
 
1.5.3 Animals models of cough and sensory nerve activation 
In the evaluation of novel anti-tussives, appropriate non-human models are useful to 
validate the effectiveness of compounds prior to clinical trials (Mackenzie et al., 2004). As 
will be apparent from Section 1.2, animal models of evoked cough and sensory nerve 
activation have been used extensively to derive our knowledge of the airway afferent 
nerves involved in the cough reflex. These same models can be used to examine the 
efficacy of new anti-tussives, as well as their activity on the sensory nerves that evoke 
cough.  
 
Evoked cough 
In cats, dogs, rabbits and guinea pigs a cough response resembling the human reflex 
can be evoked by inhalation of the same chemical stimuli (capsaicin and CA) that are 
used to evoke cough in humans in clinical studies (Mackenzie et al., 2004). Which of 
these animals possesses a cough reflex most similar to humans is debatable; however, 
the European Respiratory Society Guidelines on the assessment of cough state “The 
most useful animal model of cough is the conscious guinea pig” (Morice et al., 2007a). 
This recommendation is based on the cost efficiency of using larger animals such as 
dogs, cats and rabbits – the guinea pig is the smallest species with a cough response 
similar to that observed in man (Mackenzie et al., 2004). Whilst they are commonly used 
in experimental research, rats and mice, are unsuitable for cough studies, as rats have 
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anatomically divergent afferent cough input compared to man, and mice do not cough 
(Korpáš & Tomori, 1979; Morice et al., 2007a).  
 
The most compelling evidence supporting the use of the guinea pig as a suitable model 
species for the evaluation of cough therapeutics is that guinea pigs and human subjects 
have similar cough reflex sensitivity to the most commonly used tussive stimuli (capsaicin 
and CA) used in clinical cough studies (Laude et al., 1993).  
 
Sensory nerve activation as a proxy for cough 
Models of sensory nerve activation have been developed in the guinea pig to examine 
the mechanisms by which the cough reflex is initiated (see Introduction 1.2). These 
models may be used to examine the action of anti-tussives on the activation of sensory 
nerves involved in evoking cough.  
 
Three different models of sensory nerve activation were selected for use in this thesis, 
which together allow a comprehensive examination of the action of compounds on 
sensory nerve activation: 
• Recording of the depolarisation in whole isolated vagus nerve trunks induced by 
tussive stimuli (see Methods 2.3). This in vitro technique allows relatively high-
throughput, cost-efficient pharmacological evaluation of the effect of anti-tussives 
on sensory nerve activation by the same stimuli that evoke cough in vivo. 
Furthermore, the same technique can be used to examine sensory nerve 
activation in human and mouse vagus nerves. This allows the translation of 
results into a relevant human tissue, and also the use of genetically modified 
knock-out mouse tissue. Whilst mice do not cough, in this preparation murine 
vagus nerves respond similarly to the same tussive stimuli as human and guinea 
pig vagus nerves.  
• Recording of calcium influx induced by tussive stimuli in isolated airway-
terminating single afferent neurons (see Methods 2.4). This in vitro technique 
allows determination of the effects of compounds specifically on individual 
airway-terminating neurons, rather than on all the nerve fibres in the vagus nerve, 
as in the isolated vagus nerve preparation.  
• Recording of in vivo single afferent nerve fibre firing evoked by aerosolised 
inhaled tussive stimuli (see Methods 2.5). This technique allows determination of 
the effect of compounds on individual nerve fibre types (e.g. C-fibre). Compared 
to the isolated vagus nerve and neuron techniques, this technique uniquely 
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allows determination of the effect of compounds acting on the nerve termini within 
the airways, and assesses action potential firing as an end-point.  
 
The principles and methodology of each of these techniques is discussed further in 
Chapter 2. 
 
Modeling the disease-modified cough reflex 
Using experimental animals, such as the guinea pig, in vivo models of enhanced 
capsaicin- and CA-induced cough and sensory nerve activation can be generated by 
exposing animals to cigarette smoke (Karlsson et al., 1991; Bergren, 2001a; Lewis et al., 
2007). It is thought that these models provide a good system to study COPD-enhanced 
cough, as they display a similar phenotype to COPD patients, induced by a relevant 
causal agent (Bolser, 2004). 
 
In the first published model of in vivo CS-enhanced cough responses, guinea pigs were 
exposed to cigarette smoke for 1h, twice daily, over two weeks, demonstrating enhanced 
cough sensitivity to capsaicin and CA (Karlsson et al., 1991). In a more chronic model of 
90 days (30min exposure/day), Bergren et al. (2001a) demonstrated similarly enhanced 
capsaicin-, and also BK-induced cough responses in guinea pigs.  
 
More recently, in the model developed by the Respiratory Pharmacology group (NHLI, 
Imperial College), guinea pigs exposed to CS for 1h, twice daily, for 8 days, showed 
enhanced capsaicin and CA cough responses. These enhanced cough responses 
corresponded with enhanced capsaicin and CA responsiveness of isolated vagus nerves 
from CS-exposed guinea pigs (Wortley et al., 2011). This model aims to mimic the 
enhanced cough reflex sensitivity observed in chronic cough patients, particularly chronic 
cough in COPD, where CS is the predominant risk factor for development for the 
disease.   
 
1.5.4 Outline of thesis structure 
This thesis has been organised in a modular fashion, with Chapters 3, 4, & 5 examining 
the anti-tussive efficacy and mechanisms of action of each class of compound separately 
using in vivo and in vitro models of cough and sensory nerve activation. In chapter 6, the 
efficacy of each compound will be examined in a guinea pig model of enhanced sensory 
nerve activation and cough induced by CS-exposure.  
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2.1 Human and animal tissue; ethics & welfare 
Male Dunkin Hartley guinea pigs and male C57Bl/6 mice were purchased from Harlan 
(Bicester, UK). Experiments were approved by the Imperial College London Ethical 
Review Process committee, and performed in accordance with the UK Home Office 
guidelines for welfare based on the Animals (Scientific Procedures) Act 1986, under a 
Home Office project licence (PPL 70/7212). 
 
Human vagus, as part of whole or partial lung tissues, was received from either the 
Harefield Hospital (HH: London, UK), or from various locations in the US via the 
International Institute for the Advancement of Medicine (IIAM: NJ, US). Tissue received 
from HH was either recipient or donor tissue unsuitable for transplant. Tissue received 
from IIAM was donor tissue unsuitable for transplant. Tissue received from all locations 
was approved by local Human Tissue Ethics Committee.  
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2.2 In vivo cough challenge and cough counting 
Guinea pigs were exposed to an aerosolised tussive agent (capsaicin or CA) for set 
periods of time, with the numbers of coughs recorded. At a set time before cough was 
evoked/recorded, animals could be dosed with a test compounds in order to evaluate the 
anti-tussive effect of the compound on either naïve, or on CS-enhanced cough. 
 
2.2.1 Cough challenge apparatus 
Two Perspex plethysmography chambers (Buxco, US) were connected to a central 
Aerogen nebuliser (Buxco, US) as illustrated in Figure 2.1. A conscious, unrestrained 
guinea pig was placed into each of the chambers, so that the two animals could be 
simultaneously challenged with aerosolised solution of tussive agent, dispersed from the 
nebuliser into the two chambers. The aerosolised tussive agent was administered for 5 
minutes, after which the nebuliser was set to remove the aerosol from the chambers. The 
number of coughs was recorded for 10 minutes in total, with the recording time 
commencing at the start of nebulisation, and continuing for 5 minutes after the end of 
nebulisation. 
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Figure 2.1 Diagram of apparatus for objective cough counting 
Animals were placed in plethysmography chambers (see picture top left, cartoon bottom 
left), into which an aerosol of tussive agent was nebulised). Plethysmography chambers 
were fitted with a microphone and pressure transducer connected to a computer to 
visualise breathing patterns (top right). Coughs were manually counted by listening to the 
speaker output from the microphones, confirmed by observing the characteristic posture 
of the animals and spike in breathing pattern on the computer monitor. 
 
2.2.2 Data Recording 
Microphones, present in both chambers, were connected to an amplifier, and thence to 
both a speaker and a computer running cough analyser software (Buxco, USA). In this 
way, coughs were recorded by software analysis of an explosive cough signature, and 
confirmed by a trained observer comparing the sound output to the characteristic opening 
of the mouth, and the altered stance and posture of the animal. 
 
Figure 2.1. Diagram of apparatus for objective cough counting 
Animals were placed in plethysmography chambers (see picture top left, 
cartoon bottom left), into which an aerosol of tussive agent was 
nebulised). Plethysmography chambers were fitted with a microphone and 
pressure transducer connected to a computer to visualise breathing 
patterns (top right). Coughs were manually counted by listening to the 
speaker output from the microphones, confirmed by observing the 
characteristic posture of the animals and spike in breathing pattern on the 
computer monitor. 
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breathing pattern 
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2.3 Isolated vagus nerve recordings 
In vivo cough experiments in guinea pigs can be expensive, and require the use of 
multiple animals per group for a single concentration of a drug. The isolated vagus 
recording system described in this section has some advantages in the pharmacological 
evaluation of potential anti-tussives, allowing multiple drugs and concentrations to be 
evaluated in a single animal. Another significant advantage is that isolated vagus nerve 
from multiple species, including guinea pigs, humans and mice can also be used. Thus 
guinea pig tissue can be used to parallel cough experiments, human tissue can be used 
to determine whether findings translate to humans, and the use of mouse tissue allows 
examination of the effectiveness of compounds in tissue from genetic knock-out animals 
for specific proteins (receptors/ion channels etc). Whilst mice do not cough, the vagus 
nerve of mice has been shown to respond to the same agents that stimulate both a 
response in guinea pig vagus, and also cause cough in guinea pigs (Maher et al., 2009; 
Grace et al., 2012). 
 
 2.3.1 Vagal nerve dissection 
Human tissue 
Human whole lungs were received either dry (Harefield Hospital within 3h of transplant) 
or in isotonic saline (US locations, within 48h of cross-clamp) on ice. On receipt, the 
whole lungs were immersed in modified KH (prepared as in previous section) solution 
which was bubbled with 95% O2, 5% CO2. The vagal nerves were identified running 
parallel to the trachea and bronchi, and dissected from the lungs. Extraneous connective 
tissue was then removed, and the resultant nerve tissue was then de-sheathed. The 
resultant human vagus nerve was then cut into 10-15mm long sections for use in the 
recording apparatus. Care was taken during dissection and for the duration of the 
experiments to ensure that the vagus nerve was not crushed or stretched, and remained 
in oxygenated KH solution.  
 
Animal tissue 
Guinea pigs and mice were sacrificed by injection of pentobarbitone (200mg.kg-1, i.p.), 
following which a midline incision was made to remove the skin on the dorsal side of the 
thorax. The ribcage, thyroid and connective tissue and smooth muscle above the vagus 
nerve were then removed to reveal the vagal nerves running from the base of the skull to 
the heart. Both vagal nerves – caudal to the nodose ganglion and proximal to the heart – 
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were removed, and placed into modified KH (prepared as in previous section) solution 
which was bubbled with 95% O2, 5% CO2. The nerve tissue was then cleared of any 
remaining connective tissue, de-sheathed, and cut into sections 10-15mm long. Care 
was taken throughout dissection and experimentation to ensure that the vagus nerve was 
not crushed or stretched, and remained in oxygenated KH solution.  
 
2.3.2 Apparatus/principles 
Dissected pieces of vagal nerve were mounted in a grease-gap recording chamber (Fig. 
2.2) by drawing nerves through a narrow channel (2 mm diameter, 10 mm long) within a 
Perspex block (custom made). Petroleum jelly was carefully injected through a side-port 
into the center of this channel – extending approx. 4-6mm along the channel – thus 
providing an area of high resistance that electrically and chemically isolated the two ends 
of the nerve. A hollow glass rod of 1.5mm diameter was inserted into a Ag/AgCl-pellet 
half-cell electrode (Mere 2 flexible electrodes, WPI, UK), with the air-spaces carefully 
filled with KH solution to avoid air bubbles. The end of the glass rod was then positioned 
to made contact with one end of the nerve, with a similarly prepared electrode making 
contact with the opposite end. The electrodes were connected to a DAM50 amplifier unit 
(WPI, UK), which amplified the DC potential signal (x10 gain, high filter 1KHz, 5Hz 
sample rate). The amplified signal was then recorded on a chart recorder (LectroMed 2, 
LectroMed, UK [now Digitimer, UK]). One end of the nerve was constantly perfused with 
KH solution at a rate of 2ml.min-1 to allow delivery of stimuli and test compounds; the 
other end remained in a chamber containing KH. KH was bubbled with 95% O2/5% CO2 
and maintained at 37oC using a thermal jacket and water bath. 
KH and compounds dissolved in KH were placed in containers situated above the 
Perspex chamber, and were perfused through a water jacketed section of rubber tubing, 
with an in-line switch to select which solution to perfuse (Fig. 2.2).  
 
This system does not directly measure action potentials or firing of the nerve, instead it 
indirectly measures the compound depolarisation of the membranes of all the nerve 
fibres within the vagus nerve, by recording the difference in the ionic potential of the two 
ends of the nerve. In the nerve ending that is exposed to perfusate containing an 
activating ligand at sufficient concentration to cause depolarisation there is an influx of 
predominantly sodium ions from the extracellular KH solution (from high Na+) in to the 
axon cytosol (to low Na+) (see Introduction 1.1.1); however, the net effect of the 
movement of ions during depolarisation of a nerve is a lowered concentration of positive 
ions in the KH solution within the glass tube near the Ag/AgCl electrode, which leaves the 
Cl- ions in a ‘freer’ state to react with the electrode pellet. The difference between the 
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increased potential on the electrode at this perfused end of the nerve, and the unaltered 
equilibrium at the opposite end of the nerve is amplified and recorded by the chart 
recorder.  
 
Figure 2.2 Diagram of apparatus for isolated vagus nerve depolarisation 
recordings 
Vagus nerve dissected from guinea pigs or mice was drawn into a channel in a perspex 
chamber filled with KH solution. KH was constantly perfused onto the left side of the 
nerve through a section of water-jacketed tubing, maintaining the perfusate at 37°C. A 
series of switches allowed changing of the perfusate from KH alone to various 
compounds or combinations of compounds dissolved in KH. Ag/AgCl half-cell electrodes 
were placed in contact with both sides of the vagus nerve, which were electrically 
isolated by injecting petroleum jelly into the centre of the channel. The signal from the 
electrodes was passed through an amplifier and the resulting signal was output onto a 
chart recorder. 
 
There are three potential caveats to note when considering the results obtained using 
this apparatus: firstly, that the depolarisation measured is not necessarily equal to firing 
of the nerve fibre, as a depolarisation may not be of sufficient magnitude to generate an 
action potential. Secondly, the vagus nerve supplies innervating fibres not just to the 
airways, but also to other mid-line organs such as the heart and gut. Thirdly, the cell 
bodies and nerve termini are not present in the isolated vagus trunks, and there may be 
differences between the receptors and associated signaling proteins in the plasma 
membranes of the nerve terminus and the nerve axon. 
Figure 2.2. Diagram of apparatus for isolated vagus nerve 
depolarisation recordings 
Vagus nerve dissected from guinea pigs or mice was drawn into a channel 
in a perspex chamber filled with KH solution. KH was constantly perfused 
onto the left side of the nerve through a section of water-jacketed tubing, 
maintaining the perfusate at 37°C. A series of switches allowed changing 
of the perfusate from KH alone to various compounds or combinations of 
compounds dissolved in KH. Ag/AgCl half-cell electrodes were placed in 
contact with both sides of the vagus nerve, which were electrically isolated 
by injecting petroleum jelly into the centre of the channel. The signal from 
the electrodes was passed through an amplifier and the resulting signal 
was output onto a chart recorder. 
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However, despite these caveats, it should be noted that there is a good correlation 
between the compounds that activate the vagus nerve in this apparatus, also cause 
cough in vivo, whilst those that inhibit induced depolarisation also inhibit induced cough 
(Birrell et al., 2009; Freund-Michel et al., 2010; Grace et al., 2012). This system is also 
amenable to pharmacology that would be difficult & expensive in vivo, and has the further 
advantage that as the nerve is isolated the effects of potential anti-tussive drugs may be 
considered for their effect on sensory nerves, separate from any bronchodilator effects. 
Furthermore, it should be noted that where practicable key experiments were performed 
using calcium imaging of isolated airway-terminating neuronal cell bodies, recording of 
action potentials in in vivo single chemosensitive airway-terminating C-fibres, and most 
importantly, in vivo cough.  
 
2.3.3 Measurements/recording protocol 
The following protocol was used to measure either depolarisation/stimulation, or inhibition 
of stimulation of the vagus nerve, with variations in incubation timings and concentrations 
of drugs.  
 
For examining a compound for potential anti-tussive activity, the following protocol was 
used to assess inhibition of depolarisation by a stimulating agent such as capsaicin. Two 
to three control stimulations were performed (incubation with drug for 2 min, ‘wash’ to 
baseline with KH, repeat) to give two consecutive depolarisations of consistent 
magnitude. Following wash of the final control stimulation, the test compound was 
incubated (by constant perfusion) for at least 10 min (incubation times varied for each 
compound – see relevant results chapter for details). Following incubation, both 
stimulating agent and test compound were perfused onto the nerve for 2 min, following 
which the nerve was perfused with KH alone for 10 min to ‘wash’ any remaining 
compound(s) from the nerve. The nerve was then perfused with stimulating agent alone 
for 2 min, with this final stimulation serving to demonstrate that the test compound can at 
least be partially washed off, and that the nerve remains viable at the conclusion of the 
experiment. Only one concentration of any single test compound was examined on any 
single piece of nerve, from any one individual animal or patient. 
 
2.3.4 Data recording 
The chart recorder was calibrated using a 1mV pulse from the pre-amplifiers to set a 
scale of 1cm:0.1mV. A measurement was taken of the distance from the baseline prior to 
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application of stimulating agent (i.e. capsaicin) to the peak of a response following 
application to calculate the magnitude of depolarisation. For inhibition studies, the 
average magnitude of two consistent control stimulations (within 10% of each other) was 
taken. The magnitude of depolarisation in the presence of test compound(s) was then 
compared to the control stimulation to give percentage inhibition, according to the 
equation given in Methods 2.9. 
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2.4 Isolated neuron recordings 
The general premise of this technique was to assess the effect of potential anti-tussives 
on intracellular calcium increases in isolated primary airway-terminating single 
chemosensitive neurons. Whilst this is also an in vitro technique, it allowed examination 
of the effect of the test compounds in only neurons that had airway terminating 
processes, rather than on all the nerve fibres in the vagus nerve, as in the isolated vagus 
recordings. This methodology used in this section is similar to that described in Dubuis et 
al. (In Press), and Grace et al. (2012).  
 
2.4.1 Staining of airway-terminating neurons 
Male Dunkin Hartley guinea pigs (250-400g) were i.n. dosed with 1ml.kg-1 of solution of 
DiI (DiIC18 3 1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbo-cyanine perchlorate, 0.15 
mg.ml-1). DiI was dissolved in 100% ethanol and diluted on the day of use to give a final 
vehicle of 2%v/v ethanol in 0.9% saline. DiI is a lipophilic fluorophore that passively 
integrates into the outer lipid layer of plasma membranes. Once in the airways, the dye 
enters the outer layer of the plasma membrane of any cells with which it comes in 
contact, including neurons with termini in and very proximal to the airways (e.g. within 
epithelium). The dye then diffuses laterally in 2 dimensions across the whole cell 
membrane, including in a retrograde direction along nerve axons, to the cell bodies in the 
sensory ganglia that supply the airways; primarily nodose and jugular neurons (Hofmann 
& Bleckmann, 1999). Guinea pigs were dosed with DiI 2-3 weeks prior to 
experimentation; this allowed time for the dye to reach the plasma membrane around the 
cell bodies, with a reported rate of diffusion along axolemma of approximately 6mm per 
day (Lukas et al., 1998), but reduced the potential for trans-neuronal diffusion of the dye 
into the membranes of non-airway terminating neurons (Hofmann & Bleckmann, 1999; 
Lieu et al., 2012).  
2.4.2 Ganglia cell dissection and neuron dissociation 
Guinea pigs were killed by injection of sodium pentobarbitone (200 mg.kg-1 i.p.). The skin 
was removed from the head of the animal, and the sternocleidomastoid and trapezius 
muscles were removed. Then the jawbone was cut and remaining connective tissues 
were removed from the lateral sides and dorsal portion of the skull. A hole was made in 
the skull at the intersection of the interparietal and parietal bones, which was expanded 
to remove a section of the skull by cutting laterally across the parietal bones, and then 
along the frontal ridge above the eyes. The cerebellum was then removed by carefully 
cutting its connections to the optical and aural nerves, and the spinal cord. Inverted ‘V’ 
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shaped cuts were then made in the squamosal and occipital bones immediately anterior 
and posterior to the tympanic bulla. The tympanic bulla on one side of the animal was 
then levered partially out of the skull, whilst carefully cutting any connective tissues, to 
reveal the nodose and jugular ganglia lying on the occipital bone underneath the 
tympanic bulla. The jugular and nodose ganglia were identified by both their position and 
their characteristic shapes, as described below and illustrated in Fig. 2.3. The nodose 
ganglion is more distal to the cerebellum, and is ovoid in shape with a slightly striated 
appearance. It is connected directly to the jugular ganglion, which is approximately 4mm 
more caudal to the cerebellum, and possesses a more triangular shape, with a ‘starburst’ 
of connected nerves. The membrane covering the jugular ganglion was carefully 
shredded to allow the removal of the ganglion, which was then placed in ice cold HBSS  
 
 
Figure 2.3 Anatomy of guinea pig vagal nerves and ganglia 
[A] Location of cuts to remove the ear bone (tympanic bulla). [B] location of jugular and 
nodose ganglia once the ear bone has been removed. [C] Illustration, and [D] photograph 
of the shape of the dissected nodose and jugular ganglia (highlighted in red in the 
illustration). [A-C] reproduced from Dubuis et al. (2013) Curr. Prot. Pharmacol. In press 
[D] Photograph reproduced from Nassenstein et al. (2010) J Physiol 588 (23) 4769–
4783.  
 
Figure 2.3. Anatomy of guinea pig vagus nerve/ganglia location 
a) Location of cuts to remove the ear bone (tympanic bulla). b) location of 
jugular and nodose ganglia once the ear bone has been removed. c) 
Illustration, and d) photograph of the shape of the dissected nodose and 
jugular ganglia (highlighted in red in the illustration). a-c) resproduced 
from Dubuis et al., (2013) Curr. Prot. Pharmacol. In press d) Photograph 
reproduced from Nassenstein et al., (2010) J Physiol 588 (23) 4769–4783.  
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Figure 1. Dissection of the vagal ganglia in guinea pigs and mice
The right vagus and accompanying ganglia were dissected in guinea pigs (left photograph) and mice (right
photograph). Compared to the guinea pig in which the nodose and the jugular ganglion are clearly separated,
mice possess a fused jugular nodose complex.
of the ganglion whereas the caudal pole of the ganglion
comprised non-neural crest (placodal) neurons. In several
ganglia, a significant number of neural crest neurons were
observed down to the cent al body of the ganglion (Fig. 2).
In about 1 in 3 mice a jugular ganglion, entirely consisting
of neural crest derived cells, can be recognized as the top
half of an hourglass like structure on the vagus.
Calcium imaging
In a previous study with guinea pigs we noted that
the nodose C-fibre terminals in the respiratory tract
responded strongly with action potential discharge to
the P2X-2/3 selective agonist α,β-methylene ATP, whereas
the jugular neurons were categorically unresponsive. We
also noted at the level of the cell body that the nodose
neurons responded to ATP or α,β-methylene ATP with
a large persistent inward current that was explained by
the presence of both P2X2 and P2X3 receptors. Jugular
neurons expressed P2X3 but not P2X2 receptors and
responded to ATP with a very transient inward current,
which is consistent with the current signature of P2X3
homomeric receptors (Kwong et al. 2008).
We evaluated the α,β-methylene ATP responsiveness in
mouse vagal ganglion neurons. Using the Wnt1Cre/R26R
mice, we dissociated the vagal ganglion complex (8
ganglia from 4 mice) and evaluated the calcium
rise in β-galactosidase+ neural crest neurons and
in β-galactosidase− placodal neurons. About 58%
Figure 2. X-Gal staining of the jugular nodose
complex in mice
In order to evaluate the localization of neural crest
derived and placodal neurons within the jugular–nodose
complex, X-Gal staining was performed in
Wnt1Cre/R26R mice. Neural crest derived cells formed
the rostral pole of the ganglion whereas the body and
caudal pole of the ganglion comprised the placodal cells
(A–D). A jugular ganglion, entirely consisting of neural
crest derived cells, can be recognized as the top half of
an hourglass like structure on the vagus in some ganglia
(C and D).
C⃝ 2010 The Authors. Journal compilation C⃝ 2010 The Physiological Society
) at IMPERIAL COLLEGE LONDON on July 28, 2011jp.physoc.orgDownloaded from J Physiol (
a b 
c d 
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(mM: KCl, 5.33; KH2PO4, 0.441; NaCl, 138; Na2HPO4.7H2O, 0.3; glucose, 5.6; HEPES, 5; 
pH 7.4). The remaining jugular ganglion underneath the opposite tympanic bulla was 
then collected in the same manner. 
 
The jugular ganglia were placed onto a glass petri dish in HBSS at room temperature, 
and were freed of connective tissues under a microscope at 2x magnification. The 
ganglia were then cut into quarters to expose the inside of the ganglion. In order to 
isolate sufficient neurons, both ganglia from a single animal were digested together 
during the following enzymatic digestion process. A two-step process of incubation with 
papain and then collagenase/dispase enzymes was used to break down extracellular 
matric proteins and collagen. Ganglia were then placed in Papain Activating Solution 
(PAS; L-Cysteine, 0.04%w/v; EDTA, 0.5mM; CaCl2, 1.5mM; in HBSS) which had been 
pre-incubated with Papain (200U.ml-1) for 30 min at 37°C. The papain solution containing 
the ganglia was gently agitated every 5min, and after exactly 30min was centrifuged for 
2min at 1400rpm and 22°C. The papain solution was then removed carefully, and the 
ganglia were incubated in a collagenase/dispase solution (collagenase IV, 10mg.ml-1; 
dispase II, 12mg.ml-1; in HBSS) for 40min at 37°C, again with gentle agitation every 5 
min. Cells were then centrifuged again for 2min at 1400rpm and 22°C to allow removal of 
supernatant. A trituration process was then used to break up any remaining larger 
(visible) clumps of cells. Cells were resuspended in HBSS, and glass Pasteur pipettes 
with successively smaller tip sizes (ranging from 1-0.3mm) was used to agitate larger 
clumps of cells until they could no longer be seen. The solution of cells was then pipetted 
into L15 medium containing Percoll (20%v/v), which was then centrifuged for 9min, at 
1400rpm and 22°C in order to separate cells from any remaining larger cellular fascia. 
Supernatant was aspirated and the pellet was resuspended in L15 medium, before 
another being centrifuged again for 3min at 2300rpm and 22°C. The supernatant was 
then removed, and cells were resuspended in complete F-12 medium (containing 10%v/v 
FBS, 100U.ml-1 penicillin, and 0.1mg.ml-1 streptomycin). Plastic cell culture dishes (PA, 
US) used for fluorescence microscopy (hereafter referred to as fluorodishes) were 
prepared 24h previously, by applying (0.01%w/v) poly-d-lysine for 2h, followed by laminin 
(31.25µg.ml-1) for 22h, both in HBSS, to the base of the fluorodishes 24h prior to isolation 
of neurons, in order to aid cell adherence. The remaining laminin solution was then 
removed and the base of the dish was washed with HBSS, before 20µl of resuspended 
cells in complete F-12 was carefully placed into the centre of the fluorodish. The cells 
were incubated for 2h at 37°C (95% O2, 5% CO2) to allow adherence to the Poly-D-
Lysine/laminin-coated centre of the fluorodish, before a further 2ml of complete F-12 
media was added and cells were incubated overnight at 37°C (95% O2, 5% CO2).  
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2.4.3 Fluorescence imaging dyes 
Within 24h of isolation, neurons were loaded with the calcium-binding fluorophore Fura2. 
Fura2 was selected to avoid overlapping excitation and emission wavelengths with the 
DiI already present in the cell membranes of the airway terminating neurons (Table 2.1). 
 
 
Table 2.1 Maximum excitation/emission wavelengths for imaging dyes 
 
Fura2 is a ratiometric Ca2+-binding dye with two excitation/emission profiles for its Ca2+-
bound and -unbound states (Table 2.1). Both Ca2+-bound and Ca2+-unbound excitation 
wavelengths were used in fast sequence to generate the two respective emission 
profiles, and the levels of the two emissions related, to give an arbitrary unit of Ca2+-
bound Fura2 dye as a proportion of the total Fura2. The use of a ratiometric dye negates 
the variability associated with local differences in concentration of the dye and thickness 
of the cell. Cells were incubated with 3µM Fura2-AM in extracellular solution (ECS – KCl, 
5.4; NaCl, 136; MgCl2, 1; CaCl2, 1.8; NaH2PO4, 0.33, D-glucose, 10; HEPES, 10; all mM 
in dH2O; pH to 7.4 at 37°C with NaOH) for 40 min at room temperature in the dark. 
Fura2-AM is the esterified form of Fura2, which is hydrophobic, allowing passive 
movement through cell membranes into the cytoplasm. Once in the cytoplasm, 
intracellular esterases present in the cytosol cleave the hydrophobic AM (acetoxymethyl 
ester) group, leaving Fura2, which is then unable to pass back out through the cell 
membrane. The Fura2-AM solution was then aspirated, and the cells were incubated with 
ECS for a further 30min in the dark at room temperature, to allow the dye to be fully de-
esterified (Takahashi et al., 1999).  
 
2.4.4 Apparatus/recording principles 
Once neurons had been isolated from jugular ganglia and loaded with fluorescent dyes, 
they were then placed onto the stage of an inverted epi-fluorescence type microscope 
(Zeiss Axiovert 200, Carl Zeiss Microscopy, UK). The microscope was mounted on an 
anti-vibration table (TMC 63-500, Scientifica, UK) and the microscope stage was 
surrounded by an incubation chamber (XL-3 Incubator, Carl Zeiss Microscopy, UK) 
maintained at 37°C and 5% CO2. An epi-illuminator (HBO 50 100W Mercury/Xenon arc 
Dye name Localised to Responds to Max excitation λ Max emission λ 
DiI Plasmalemma n/a 550nm 570nm 
Fura2 (Ca2+-bound) Cytoplasm Ca2+ binding 340nm 520nm 
Fura2 (unbound) Cytoplasm Ca2+ binding 380nm 480nm 
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lamp, Carl Zeiss microscopy, UK) and a tungsten-halogen lamp with heat filter (HXP 100, 
Carl Zeiss microscopy, UK) were used as light sources for bright-field phase contrast 
illumination. Sets of dichromatic mirrors and filters (given in Table 2.2) were used to 
excite the fluorescent dyes and record emissions at the appropriate wavelengths (see 
Table 2.1), with an Optoscan monochromator (Cairn Research, UK) used to rapidly 
change the wavelength of the excitation light.  
 
Dye name Excitation filter Mirror Emission filter 
DiI BP 531/40 BS 565 BP 593/40 
Fura2 (Ca2+-bound) BP335/7 BS 410 BP 520/10 
Fura2 (unbound) BP 387/11 BS 410 BP 520/10 
Table 2.2 Filters and mirrors used to excite and record emissions from fluorescent 
dyes (Carl Zeiss Microscopy, UK) 
 
Neurons were observed using an air objective 20x magnification lens (LD Plan-Neofluar 
KORR air objective 0.4f aperture 7.9mm focal distance, Carl Zeiss Microscopy, UK). A 
cooled fast-acquisition CCD camera was used to view and record images from the 
microscope on a computer using the Simple-PCI software suite (Hamamatsu Corp., 
USA). Simple-PCI was also used to control the filters and shutter during the experimental 
protocol. Focus was locked during the experimental recording, as variations in focus may 
cause differences in the light intensity recorded. In order to avoid photo-bleaching – 
degradation of the dye when exposed to light for longer periods – exposure times of 
200ms (Ca2+-bound) and 10ms (Ca2+-unbound) were used for excitation of Fura-2 during 
the experiment. The software was set to alternate the filters to expose the neurons in 
sequence to the excitation light for Ca2+-bound Fura-2, then immediately afterwards 
(within 100ms) to Ca2+-unbound Fura-2, recording the emission from each excitation as 
an image. One image was taken of emission from Ca2+-bound and Ca2+-unbound every 
5s (or 30s during longer incubation periods) during the experimental protocol described 
below. In this way, two parallel series of both Ca2+-bound and Ca2+-unbound Fura-2 
emissions were recorded over the course of the experimental protocol.  
 
Within the incubation chamber, a perfusion system for the delivery of ECS containing the 
different compounds to be used was set up. This custom-made delivery system was 
designed to rapidly switch between perfusion of different compounds, allowing a 
complete change of the solution bathing the cells in 3s, whilst maintaining a constant 
volume of 600µl in the fluorodish (Fig. 2.4). All solutions were maintained at 37°C and 5% 
CO2 during the experimental protocol described in the following section. 
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Figure 2.4 Diagram of apparatus for [Ca2+]i imaging of isolated neurons 
Isolated jugular ganglion neurons adhering to a laminin-coated fluorodish were placed 
onto a microscope stage. Airway-terminating neurons were identified by shape, size and 
presence of DiI staining. The microscope was set to record a series of time lapse images 
of Fura-2 calcium dye emission, whilst ECS alone, or ECS containing dissolved 
compounds was perfused from sealed tubes into the fluorodish by positive air pressure. 
Solutions were removed from the opposite side of the fluorosdish to a sealed waste 
container using negative air pressure, maintaining a volume of 600 µl in the fluorodish. All 
equipment illustrated, except filter wheel, dichromic mirrors and sealed waste container 
were within an incubator hood maintained at 37°C and 5% CO2.  
 
2.4.5 Measurements/recording protocol 
Fluorodishes of isolated jugular ganglion cells were mounted on the microscope stage, 
and neurons were focused in the field of view using bright-field illumination at 20x 
magnification. Cells were then excited with the correct wavelength of light for DiI, in order 
to identify those cells that contained the dye, and were therefore the cell bodies of 
airway-terminating neurons. The field of view was then adjusted as required to fit as 
many airway-terminating cells in one field as possible. Once the field of view had been 
selected, the focus was adjusted and locked for the recording protocol. The Simple PCI 
software was then set to record a series of time-lapse images of Fura-2 emissions as 
described in the previous section.  
 
Neurons were first exposed to ECS containing 50mM of potassium chloride (K50: KCl, 50; 
NaCl, 91.4; MgCl2, 1; CaCl2, 2.5; NaH2PO4, 0.33, D-glucose, 10; HEPES, 10; all mM in 
Figure 2.4. Diagram of apparatus for calcium imaging of isolated 
neurons 
Isolated jugular ganglion neurons adhering to a laminin-coated fluorodish 
were placed onto a microscope stage. Airway-terminating neurons were 
identified by shape, size and presence of DiI staining. The microscope 
was set to record a series of time lapse images of Fura-2 calcium dye 
emission, whilst ECS alone, or ECS containing dissolved compounds was 
perfused from sealed tubes into the fluorodish by positive air pressure. 
Solutions were removed from the opposite side of the fluorosdish to a 
sealed waste container using negative air pressure, maintaining a volume 
of 600 µl in the fluorodish. All equipment illustrated, except filter wheel, 
dichromic mirrors and sealed waste container were within an incubator 
hood maintained at 37°C and 5% CO2.  
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dH2O; pH to 7.4 at 37°C with NaOH) for 15s, which induces a depolarisation of the cell 
membrane, via an increase in intracellular calcium. Neurons were then perfused with 
ECS (‘wash’) until Fura-2 emission levels returned to baseline. This initial stimulation with 
K50 was used as a control response, to which all further responses were normalised. 
Neurons were then perfused with the tussive agent for 30s, to induce an increase in 
intracellular calcium, which was washed to baseline by perfusion with ECS. A second 
response to the tussive agent was then induced in the same manner, before the potential 
anti-tussive drug being tested was perfused and then incubated with the cells for an 
appropriate period (incubation times varied for each compound – see relevant results 
chapter for details). Following incubation, both tussive agent and test compound were 
perfused together for 30s, following which any response was washed by perfusion with 
ECS for 5min. The neurons were then perfused with the tussive agent alone for 30s, with 
this final tussive agent stimulation serving to demonstrate that the test compound can at 
least be partially washed off. Finally, after a wash to baseline with ECS, another K50 
stimulation was performed, and this final stimulation with K50 was compared to the initial 
K50 response, in order to confirm that the neurons remained viable at the end of the 
experiment. Only one concentration of any single test compound was examined on any 
single piece of nerve, from any one individual animal or patient. 
 
2.4.6 Data recording 
As described in Methods 2.5.4, data was recorded by Simple-PCI software as two 
parallel set of images (image stacks) showing, respectively, emissions of Fura-2 excited 
at the relevant wavelengths for Ca2+-unbound and Ca2+-bound forms of the dye. In order 
to quantitate the levels of emission from individual cells, each cell was individually 
selected using ImageJ (64-bit, version 1.43u, NIH, USA), along with a representative 
equivalent size area of background. The software then quantified the light emission level 
of each selected area for each image in the sequence (each frame), and the data was 
output to MS Excel (version 14.2.5, Microsoft, USA). The emission value for each cell 
then had the background light level from the same frame subtracted. For each cell, this 
left two series of quantified numbers for emission levels of Ca2+-unbound and Ca2+-bound 
forms of Fura-2. The light emitted by Ca2+-bound Fura-2 was then divided by the light 
emitted by Ca2+-unbound Fura-2 to generate a sequence of values for each frame in the 
recording. The use of this ratio corrects for any degradation of the dye due to photo-
bleaching over longer recordings, and also for inter-experimental differences in loading 
efficiency of Fura-2. The sequence of ratios was then input to the Origin software 
package (version 8.6, OriginLabs Corp., USA), along with the time-stamp for each frame, 
in order to generate a graph of emission ratio over time. The graph was then used to 
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calculate Area Under the Curve (AUC) for each response to tussive agent stimulation. 
AUC was preferred over peak magnitude to take into account the multiphasic shape of 
the calcium responses.  
All AUC values for each cell were then normalised as a percentage of the size of the 
initial K50 response for the same cell, as described in Methods 2.9.1.  
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2.5 In vivo single afferent fibre recording 
The general premise of this technique was to assess the effect of potential anti-tussive 
compounds on the in vivo firing activity of a single afferent airway-terminating C-fibre in 
response to capsaicin. This technique has the advantage of the compounds acting on the 
nerve termini, where action potentials would normally be evoked by tussive stimuli, and 
measuring nerve firing as an end-point, compared to the isolated vagus nerve and 
neuron experiments described previously.  
 
2.5.1 Surgery and apparatus 
Male Dunkin Hartley guinea pigs (400–750g, Harlan, UK) were anaesthetised with 
urethane (i.p. 1.5g.kg-1), supplemented with additional urethane as required. The animal 
was then ventilated, and surgery was performed to setup the nerve fibre recording 
system, as described below and in Adcock et al. (2003), and summarised in Figure 2.5. 
The trachea was cannulated to maintain blood gases and pH at physiological levels by 
artificial ventilation (Ugo Basile small animal ventilator – tidal volume 10ml.kg-1, 50-60 
breaths.min-1 room air). A nebuliser (Aerogen nebuliser, Buxco) was connected via a side 
arm in line with the ventilator and tracheal cannula, for the delivery of aerosolised vehicle 
or drugs to the airways. The right carotid artery was cannulated (passed to the ascending 
aorta/aortic arch) to continuously measure systemic arterial blood pressure and heart 
rate using the Spike2 software data acquisition system via a CED Micro1401 interface. 
The same software also recorded tracheal pressure from a pressure transducer 
connected to a side arm of the tracheal cannula. Body temperature was monitored with a 
rectal thermometer, and maintained at 37ºC with a heated blanket and control unit 
(Harvard Apparatus, UK). Animals were paralysed by vecuronium bromide, initially 
administered at a dose of 0.10 mg kg-1 (i.v. into cannulated right jugular vein), followed 
every 20min with 0.05mg kg-1 i.v. to maintain paralysis. The depth of anaesthesia was 
assessed throughout the experimental protocol by monitoring heart rate and blood 
pressure. 
 
A cervical incision was made to locate the cervical vagus nerves, which were dissected 
free from the carotid artery, sympathetic and aortic nerves and then cut at the central 
end. The left vagus nerve was cleared of its surrounding fascia for sensory nerve fibre 
recording. The skin and muscle in the neck around the cervical incision were tied to a 
metal ring to form a well, which was filled with light mineral oil. Thin filaments of nerve  
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Figure 2.5 Diagram of apparatus for single fibre nerve recordings 
Top: Anaesthetised guinea pigs were carefully dissected to reveal the vagus nerves, 
which were both cut posterior to the vagal ganglia. The left vagus nerve was teased, and 
a single nerve was placed onto a platinum recording electrode, connected to a digital 
oscilloscope, outputted to Spike2 software on a computer to record nerve action 
potentials. Animals were ventilated and tracheal pressure was monitored via an intra-
tracheal cannula. Nebulised drugs were delivered via a side-arm of the tracheal cannula. 
Bottom: representative traces showing effect of capsaicin on tracheal pressure and 
action potentials. 
 
were teased from the vagus nerve, under a binocular microscope, until a single nerve 
fibre was left. Bipolar Teflon-coated platinum electrodes (exposed at the tips) were used 
for recording purposes, with the single nerve fibre positioned on the recording electrode, 
and the reference electrode placed on the nerve fascia. Electrodes were connected to a 
pre-amplifier head-stage (Digitimer NL100K) to record action potentials. The signal was 
amplified (Digitimer NL104), filtered (Digitimer NL125) and passed through a Humbug 
noise reducer (AutoMate Scientific) before input into the Micro1401 interface and the 
Spike2 software and monitored on a digital storage oscilloscope (Tektronix DPO 2012). 
The software allows pulse train counting over selected time periods. The input signal is 
also fed through an audio amplifier to a loud speaker.  
 
Figure 2.5. Diagram of apparatus for single fibre nerve recordings 
Top: Anaesthetised guinea pigs were carefully dissected to reveal the 
vagus nerves, which were both cut posterior to the vagal ganglia. The left 
vagus nerve was teased, and a single nerve was placed onto a platinum 
recording electrode, connected to a digital oscilloscope, outputted to 
spike2 software on a computer to record nerve action potentials. Animals 
were ventilated and tracheal pressure was monitored via an intra-tracheal 
cannula. Nebulised drugs were delivered via a side-arm of the tracheal 
cannula. Bottom: representative traces showing effect of capsaicin on 
tracheal pressure and action potentials 
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Conduction velocities were measured to distinguish slow-conducting non-myelinated C-
fibres from fast-conducting myelinated Aδ-fibres. Conduction velocity was measured by 
stimulation of the vagus nerve close to the thorax with bipolar silver electrodes, using a 
supra threshold voltage at 0.5ms, 1Hz (Grass stimulator) and relating the time from 
stimulus to response to the measured distance between stimulating and recording 
electrode.  
 
2.5.2 Nerve fibre identification 
As discussed in Introduction 1.2, sensory nerves innervating the lungs have been 
classified as belonging to one of several categories of nerve fibre type. Single vagal 
nerve fibres in the recording apparatus described here can be identified as belonging to 
one of three groups of airway sensory nerve endings, i.e., slowly adapting stretch 
receptors (SARs), irritant receptors (rapidly adapting stretch receptors, RARs, Aδ-fibres) 
and pulmonary/bronchial C-fibre receptors using several criteria (Adcock et al., 2003). 
These criteria include pattern of spontaneous discharge, response to hyperinflation and 
deflation, adaptation indices (AIs), response to capsaicin aerosol administration and 
conduction velocities. As a rule, a receptor that possessed no obvious pattern to the 
spontaneous activity (often very sparse), did not respond to hyperinflation/hyperdeflation 
but responded to capsaicin aerosol was used for experimentation. At the conclusion of 
the experimental protocol, verification of a C-fibre was confirmed by determination of 
conduction velocity as described above. 
 
2.5.3 Measurements/Recording protocol 
After surgery, and identification of a capsaicin-sensitive fibre that was quiescent to 
overinflation/deflation, as described above, the following protocol was used to record 
inhibition of capsaicin-evoked responses by the potential anti-tussive compounds. 
After a baseline recording of at least two minutes, capsaicin (100µM) was administered 
by aerosol for 15 s, and the changes in nerve fibre firing, intratracheal pressure and 
blood pressure were recorded until baseline levels were re-established. After an interval 
of 10 min, vehicle (0.1% DMSO in PBS) was administered by aerosol for 1min while 
recording variables. After another interval of 10 min, the capsaicin aerosol (15 s, 100 µM) 
was repeated (internal vehicle control response). After another 10 min interval, either 
vehicle (0.1% DMSO in PBS) or anti-tussive compound (see Sections 3.2.2 & 4.2.2) was 
administered. A final capsaicin aerosol (15 s, 100 µM) was administered 20min after 
vehicle/drug administration. 
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2.5.4 Data Recording 
Action potentials and tracheal pressure were recorded using the Spike2 software 
package. This software package was used to output data into MS Excel (Microsoft, USA), 
which was then used to calculate % inhibition of capsaicin responses, as described in the 
equation in Methods 2.9.1.   
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2.6 In vivo cigarette smoke exposures 
Guinea pigs were exposed to cigarette smoke (CS) from research cigarettes (3R4F - with 
filters removed; University of Kentucky, KY) for 1h, twice daily for 8 days, as shown in 
Figure 2.6. Animals had ad libitum access to food and water at all times, except during 1h 
CS exposures.  
 
Figure 2.6 Diagram of timings of cigarette smoke exposures 
Animals were exposed to cigarette smoke twice daily (top panel), with a 4 hour gap 
between exposures (bottom panel), before animals were used for either in vivo cough 
studies or in vitro vagus nerve recordings. 
 
The smoke was generated using a negative pressure system to draw air through lit 
research cigarettes, as illustrated in Figure 2.7. A pump was used to draw air, at a 
constant flow-rate of 1.5L.min-1, through a pinch-valve system. The pinch valve system 
was set to draw from a lit cigarette for 2s, with room-air being continuously drawn into the 
chamber for the remaining period (4s). This generated a mock ‘puff’ on the cigarette, with 
each 6s ‘cycle’ drawing 50ml of smoke followed by 100ml of room air. When the lit 
cigarette burned to the writing on the lower end, a new cigarette was placed in the pinch-
valve and re-lit manually. The air and smoke from the pinch valve system was drawn into 
a Teague chamber (255L volume) housing the animals, where a fan at the bottom of the 
chamber dispersed the smoke evenly throughout. Air extracted from the chambers was 
vented from the facility.  For air-exposed negative-control comparator groups, the same 
protocol was applied, except the cigarette was not lit. Each exposure period of one hour 
consisted of 50 minutes of ‘active’ smoke exposure, with 10 minutes at the end allocated 
for venting of cigarette smoke, when the flow was increased to maximum and set to draw 
room air only.  
 
Figure 2.6. Diagram of timings of cigarette smoke exposures 
Animals were exposed to cigarette smoke twice daily (top panel), with 
a 4 hour gap between exposures (bottom panel), before animals were 
used for either in vivo cough studies or in vitro vagus nerve recordings. 
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Tobacco Smoke Particulate (TSP) levels were assessed at the midpoint of each 
exposure, to ensure consistency in the levels of cigarette smoke particulates.  To assess 
TSP, a volume of air was drawn from the exposure chamber, over 1min, through a 
borosilicate glass microfiber filter (Pallflex, Pall Corporation, UK). The TSP value was 
calculated as the ratio of the change in filter weight compared to the volume of air drawn 
through the filter. Animals were weighed prior to the first exposure and on cull days. 
 
Figure 2.7 Diagram of apparatus for CS exposures 
Animals are housed in open cages (not shown), which are placed in a larger chamber, 
sealed except for inlet and exhaust fixings. A lit cigarette is placed in one of the pinch 
valve openings, and air is then drawn by negative pressure alternately from the room (4 
s) or through the cigarette (2s). The air and CS passing along tubing into the chamber 
containing the animals, and is then distributed by a small fan. The exhaust fan then pulls 
the air/CS mixture across to, and then out of, the other side of the chamber.  
 
Figure 2.7. Diagram of apparatus for CS exposures 
Animals are housed in open cages (not shown), which are placed in a 
larger chamber, sealed except for inlet and exhaust fixings. A lit cigarette 
is placed in one of the pinch valve openings, and air is then drawn by 
negative pressure alternately from the room (4 s) or through the cigarette 
(2s). The air and CS passing along tubing into the chamber containing the 
animals, and is then distributed by a small fan. The exhaust fan then pulls 
the air/CS mixture across to, and then out of, the other side of the 
chamber.  
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2.7 Provision and genotyping of knock-out mice 
2.7.1 Knock-out mice 
Mice homozygous for mutated alleles of the β2-adrenergic receptor were kindly provided 
by Professor Harding, NHLI, Imperial College (see Nikolaev et al., 2010).  
 
Mice homozygous for mutated alleles of the β3-adrenergic receptor were kindly provided 
by Professor Lowell, via Johns Hopkins University, US (see Mantzoros et al., 1996).  
 
Mice containing at least one mutated AC6 allele were kind gifts provided by Dr Hammond 
of the University of California, San Diego. Breeding pairs of mice containing at least one 
mutated allele were bred in-house at Imperial College to generate a colony of  
adcy6-/- mice. Mice were confirmed to be homozygous for the mutant (KO) allele by 
amplifying the KO sequence using PCR and visualising the product on an agarose gel by 
electrophoresis.  
 
2.7.2 DNA extraction 
DNA was extracted from tail tips taken from mice using an extraction kit (‘Extracta DNA 
prep for PCR’, Quanta, UK) according to the manufacturers instructions. Briefly 0.5cm of 
tail was removed and placed into an eppendorf tube, and 75µl of extraction buffer was 
added to each tube. The tail samples in buffer were then heated (95°C; 30min) before 
being allowed to cool to room temperature. Then 75µl of stabilization buffer was added to 
the sample tube, and the concentration of DNA in the samples was assessed by 
spectrophotometry at wavelengths of A260/A280 on a GeneQuant RNA/DNA quantifier 
(Amersham Pharmacia, UK). Samples were then adjusted to 10ng.ml-1 by dilution with 
nuclease-free water.  
 
2.7.3 Genotyping of samples by Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) is used to amplify a select sequence of DNA between 
a pair of primers. Nuclease-free water was added to a reaction mixture containing 50ng 
extracted DNA sample (5µl), reaction buffer (5µl), 0.2mM dNTPs (1µl), 2mM MgCl2 (2µl), 
1.25U Taq polymerase (0.2µl), and forward and reverse primers (1µl each), to give a total 
reaction volume of 25µl (reagents purchased from Applied Biosystems, UK). The reaction 
tubes were placed into an ABIprism 96 well plate (Applied Biosystems, UK), and the PCR 
reaction was run in an ABIprism 7000 PCR machine (Applied Biosystems, UK). The 
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samples were heated to 94°C (2min) to denature the DNA strands, followed by 40 cycles 
of three alternating temperatures to allow annealing of primers, extension of primers by 
the Taq Polymerase enzyme, and denaturing of DNA strands to allow further 
amplification upon repeating of the temperature cycle. The temperatures and timing of 
the cycles are specific to the primers used, and the length of the expected DNA product; 
details of forward and reverse primers and reaction times and temperatures are given in 
the methods section of the relevant chapter. The number of cycles was selected to 
maximise the amplification of the DNA product without increasing non-specific Taq 
polymerase activity that can occur with greater numbers of cycles (Kramer & Coen, 
2001). The PCR reaction was stopped by cooling the reaction to 4°C.  
 
2.7.4 Visualisation of PCR product by electrophoresis 
The PCR product was visualised alongside a relevant DNA ladder by agarose gel 
electrophoresis. The samples were placed into wells on an agarose (2%) gel in Tris 
Borate EDTA (TBE) buffer containing 0.05µg.ml-1 Safeview Nucleic Acid Stain (NBS 
Biologicals Ltd, UK). A voltage of 80V was applied to the gel for 1h, and the stained DNA 
was then visualized under UV light and photographed. The DNA ladder used was 
dependent on the size of the expected product.  
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2.8 Measurement of mRNA levels to assess gene expression 
2.8.1 Principles of gene expression assessment 
In order to assess the expression of specific target genes in vagal ganglia cells, 
quantitative, or real-time polymerase chain reaction (q-PCR) was performed on RNA 
extracted from mouse ganglia cells.  
 
DNA is essentially a stable repository of all the information required to make any of the 
proteins of any cell type in an individual organism. DNA encodes the information required 
to make proteins in sequences of nucleotide base pairs. In order for a protein to be 
expressed in a cell, the DNA sequence encoding that protein must be transcribed to 
messenger RNA (mRNA). Like DNA, mRNA encodes information in nucleotide base 
pairs (with some differences), but unlike DNA can leave the nucleus. This allows mRNA 
to bind with ribosomes in the cytosol and on the endoplasmic reticulum (via leader 
sequences on the 5’ end of the mRNA). Ribosomes translate mRNA sequences into 
amino acid sequences, thereby creating proteins. Therefore assessing the expression of 
specific mRNAs in a cell type can be used as an approximate proxy for the expression of 
a protein in the same cells. The major caveat to this is that protein expression can be 
suppressed via other regulatory processes in the cell, despite the expression of it’s 
corresponding mRNA sequence. However, in general, whilst levels of mRNA expression 
do not always correlate well with levels of protein expression, expression of a specific 
mRNA gives an indication that a specific protein is expressed in a cell type (Gry et al., 
2009; Vogel & Marcotte, 2012).  
 
In order to assess the level of gene expression in ganglia cells, RNA was first extracted 
from those cells by dissolution of the cell membranes, according to a protocol designed 
to ensure that the RNA is not degraded or contaminated (see Methods 2.8.2). Once the 
levels of mRNA had been normalised to a known level, all the mRNA sequences in a 
sample were then transcribed into complementary DNA sequences (cDNA), using a 
reverse transcription enzyme (see Methods 2.8.3). The production of cDNA provides a 
more stable transcript of the original mRNA sequences that can be used with the primers 
and probes for DNA used in PCR reactions. The expression of target mRNA was then 
determined by measuring levels of the target cDNA transcript using q-PCR (see Methods 
2.8.4). This technique involves the use of a reporter dye attached to a specific antisense 
oligonucleotide probe that binds to the target cDNA strand. As DNA polymerase 
replicates the cDNA strand, the reporter dye is displaced from the probe, causing 
enhanced fluorescence of the dye. The level of fluorescence emitted is proportional to 
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the number of times the cDNA target is replicated, so that the relative expression of the 
target cDNA can be determined.  
 
2.8.2 RNA extraction 
RNA was extracted according to a method previously described by McCluskie et al. 
(2004). Mouse vagal ganglia were dissected similarly to the method described for guinea 
pig ganglia dissection (see Methods 2.4.2), except in the mouse the jugular and nodose 
ganglia are fused into a single vagal ganglia instead of being separate entities. The pair 
of vagal ganglia from each mouse were dissected, cleared of connective tissue and then 
cut into quarters and transferred to a 2ml Eppendorf tube. All tubes used had been 
autoclaved in order to ensure that they did not contain active ribonucleases, which would 
otherwise cause the catalytic degradation of RNA. TRI Reagent (1ml, Sigma, UK) was 
added to the tubes, which were then mixed by several inversions. RNA, DNA and protein 
dissolve in TRI Reagent due to its guanidine thiocyanate and phenol composition. 
Sample tubes were centrifuged (15,000 x g; 15min; 4°C) to remove insoluble material 
(i.e. extracellular membranes). The supernatant (containing dissolved RNA, DNA and 
protein) was transferred to a new 2ml Eppendorf tube left to stand (5min, room 
temperature) to ensure complete dissociation of nucleoprotein complexes. Chloroform 
(0.2ml, Sigma, UK) was added, and the tubes were vigorously shaken (15s) and left to 
stand (15min, room temperature) before centrifugation (15,000 x g; 15min; 4°C). 
Following centrifugation, the solution separated into 3 phases: a dense organic phase 
containing proteins, an interphase containing DNA, and an aqueous phase containing the 
RNA. The aqueous phase was removed to a new Eppendorf tube, and was then mixed 
with approximately 1:10 (v/v) isopropanol (Sigma, UK) and left to stand (5min, room 
temperature) before being centrifuged (12,000 x g; 10min; 4°C). The resultant 
supernatant was transferred to a new Eppendorf tube and more isopropanol was added 
(to give a total of 0.5 ml isopropanol). Samples were inverted once to mix, left to stand 
(5min, room temperature) and centrifuged (12,000 x g; 10min; 4°C), causing the RNA to 
precipitate as a pellet. The supernatant was then removed (NB samples were kept on ice 
from this point forward), 70% v/v ethanol was added to the tube and mixed (5s vortex), 
centrifuged (12,000 x g; 5min; 4°C), and the supernatant was then removed before the 
pellet was left to air dry (5min).  
RNA pellets were dissolved in 50µl nuclease-free water using a vigorous pipetting action. 
A small sample was then taken and diluted 1:10 in nuclease-free water in a UV-
transparent 96-well plate. The purity and concentration of the RNA samples was 
measured on a BioTek PowerWave XS microplate spectrophotometer (BioTek) at 
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wavelengths A260/A280. Samples were then accordingly adjusted to 0.05mg.ml-1 using 
nuclease-free water.  
 
2.8.3 cDNA synthesis 
RNA samples (0.5µg in 10µl) were reverse transcribed using TaqMan reverse 
transcription reagents (Applied Biosystems, UK). The reverse transcriptase master mix 
contained TaqMan RT buffer (5µl), MgCl2 (5.5mM; 11µl), deoxyNTP mixture (500µM per 
NTP; 10µl), random hexamers (2.5µM; 2.5µl), RNase inhibitor (0.4 U.µl-1; 1µl) and 
MultiScribe reverse transcriptase (1.25 U.µl-1; 1.25µl). The final reaction mixture 
(adjusted to 50µl with nuclease-free water) was incubated using a thermal cycler (10min; 
25°C, then 30min; 48°C and 2min; 95°C - model 480; Perkin Elmer, US) to generate 
cDNA transcripts. cDNA samples were frozen at -80 °C until required. 
 
2.8.4 TaqMan real-time PCR 
The cDNA transcripts were prepared for real-time PCR amplification. Each reaction 
mixture contained TaqMan universal master mix (containing Taq DNA polymerase; 
12.5µl), sample cDNA (7.5ng in 3µl), Assay on Demand reagent (contains target gene 
specific primers and probe; 1.5µl) or 18S internal control (1.5µl) (all reagents from 
Applied Biosystems, UK). The final reaction mixture was adjusted to 25µl with nuclease-
free water, and amplified using an ABI PRISM 7000 TaqMan machine (Applied 
Biosystems). The amplification protocol comprised 1 cycle for 2 minutes at 50°C, 1 cycle 
for 10 minutes at 95°C and 40 cycles of 95°C for 15 seconds and 60°C 1 minute. The 
principle of the TaqMan real-time PCR amplification process is described briefly below. 
 
The premise of the q-PCR technique is that it allows measurement of the levels of 
specific target cDNA sequences by using fluorescent probes for specific sequences of 
DNA present in the target gene. These probes are short antisense oligonucleotide 
sequences that specifically bind to the target cDNA, and have a fluorescent reporter dye 
attached to their 5’ end and a quencher dye attached to their 3’ end. In close proximity 
the quencher dye reduces the fluorescence emitted by the reporter dye, and in the intact 
probe, the proximity of the two ends with the reporter and quencher dyes bound, is such 
that the fluorescence emitted by the reporter dye is significantly reduced. In the reaction 
mixture, if the target cDNA is present, the probe anneals to the specific target sequence 
on the cDNA of interest, downstream of the primer sequence. The reaction mixture also 
contains primers for the cDNA of interest and DNA polymerase. The primers bind to 
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specific sequences on the target cDNA, which allows the binding of DNA polymerase, 
which then (under the reaction conditions) begins to copy the cDNA downstream of the 
primer. As the new antisense cDNA strand is extended to the probe, the 5’ nuclease 
activity of DNA polymerase cleaves the reporter and quencher dyes. Without binding to 
the probe to hold the quencher dye in proximity, the fluorescent emission of the reporter 
dye increases. The probes and primers are provided in excess, so that the level of 
fluorescence of the reporter dye increases with each new copy of the cDNA target that is 
transcribed. In addition to the genes of interest, the levels of RNA expression of a control 
target were also assessed in the same samples in parallel q-PCR reactions. The control 
gene selected was 18S ribosomal RNA, a so-called ‘housekeeping gene’, which is 
abundantly present in all eukaryote cells and is commonly used as a control for RNA 
quantification (Suzuki et al., 2000). The fluorescence from the reporter for the target 
cDNA probe can be compared to the fluorescence from the reporter for the control cDNA 
probe to give the relative expression of the gene of interest in the sample.  
 
2.8.5 Analysis of q-PCR results 
Results were analysed using ABI PRISM 7000 Sequence Detection System software 
program (Version 1.2.1, Applied Biosystems, UK). A threshold was set manually on the 
amplification plot within the geometric (linear) phase of amplification, following guidelines 
supplied by Applied Biosystems. The threshold cycle (Ct) is the cycle number at which 
the level of fluorescence from a particular reporter exceeds the set threshold, and so Ct 
values are inversely proportional to the initial copy number, such that a lower Ct value 
denotes a higher concentration of the target in the initial sample. Ct values given by 
reporter dye emission from target probes were normalised to the Ct value for the 
emission from the 18s control probe to give the relative expression of the target mRNA 
(ΔCt). In order to take into account the exponential amplification reaction, the expression 
data was transformed and is presented here as 2-ΔCt. 
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2.9 Data analysis and statistics 
2.9.1 Data Manipulation and Statistical Analysis 
Statistical Analysis 
The type of statistical analysis used is indicated in figures describing the relevant data. A 
summary of the types of data analysed with each statistical test used in this thesis is 
provided below: 
• Where data was normalised to an internal control (i.e. isolated vagus nerve, neuron 
and in vivo single fibre experiments), statistical analysis was performed on the raw 
data rather than the normalised data. In these cases, the analysis used was a paired 
students t-test, comparing the response in the presence of vehicle or test compound to 
the initial control response.  
• Where a comparison was made between the mean responses in two separate groups 
of animals (i.e. cough studies), a Mann-Whitney U test was used comparing responses 
in vehicle-treated to responses in drug-treated groups. 
• Where a comparison was made between the mean responses of more than two 
separate groups of animals (i.e. cough studies with more than 1 dose/drug being 
tested), a Kruskal-Wallis test was used, with Dunn’s post-hoc analysis to compare 
responses in the vehicle-treated group to responses in each of the drug-treated 
groups. 
 
Normalisation/presentation of data 
Data is presented throughout as mean ± standard error of the mean (SEM).  
 
In both isolated vagus nerve and isolated neuron experiments, data is presented as 
percentage inhibition – that is to say the magnitude of a response in the presence of 
vehicle or test compound compared to the magnitude of the respective internal control 
response. The data is modified for presentation here in order to reduce and/or simplify 
the number of figures required. As noted above, statistical analysis was performed on 
raw data, in order to avoid altering the distribution of the data to be analysed. The 
equations used to calculate percentage inhibition for isolated vagus and isolated neuron 
datasets are provided below: 
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Equation for calculation of percentage inhibition in isolated vagus nerve and single fibre 
nerve recording datasets: %  𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100 − !"#$%&#"  !"  !"#$#%&#  !"  !"!!"#$/!"#$!"#$  !"  !"!#!$%  !"#$%"&  !"#$%&#"# ×100   
NB Response refers to the magnitude of depolarisation evoked by 2min incubation with 
the tussive agent being examined in the dataset in question. 
 
Equation for calculation of percentage inhibition in isolated neuron calcium recording 
datasets: %  𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100 − !"#$%&#"  !"  !"#$#%&#  !"  !"#$%&$  !"  !"!!"#$/!"#$!!"  !"#$%&#" ×100   
NB Response refers to the magnitude of depolarisation evoked by incubation with K50 
for 30s at the beginning of all experiments. 
 
2.9.2 Data analysis software 
Statistical Analyses 
All statistical analysis was performed as described above using Graphpad Prism (version 
5.0 or 6.0, Graphpad Software, USA) running on the Mac OSX 10.7 or 10.8 operating 
system (Apple Computers Ltd, USA).  
 
Normalisation of data 
Normalisation of vagus and neuron responses to internal controls was calculated as 
described in the equations above, using Excel for Mac 2011 (version 14.2.5, Microsoft, 
USA) running on the Mac OSX 10.7 or 10.8 operating system.  
 
Quantification of light emission from Ca2+ and voltage-sensitive dyes 
Quantification of light emission intensity from individual neurons was calculated using 
ImageJ64 (version 1.43u, NIH, USA). Area under the curve (AUC) of the light emission 
data from ImageJ64 was calculated using Microcal Origin (version 6.0, Microcal 
Software, USA). 
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Operating Systems 
All software was running on the Mac OSX 10.7 or 10.8 operating system (Apple 
Computers Ltd, USA), except Microcal Origin, which was running on Windows 7 (Service 
Pack 1, Microsoft, USA). 
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3.1 Introduction/Rationale 
The short-acting β2-adrenergic receptor agonists (SABA) terbutaline and fenoterol, 
sometimes prescribed as bronchodilators, have previously been shown to have a direct 
anti-tussive effect via an action on vagal sensory nerves; inhibiting capsaicin-induced 
cough in guinea pigs, and also depolarisation of guinea pig and human vagus nerve 
(Freund-Michel et al., 2010). The mechanism proposed involved an atypical cAMP/PKG-
dependant pathway, where activation of the β2-adrenoceptor led to an increase in cyclic 
AMP (cAMP), activating Protein Kinase G (PKG) and the downstream opening of large-
conductance calcium-activated potassium channels (BKca) (Freund-Michel et al., 2010).  
 
The aim of this chapter was to follow up these findings by studying the impact of two 
structurally different, clinically relevant, long acting β2 adrenoceptor agonists (LABAs), as 
well as the action of β1-, and β3-adrenergic receptor agonists, on sensory nerve 
depolarisation and cough. The secondary aim of this chapter is to examine the signaling 
pathways mediating the anti-tussive action of β-adrenergic receptor agonists in sensory 
nerves.  
 
In order to fulfill these aims, the anti-tussive activity of two LABA compounds was 
investigated, namely formoterol and olodaterol, which are, in widespread clinical use and 
in clinical development, respectively. These compounds were evaluated for their ability to 
inhibit capsaicin-evoked cough and firing of sensory C-fibres in guinea pigs, and also 
capsaicin-induced calcium responses in guinea pig isolated airway-terminating airway 
neurons. 
 
The isolated vagal nerve recording system (as described by Freund-Michel et al., 2010) 
was then used to investigate the mechanism of action of β-adrenergic receptor agonists 
on sensory nerves, as a much more pharmacologically amenable and cost-effective 
assay system. In this preparation, the ability of the LABA compounds, as well as β1-, and 
β3-adrenergic receptor agonists to inhibit depolarisation induced by capsaicin, and range 
of other cough-inducing agents was assessed. Furthermore, using this preparation, the 
signaling of all of the β-adrenoreceptor agonists was assessed using a range of 
pharmacological and genetic tools. Initially it was confirmed that the β-adrenergic 
receptor agonists act through their respective receptor sub-types to exert their effects on 
sensory nerve depolarisation. Finally, the involvement of adenylyl cyclase and BKCa in 
mediating the actions of these agonists on sensory nerves was investigated, as key parts 
of the signaling pathway proposed to be to be involved in β2-adrenergic receptor agonists 
activity on sensory nerves.  
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3.2 Methods 
3.2.1 Determining the effect of LABAs on capsaicin-induced cough in the 
conscious guinea pig 
In order to examine the effect of each of the LABA compounds, male Dunkin Hartley 
guinea pigs were place in a Perspex chamber to receive either aerosolised vehicle (0.1% 
DMSO in Phosphate Buffered Saline – PBS), olodaterol (0.3 - 3µg.ml-1), or formoterol 
(3µg.ml-1) for 10min (approx. aerosolised volume 10ml), 50min prior to challenge with 
capsaicin. Animals were moved to a separate Perspex chamber attached to a 
microphone where coughs could be observed and recorded, and Penh (enhanced pause, 
a measure of bronchoconstriction) levels could be analysed. A baseline recording of 
Penh and cough was taken for 5min prior to the experiment. Capsaicin (60µM) was then 
administered by aerosol for 5min, during which time coughs were counted and Penh 
recorded, as well as for a further 5min post-exposure, using the Buxco Cough Analyser 
as described in Methods 2.2 (events depicted as timeline in Figure 3.1).  
 
Figure 3.1 Timeline of events in the in vivo cough study 
Guinea pigs were treated with nebulised vehicle, formoterol, or olodaterol (n=6) at time 0 
for 10min. Guinea pigs then breathed room air with food and water ad libitum for 50min 
before being placed in a Buxco cough chamber – where cough and Penh were recorded 
for a total of 10min, 5min while capsaicin was administered and 5min after administration. 
 
The timings, doses and vehicle used in this protocol were selected from Bouyssou et al. 
(2010), where these concentrations of these LABAs were found to be effective at 
preventing bronchospasm. Note however, the route of administration was changed to 
inhaled aerosol, as the light anaesthesia required for intratracheal dosing can impact on 
the cough response. 
3.2.2 Determining the effect of LABAs on guinea pig airway-terminating C-
fibre firing 
The general premise of this technique was to assess the effect of potential anti-tussive 
compounds on the firing activity of a single afferent airway-terminating C-fibre in 
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response to capsaicin. To that end, surgery and setup was performed as described in 
Methods 2.6 to allow assessment of action potentials generated by capsaicin aerosol in 
single afferent C-fibres of anaethetised and artificially ventilated guinea pigs.  After 
surgery and setup, the animals were allowed to stabilise for at least 30min. After a control 
baseline recording of at least 2min, capsaicin (100µM) was administered by aerosol for 
15s and changes in fibre activity, intra-tracheal pressure and blood pressure were 
continuously recorded until baseline or a steady state was re-established. After 10min, 
the capsaicin aerosol (15s, 100µM) was repeated. After a further 10min, either vehicle 
(0.1% DMSO in PBS), oladaterol (BI-1744-CL, 3µg.ml-1) or formoterol (3µg.ml-1) were 
administered by aerosol to the lungs for 1min. A final capsaicin aerosol (15s, 100 µM) 
was administered 20min after vehicle/drug administration. 
 
3.2.3 Determining the effect of LABAs on capsaicin-induced responses in 
isolated airway jugular ganglia neurons 
Male Dunkin-Hartley guinea pigs were euthanised, jugular ganglia were removed, and 
individual jugular ganglia neurons were isolated as described in Methods 2.4. The jugular 
and nodose ganglia contain the majority of the cell bodies for airway terminating vagal 
neurons. Previous data in our group indicated that a greater proportion of jugular ganglia 
neurons respond to capsaicin (Grace et al., 2012). For this reason only jugular neurons 
were used to examine the inhibitory effects of LABA compounds.  
 
As described previously (Methods 2.4.1) guinea pigs had been i.n. dosed with DiI, a 
retrograde tracer dye, therefore airway-terminating neurons isolated from these animals 
could be identified by the DiI present in their plasma membranes. Isolated neurons were 
incubated (37°C, 5%CO2) overnight in complete F12 media (containing penicillin and 
streptavidin), in order to allow adherence to poly-D-lysine- and laminin-coated 
fluorodishes. Immediately prior to imaging experiments, cells were incubated with the 
calcium sensitive dye Fura-2AM.  
 
To test the effect of LABA compounds on the release of calcium in the ganglia, cells were 
acquired using a confocal epi-fluorescence microscope, and sensory neurons were 
identified by their body characteristics (20-30µM diameter) and light diffraction in phase 
contrast, whilst DiI emission was used to identify airway-terminating neurons. The 
fluorodish was connected to a pressurised perfusion system that allowed rapid change of 
the bath solutions as per the following protocol:  
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An initial control response to application of K50 solution (50mM hyper-potassium solution 
containing; 50mM KCl; 91.4mM NaCl; 1mM MgCl2; 1.8mM CaCl2; 0.33mM NaH2PO4; 
10mM D-Glucose; 10mM HEPES; pH adjusted with NaOH to 7.4) was used to assess 
cell viability, and this response was used to normalise all subsequent responses within 
each cell. After perfusion with ECS to remove the K50 solution and allow recovery of 
calcium and voltage dye emissions back to baseline, cells were then stimulated twice 
with capsaicin (1µM) as control responses followed by a wash with ECS to recover 
baseline levels. The cells were then incubated with vehicle (0.1% DMSO in ECS), 
formoterol, or olodaterol (both 0.01, 0.1 or 1nM) for 10min, and then re-stimulated with 
capsaicin in the presence of test compounds. ECS was then perfused for 5min to remove 
capsaicin and LABA compounds, following which a final capsaicin stimulation and K50 
application were used to confirm that capsaicin responses recovered once the drug was 
removed, and that the cell(s) remained viable.  
 
3.2.4 Determining the effect of β-agonists on isolated vagus nerve 
depolarisation 
The following experimental protocol was used to examine the effects of agonists of the 
different β-adrenergic receptors (subtypes β1, β2, and β3) on isolated vagus nerve 
depolarisation induced by capsaicin – see Table 3.1 for details of agonists. Following 
sacrifice of the guinea pig and dissection of the vagus nerve as outlined previously 
(Methods 2.3), the isolated nerve was allowed to equilibrate for 10min in the grease-gap 
chamber, following which capsaicin (1µM, Fluka Biochemika, Switzerland) was perfused 
for 2min, causing depolarisation. The nerve was then ‘washed’ (perfusion of KH alone) 
until the signal returned to baseline. Two reproducible responses to the capsaicin were 
recorded in this way, following which the vagus nerve was incubated with a concentration 
of vehicle or β-agonist compound as listed in Table 3.1. β1- and β3-agonists were 
incubated for 10min according to a protocol for examining efficacy in this system as  
 
Agonist Supplier Target Vehicle 
(0.1%v/v in KH) 
Concentration  
(-log[M]) 
Incubation time  
(min) 
Denopamine 
Formoterol 
Sigma, UK 
Sigma, UK 
β1  
β2  
DMSO 
DMSO 
8, 7, 6, 5, 4 
10, 9, 8, 7, 6 
10 
20 
Olodaterol 
BRL37344 
Sigma, UK 
Sigma, UK 
β2  
β3  
DMSO 
dH2O 
10, 9, 8, 7, 6 
8, 7, 6, 5, 4 
20 
10 
 
Table 3.1: Concentrations of LABA compounds used on vagus nerve 
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adapted from Freund-Michel et al. (2010). The β2-agonists were incubated for 20min, a 
time point selected for maximal efficacy from Bouyssou et al. (2010). The vagus was then 
re-challenged with capsaicin, in the presence of the vehicle or agonist. Following a ‘wash’ 
period of 10min, a final stimulation of capsaicin was used to determine tissue viability. On 
each piece of nerve tissue, only one concentration of any vehicle or drug was examined. 
 
3.2.5 Examining the selectivity and mechanism of action of β-agonists using 
pharmacology (selective antagonists) in the guinea pig vagus 
Selectivity of the agonists for the respective β-adrenergic receptors was examined using 
specific antagonists for each of the 3 receptors sub-types (Table 3.2). The protocol used 
to examine agonist inhibition was modified by co-incubating antagonists with a selected 
concentration of the agonists used previously, as follows: Two control responses to 
capsaicin were generated, and then vehicle (0.1% v/v DMSO) or antagonist (0.1µM, see 
Table 3.2) were incubated for 10min, prior to 20min incubation with vehicle or agonist 
(single concentrations selected from concentration-response data) in the presence of 
vehicle/antagonist. The nerve was then stimulated with capsaicin in the presence of both 
vehicle/antagonist and vehicle/agonist, followed by a ‘wash’ period of 10min, and a final 
stimulation with capsaicin alone.  
 
 
Table 3.2 Range of agonists and antagonists used on guinea pig vagus 
Concentration selected from affinity values given in table from *(Baker, 2005) and 
+(Candelore et al., 1999) 
 
3.2.6 Confirming selectivity of β-agonists using β-receptor knock-out mouse 
vagus 
Wild-type and β-receptor knock-out mice (FVB/N background) were used to confirm the 
specificity of each β-agonist for the respective β-receptors. β2-receptor and β3-receptor 
KO mice (Adrb2-/- and Adrb3-/- respectively), along with age-matched controls also on an 
FVB/N background were kind gifts from, respectively, Professor Sian Harding (Imperial 
College), and Dr. Lili Barouch (Johns Hopkins Medical School). Unfortunately β1-receptor 
mice could not be obtained for these experiments. The experimental procedure was 
Antagonist Supplier Target Kd at human β receptor  (nM) Concentration 
   β1 β2 β3  
CGP20712A Sigma, UK β1  1.55 776.25 6456.54 0.1µM* 
ICI 118551 Sigma, UK β2  301.99 0.55 363.08 0.1µM* 
L-748337 Tocris, UK β3  199.52 158.48 3.16 0.1µM+ 
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identical to the protocol used to investigate the β-agonist effect in guinea pig vagus, 
except that fewer sections of vagus were retrieved (2 vagal nerve sections of 10-15mm) 
per animal, due to the smaller animal size. The effect of each of the different β-receptor 
agonists was compared in the wild-type, β2-receptor -/- and β3-receptor -/- mice, in order 
to confirm that only the β2- and β3-agonists effect was lost in the respective knockouts. 
  
3.2.7 The role of adenylyl cyclase in β-adrenergic receptor signaling in 
mouse vagus nerves 
Genotyping of adenylyl cyclase knock-out mice 
Mice containing at least one mutated (deletion) AC6 allele were kind gifts provided by Dr 
Tang of the University of California, San Diego. Breeding pairs of mice containing at least 
one mutated allele were bred in-house at Imperial College to generate a colony of  
adcy6-/- mice. Mice were confirmed to be homozygous for the mutant (KO) allele by 
amplifying the KO sequence using PCR and visualising the product on an agarose gel by 
electrophoresis (see Methods 2.7.4). One important note concerning the AC6 KO mice, 
however, is that the deletion of the AC6 gene, has been shown to increase the 
degradation of the AC5 isoform (Tang et al., 2008). Therefore, as it is not possible to say 
that any changes in the functional responses of tissue from these mice are due to AC6 
alone, these mice are subsequently referred to as AC5/6 KO mice.  
 
DNA samples extracted from age-matched wild-type (C57Bl/6) and AC6 KO mice were 
amplified by PCR and visualised on agarose gel by electrophoresis, as detailed in 
Methods 2.7. Primers for the wild-type and KO AC6 allelles were obtained from 
Invitrogen (UK), based on the sequences (given in Table 3.3) published by Tang et al. 
(Tang et al., 2008). Once the samples were heated to 94°C (2min) to denature the DNA 
strands, 40 PCR cycles of three alternating temperatures were used to amplify the wt and 
KO AC6 primers. Each cycle consisted of heating to 94°C for 30s, to 58°C for 45s, and 
72°C for 3min. Finally the samples were maintained at 72°C for 10min, and then cooled 
to 4°C for at least 5min to stop the reaction.  
 
Primer target Primer direction Primer sequence Concentration 
AC6 wild-type allele Forward GGAGACCTAGAGATGGAGTG 10µM 
AC6 wild-type allele Reverse GCCACTTGTGTAGCGCCAAG 10µM 
AC6 KO allele Forward AAGATCTGCTTTGTGGGTGC 10µM 
AC6 KO allele Reverse AGCCACTGGCTCGATTCGCGTGGCG 10µM 
Table 3.3 Primers used for genotyping of AC6 wild-type and knock-out mice 
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The samples were then separated on an agarose gel by electrophoresis for 1h at 80-
100V. The expected band for the wt product was 550 base pairs (bp), and samples were 
run alongside a 50-2000bp ladder (Hyperladder 50bp, Bioline Reagents, UK). The 
expected band for the KO allele product was 2.2kbp, and samples were run alongside a 
500-5000bp ladder (Hyperladder 500bp, Bioline Reagents, UK).  
 
Primers and probes used for quantitative PCR to determine adenylyl cyclase gene 
(adcy) expression 
Mouse ganglia cells were dissected from wild-type C57Bl/6 mice, RNA was extracted 
from the ganglia and reverse transcribed, and quantitative PCR (q-PCR) was performed 
to determine the expression levels of adenylyl cyclase mRNA expression in the ganglia 
(see Methods 2.8). The expression of adenylyl cyclase sub-types 1-10 were assessed in 
the mouse ganglia, and the primers and probes used for q-PCR of these targets are 
given in Table 3.4.  
 
Target gene Primer/Probe Assay ID 
(Applied Biosystems) 
Adcy1 Mm01187829_m1 
Adcy2 Mm00467874_m1 
Adcy3 Mm00460371_m1 
Adcy4 Mm00475491_m1 
Adcy5 Mm00674122_m1 
Adcy6 Mm00475772_m1 
Adcy7 Mm00545780_m1 
Adcy8 Mm00507722_m1 
Adcy9 Mm00507743_m1 
Adcy10 Mm00557236_m1 
Rn18s (18s control) Mm03928990_g1 
Table 3.4 List of primer/probes used for q-PCR analysis of adenylyl cyclase 1-10 
sub-type expression levels 
Available from: lifetechnologies.com/uk/en/home/life-science/pcr/real-time-pcr/real-time-
pcr-assays/taqman-gene-expression 
 
3.2.8 The role of potassium channels in airway sensory nerve depolarisation 
The role of potassium channels in the β-agonist effect on sensory nerves was 
investigated by examining the effect of blockers of potassium channels on β-agonist 
inhibition of capsaicin. The blockers (and concentrations) used were selected from a 
previous investigation into the effects of short-acting β-agonists on vagus nerve 
depolarisation (Freund-Michel et al., 2010). Paxilline (1µM) was used to block large-
conductance calcium-activated potassium channels (BKCa), clotrimazole (10µM) to block 
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intermediate-conductance calcium-activated potassium channels (IKCa), apamin (1µM) to 
block small-conductance calcium-activated potassium channels (SKCa), and 
glibenclamide (10µM) to block ATP-activated potassium channels (KATP). The blockers 
were used on guinea pig vagus nerve in a similar protocol to that used to evaluate the 
effect of the selective β-receptor antagonists, except vehicle (0.1% DMSO), paxilline, 
clotrimazole, apamin or glibenclamide were used in place of the β-receptor antagonists.  
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3.3 Anti-tussive potential of β-receptor agonists 
3.3.1 LABA effect on naïve guinea pig cough 
Conscious guinea pigs were treated with aerosolised vehicle, olodaterol or formoterol 
(0.3-3µg.ml-1), and 1h later were challenged with an aerosol of capsaicin (60µM) to evoke 
cough, and number of coughs and Penh were recorded. Both olodaterol and formoterol 
at 3µg.ml-1 completely abolished the cough response to capsaicin, and olodaterol at 
1µg.ml-1 also significantly (P<0.05) inhibited capsaicin-cough compared to the vehicle 
control group (Fig. 3.2a). The capsaicin-evoked increase in Penh observed in the vehicle 
group was inhibited by both olodaterol and formoterol at the effective anti-tussive dose of 
3µg.ml-1 (Fig. 3.2b). 
 
  
Figure 3.2 Dose response of LABA effect on guinea pig capsaicin-evoked cough 
and airways obstruction 
Guinea pigs were pre-treated with aerosolised vehicle (0.1% DMSO in PBS), olodaterol 
(0.3-3µg.ml-1), or formoterol (3µg.ml-1) 1h prior to 5min aerosol of capsaicin (60µM), after 
which [A] number of coughs, and [B] Penh, a measure of bronchoconstriction, were 
recorded for a 10min period (including 5min of capsaicin aerosol plus 5min post-aerosol). 
Data displayed as mean±SEM, n=5-17, θ p<0.05 as determined by Kruskal-Wallis with 
Dunn’s post-test, comparing all columns to vehicle control. 
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3.3.2 Effect of LABA on guinea pig airway-terminating C-fibre firing 
The effect of olodaterol and formoterol on capsaicin-evoked firing of airway-terminating, 
single vagal afferent chemosensitive C-fibres and capsaicin-evoked bronchoconstriction 
was examined, as shown in the example trace below (Figure 3.3). 
 
 
Figure 3.3 Example trace of olodaterol inhibition of capsaicin-evoked action 
potential in an airway-terminating chemosensitive C-fibre 
Example trace showing the effect of olodaterol on capsaicin-evoked action potential firing 
of an airway-terminating, chemosensitive C-fibre. Lower panel shows action potential 
firing of the C-fibre, whilst upper panel shows tracheal pressure on same time-scale, with 
arrows indicating time of drug applications.  
 
At the same dose (3µg.ml-1) that inhibits the in vivo cough response, olodaterol and 
formoterol were both effective at reducing the peak firing rate and number of action 
potentials evoked by intra-tracheal instillation of a capsaicin aerosol (Fig. 3.4a&b). 
Baseline activity was recorded immediately prior to capsaicin aerosol, and there was little 
spontaneous activity in these fibres, with maximum impulse rate and total impulses of 
5.67±4.26imp.s-1 and 1.2±0.59 impulses respectively (data not shown). Both compounds 
also reduced capsaicin-evoked bronchoconstriction (Fig. 3.4c). 
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Figure 3.4 Effect of olodaterol and formoterol on capsaicin-evoked action 
potentials in airway-terminating chemosensitive C-fibres, and bronchoconstriction  
All animals were firstly exposed to aerosolised capsaicin (cap; 15s, 100µM) alone, twice 
consecutively (internal control), and then aerosolised vehicle (0.1% DMSO in PBS), 
formoterol (form; 3µg.ml-1, 1min), or olodaterol (olod; 3µg.ml-1, 1min) was administered 
10min prior to subsequent capsaicin stimulation. Single C-fibre afferent nerve responses 
were assessed by recording [A] firing rate and [B] total impulses. Capsaicin evoked 
bronchoconstriction [C] was also assessed. Data displayed as mean±SEM, n=3 where * 
p<0.05 as determined by paired students t-test compared to respective internal control 
(cap). 
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3.3.3 β-agonists effect on guinea pig airway isolated neurons 
The effect of olodaterol and formoterol on capsaicin-induced intracellular calcium flux 
was examined in single chemo-sensitive airway-terminating neurons of the jugular 
ganglia. Both olodaterol and formoterol were effective at inhibiting the capsaicin-induced 
increase in intracellular calcium levels (Fig. 3.5). 
Figure 3.5 Effect of olodaterol or formoterol on capsaicin-induced intracellular 
calcium flux in jugular airway-terminating neurons 
[A] Representative trace of olodaterol effect on capsaicin-induced intracellular calcium 
levels. Open triangles indicate K50 (50mM KCl in ECS solution, 15s) application, closed 
triangles indicate capsaicin (caps; 0.1µM, 30s) application, line indicates olodaterol (1nM, 
20min) incubation. Images above trace show false-coloured representation of calcium 
fluorescence at time-points indicated by grey arrows. [B] Summary graph shows the 
effect of formoterol or olodaterol (0.01-1nM) on capsaicin (0.1µM)-induced increases in 
intracellular calcium. Data displayed as mean %inhibition of initial capsaicin stimulations 
(internal control) ±SEM, n=4-10 cells from 3 guinea pigs, * p<0.05 as determined by 
paired students t-test compared to respective internal control. 
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3.4 Mechanism of action of β-agonists 
3.4.1 LABA and β1- and β3-receptor agonists effect on guinea pig vagus 
Denopamine (β1-receptor agonist), formoterol (LABA), olodaterol (LABA) and BRL37344 
(β3-receptor agonist) each caused a concentration-dependent inhibition of capsaicin-
induced sensory nerve depolarisation (Fig. 3.6). Notably the LABA compounds were 
effective at inhibiting capsaicin-induced depolarisation by 50% at much lower 
concentrations (approx. 10nM) than that of the β1- (100µM) and β3-agonists (1µM).  
 
 
 
Figure 3.6 Non-cumulative concentration-response of β1-/β2-/β3-agonists effect on 
capsaicin depolarisation of guinea pig vagus nerve 
Isolated guinea pig vagus nerve was incubated with vehicle, denopamine (β1-
adrenoreceptor agonist; 10nM-100µM; 10min), formoterol (β2-adrenoreceptor agonist; 
0.1nM-1µM; 20min), olodaterol (β2-adrenoreceptor agonist; 0.1nM-1µM; 20min) or 
BRL37344 (β3-adrenoreceptor agonist; 10nM-100µM; 10min) to examine the effect on 
subsequent capsaicin depolarisation. Data displayed as mean %inhibition of initial 
capsaicin stimulations (internal control) ±SEM, n=4-6, * p<0.05 as determined by paired 
students t-test compared to respective internal control. 
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3.4.2 β-agonists effect on alternative tussive stimuli 
A single concentration of each of the β-adrenergic receptor agonists that was effective at 
inhibiting capsaicin-induced vagus nerve depolarisation was evaluated for their ability to 
inhibit depolarisation to sub-maximal concentrations of acrolein (TRPA1 agonist) and the 
endogenous tussive stimuli PGE2 and bradykinin. All of the β-adrenergic receptor 
agonists evaluated were effective at inhibiting all of these alternative tussive stimuli to 
some extent (Fig. 3.7), suggesting a general mechanism of action on sensory nerve 
depolarisation rather than activity at the capsaicin receptor TRPV1.  
 
 
  
Figure 3.7 Effect of β1-, β2-, and β3-agonists on tussive stimulus induced 
depolarisation of guinea pig isolated vagus nerve 
Isolated guinea pig vagus nerve was incubated with selected concentrations of vehicle, 
denopamine (β1-adrenoreceptor agonist; 100µM; 10min), formoterol (β2-adrenoreceptor 
agonist; 10nM; 20min), olodaterol (β2-adrenoreceptor agonist; 10nM; 20min) or 
BRL37344 (β3-adrenoreceptor agonist; 1µM; 10min) to examine the effect on subsequent 
depolarisations induced by either capsaicin (1µM), acrolein (300µM), PGE2 (10µM) or BK 
(3µM). Data displayed as mean %inhibition of initial stimulations (internal control) ±SEM, 
n=3-4, * p<0.05 as determined by paired students t-test compared to respective internal 
control. 
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3.4.3 Effect of β-receptor antagonists on β-agonists inhibition 
Concentrations of denopamine (β1), olodaterol (β2), formoterol (β2) and BRL37344 (β3) 
effective at inhibiting capsaicin-induced vagus depolarisation by 50% were selected from 
Section 3.3.1 to be evaluated against selective antagonists of the β1-, β2- and β3-
receptors (0.1µM; see Methods 3.2.5 for antagonist names). Only the antagonist of each 
of the β1-, β2- and β3-receptors blocked the inhibitory effect of each of the respective β-
agonists (Fig. 3.8), indicating that the inhibition of capsaicin-induced sensory nerve 
depolarisation at these concentrations is mediated via activation of each of the specific 
receptor sub-types, and not by a crossover effect on another of the receptors.  
 
 
 
  Figure 3.8 Effect of specific β-adrenoreceptor antagonists on β-adrenoreceptor 
agonist inhibition of guinea pig vagus nerve depolarisation 
The effect of β1- (CGP20712A), β2- (ICI118551), β3- (L-748337) antagonist (all 0.1µM; 
pre-incubated for 10min) on vehicle, denopamine (β1-adrenoreceptor agonist; 100µM; 
10min), formoterol (β2-adrenoreceptor agonist; 10nM; 20min), olodaterol (β2-
adrenoreceptor agonist; 10nM; 20min) or BRL37344 (β3-adrenoreceptor agonist; 1µM; 
10min) inhibition of capsaicin-induced (1µM; 2min) depolarisation of guinea pig vagus 
nerve. Data displayed as mean %inhibition of initial capsaicin stimulations (internal 
control) ±SEM, n=4-6, * p<0.05 as determined by paired students t-test compared to 
respective internal control. 
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3.4.4 β-agonists effect in wild-type & knock-out mouse vagus 
 The inhibitory effects of the β1-, β2- and β3-agonists were examined in vagus tissue from 
wild-type (FVB/N), β2- and β3-adrenoreceptor KO (Adrb2-/- and Adrb3-/-) mice. All of the 
agonists exerted an inhibitory effect on capsaicin-induced depolarisation in wild-type 
mice, similar to that observed in guinea pig. In the β2- and β3-receptor KO mice, only the 
inhibitory effect of, respectively, the β2- and β3-agonists was lost (Fig. 3.9). This data 
further confirms that the agonist tools (at the concentrations used here) act specifically on 
their respective receptors to exert their inhibitory effect on capsaicin-induced vagus nerve 
depolarisation.  
 
Figure 3.9 β-agonists effect on capsaicin depolarisation of vagus nerve from wild-
type, β2- or β3-adrenoreceptor KO mice 
The effect of vehicle, denopamine (β1-adrenoreceptor agonist; 100µM; 10min), formoterol 
(β2-adrenoreceptor agonist; 10nM; 20min), olodaterol (β2-adrenoreceptor agonist; 10nM; 
20min) or BRL37344 (β3-adrenoreceptor agonist; 1µM; 10min) on capsaicin-induced 
depolarisation of mouse vagus nerves taken from wild-type (wt), β2-adrenoreceptor KO 
(β2-/-) or β3-adrenoreceptor KO (β3-/-) mice. Data displayed as mean %inhibition of an 
initial capsaicin stimulation (internal control) ±SEM, n=4-6, where * p<0.05 as determined 
by paired students t-test compared to respective internal control.  
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3.4.5 β-agonists effect and selectivity in human vagus 
 Key experiments performed on guinea pig vagus nerve were repeated on human vagus 
nerve tissue, in order to gauge whether the anti-tussive effects observed in guinea pig 
would be likely to translate to humans. The effect of single concentrations of denopamine 
(β1) olodaterol (β2), formoterol (β2), and BRL37344 (β3) on capsaicin-induced 
depolarisation was examined in the presence of vehicle, or selective β1-, β2- or β3- 
  
 
Figure 3.10 Effect of β-agonists ± respective antagonists on capsaicin 
depolarisation of human vagus  
[A] Representative traces of olodaterol (10nM) effect on capsaicin (cap) depolarisation of 
human vagus nerves, in presence of vehicle (upper; 0.1% DMSO) OR ICI118551 (lower; 
0.1µM). [B] The effect of β1- (CGP20712A), β2- (ICI118551), β3- (L-748337) antagonist 
(all 0.1µM; pre-incubated for 10min) on vehicle, denopamine (β1-adrenoreceptor agonist; 
100µM; 10min), formoterol (β2-adrenoreceptor agonist; 10nM; 20min), olodaterol (β2-
adrenoreceptor agonist; 10nM; 20min) or BRL37344 (β3-adrenoreceptor agonist; 1µM; 
10min) inhibition of capsaicin-induced (1µM; 2min) depolarisation of human vagus nerve. 
Data displayed as mean %inhibition of initial capsaicin stimulations (internal control) 
±SEM, n=3, * p<0.05 as determined by paired students t-test compared to respective 
internal control. 
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receptor antagonists. Similarly to the results observed in guinea pig vagus nerve tissue, 
all of the β-adrenergic receptor agonists, including the LABA compounds, were effective 
at inhibiting capsaicin-induced depolarisation of human sensory nerves (Fig. 3.10). 
Furthermore, selective β1-, β2- or β3-receptor antagonists reversed the inhibitory effect of 
the β-receptor agonists, demonstrating the agonists’ inhibitory effects are mediated via 
their respective receptors in human vagus nerve (Fig. 3.10). 
3.4.6 Involvement of adenylyl cyclase activation in β-agonists inhibitory 
effects 
In order to identify the predominant isoform of AC in mouse vagal neurons, the relative 
expression of all the adenylyl cyclase sub-types was first determined by q-PCR in 
isolated mouse vagal ganglia neurons. AC6 appeared to be the predominant sub-type in 
these neurons, being approximately 4-5 times more highly expressed than any other AC 
sub-type in mouse vagal neurons (Fig. 3.11).  
 
Figure 3.11 Relative expression of adenylyl cyclase sub-types in mouse vagal 
ganglia 
Relative mRNA expression of adenylyl cyclase (AC) sub-types 1-10 in vagal ganglia from 
wild-type C57Bl/6 mice. Data displayed as mean±SEM, n=2-3.  
 
 
Therefore in order to determine the involvement of AC in the anti-tussive activity of the β-
receptor agonists, the inhibitory effect of the agonists against capsaicin-induced 
depolarisation was compared in wild-type mice and AC5/6 KO mice. Furthermore, 
forskolin was examined in the same tissues, to determine if a direct activator of AC would 
have a similar inhibitory effect as the β-receptor agonists. A single concentration of 
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capsaicin-induced vagus depolarisation in wild-type mice (Fig. 3.12). What is more, the 
inhibitory effect of forskolin, and that of each of the β-receptor agonists, was not 
observed in vagal tissue from AC5/6 KO mice (Fig. 3.12).  
  
Figure 3.12 Effect of β1-, β2-, and β3-agonists and forskolin on capsaicin-induced 
depolarisation of wild-type or AC5/6 -/- isolated mouse vagus nerve 
The effect of vehicle, denopamine (β1-adrenoreceptor agonist; 100µM; 10min), formoterol 
(β2-adrenoreceptor agonist; 10nM; 20min), olodaterol (β2-adrenoreceptor agonist; 10nM; 
20min), BRL37344 (β3-adrenoreceptor agonist; 1µM; 10min) or forskolin (adenylyl 
cyclase activator; 10µM; 10min) on capsaicin-induced depolarisation of mouse vagus 
nerves taken from wild-type (wt), or adenylyl cyclase 5/6 knock-out (-/-) mice. Data 
displayed as mean %inhibition of an initial capsaicin stimulation (internal control) ±SEM, 
n=3-5, where * p<0.05 as determined by paired students t-test compared to respective 
internal control. 
 
Mice used for vagal tissue experiments were genotyped to confirm that they possessed 
either the wild-type or AC5/6 KO genotype. A representative sample of these results is 
shown in Figure 3.13 below. 
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Figure 3.13 Verification of genomic DNA in samples from wild-type and AC5/6 KO 
mice 
The presence of the wild-type (wt) or knock-out (KO) AC6 allele in DNA extracted from 
the tail-tips of mice used for experiments in Figure 3.12 was assessed by PCR 
amplification using specific primers for either the wt or KO allele. The DNA samples were 
stained, and run by electrophoresis across an agarose gel, alongside a DNA ladder (L) of 
known basepair (bp) sizes, and a water control (W). The stain was visualised under UV 
light and the gel was photographed. [A] shows the results of amplification in the 
presence of the wt primers, which gave an expected product of 550bp. [B] shows the 
results of amplification in the presence of the KO primers, which gave an expected 
product of 2.2kbp.  
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3.4.7 Effect of K+ channel blockers on β-agonists inhibition 
Previously, the BKCa, (but not IK, SK or KATP) potassium channel has been implicated 
with a key role in the blockade of depolarisation by fenoterol (Freund-Michel et al., 2010). 
Here, we examined the effect of blockers of these four types of K+ channel on β-receptor 
agonist inhibition of capsaicin-induced depolarisation of guinea pig vagus nerve. The 
BKCa blocker paxilline (1µM) significantly reduced the inhibitory effect of the LABA 
compounds, olodaterol and formoterol, as well as that of β1- and β3-receptor agonists 
(Fig. 3.14a). Olodaterol was still significantly effective in the presence of blockers of the 
other K+ channels (Fig. 3.14b). This data suggests that opening of BKCa channels plays a 
role in the inhibitory effects of β-agonists observed in the vagus nerve. 
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Figure 3.14 Effect of K+ channel blockers on β-agonist inhibition of capsaicin-
induced depolarisation of guinea pig vagus nerve  
[A] The effect of paxilline (BKCa blocker; 1µM; pre-incubated for 10min) on vehicle (0.1% 
DMSO), denopamine (β1-adrenoreceptor agonist; 100µM; 10min), formoterol (β2-
adrenoreceptor agonist; 10nM; 20min), olodaterol (β2-adrenoreceptor agonist; 10nM; 
20min) or BRL37344 (β3-adrenoreceptor agonist; 1µM; 10min) inhibition of capsaicin-
induced (1µM; 2min) depolarisation of guinea pig vagus nerve. [B] The effect of vehicle 
(0.1% DMSO), paxilline (1µM), clotrimazole (IKCa blocker; 10µM), apamin (SKCa blocker; 
1µM) or glybenclamide (KATP blocker; 10µM), pre-incubated for 10min, on olodaterol 
(10nM; 20min) inhibition of capsaicin-induced (1µM; 2min) depolarisation of guinea pig 
vagus nerve. Data displayed as mean %inhibition of initial capsaicin stimulations (internal 
control) ±SEM, n=3-6, where * p<0.05 as determined by paired students t test compared 
to internal control, θ p<0.05 as determined Mann-Whitney U test compared to vehicle 
control, and ⊥ p<0.05 as determined by Kruskal-Wallis with Dunn’s post-test compared to 
vehicle control. 
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3.5 Summary/Discussion 
The aim of this chapter was to examine the effect of two clinically relevant LABAs on 
sensory nerve depolarisation and cough, and further to investigate the mechanism of 
action and signaling pathways mediating any anti-tussive action of β-adrenergic receptor 
agonists in sensory nerves.  
 
The LABA compounds formoterol and olodaterol were evaluated in a guinea pig model of 
capsaicin-induced cough. At concentrations reported to be bronchoprotective against 
acetylcholine-induced pulmonary resistance in an in vivo model of bronchoconstriction 
(Bouyssou et al., 2010), both olodaterol and formoterol were effective at inhibiting 
capsaicin-induced coughs and also the firing of single airway terminating C-fibres. This 
finding suggests that these compounds are likely to be useful as anti-tussives within the 
therapeutic range for their intended bronchodilator effects. What is more, both LABA 
compounds inhibited capsaicin-evoked firing of airway-terminating C-fibres, which are 
thought to play an important role in the dysregulation of the normal cough reflex in 
respiratory diseases such as asthma and COPD (Coleridge & Coleridge, 1984). As well 
as inhibiting capsaicin-evoked firing of airway C-fibres, the LABA compounds also had an 
inhibitory effect on capsaicin-induced calcium influx in isolated airway-terminating jugular 
ganglia neurons, further suggesting that β2-receptor agonists exert their anti-tussive 
activity by inhibiting sensory nerve depolarisation, which is independent of their 
bronchodilator activity. This finding is important, as it has been suggested previously that 
β2-adrenergic receptor agonists may inhibit cough via their (non-neuronal) bronchodilator 
effect (Pounsford et al., 1985; Mulrennan et al., 2004). 
 
It was also determined that both of the LABA compounds (olodaterol and formoterol), as 
well as agonists of β1- and β3-adrenergic receptors, were effective at inhibiting capsaicin-
induced vagus nerve depolarisation in vitro. These agonists also inhibited other tussive 
stimuli, such as acrolein (TRPA1), and endogenous tussive stimuli such as PGE2 and 
BK, indicating a general inhibitory activity on sensory nerves rather than a direct effect on 
TRPV1 activation.  
 
The LABA compounds are reported to cause maximal relaxation of in vitro smooth 
muscle preparations at approximately 10nM (Bouyssou et al., 2010), which is the same 
concentration at which they caused significant inhibition of vagus nerve depolarisation in 
the isolated vagus nerve preparation. This further suggests that the LABA compounds 
would be likely to have an anti-tussive effect at the same concentrations as those used 
for bronchodilation.  
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Having established that the LABA compounds were effective at inhibiting in vivo cough, 
and that these compounds, as well as the β1- and β3-adrenergic receptor agonists, inhibit 
depolarisation of vagal sensory nerves, the receptors and signalling pathways activated 
by the agonists were examined. This is the first time that an inhibitory effect on sensory 
nerve activation has been shown by β1- and β3-adrenergic receptor agonism. Indeed, it 
has been reported that β3-adrenergic receptor agonism potentiates capsaicin-induced 
depolarisation of rat vagal chemosensitive neurons (Gu et al., 2006). Due to this 
apparent contradiction, it was important to assess the specificity of the agonist tools 
being used. Initially pharmacological tools were used in the isolated vagal preparation to 
show that the inhibitory effect of the agonists could be blocked by a single selected 
concentration of selective antagonists of the β1-, β2- and β3-adrenergic receptors. 
Furthermore it was clearly shown that the β2- and β3-adrenergic receptor agonists had no 
effect in mice lacking the respective receptors, and that all three agonists were just as 
effective in the non-respective knock-out and wild-type mice.  
 
Having thus confirmed that agonists were acting on the β1-, β2- and β3-adrenergic 
receptors to inhibit sensory nerve depolarisation, key experiments were repeated in 
human vagus nerve tissue, showing that the findings of an inhibitory effect of β1-, β2- and 
β3-adrenergic receptor agonism on sensory nerve depolarisation and therefore cough 
may be reasonably expected to translate to humans in the clinic.  
 
Much research has been conducted into the signalling of β2-adrenergic receptors in 
airway smooth muscle relaxation, with the classical view being that β2-adrenergic 
receptors couple to Gαs, inducing adenylyl cyclase activation, causing an increase in 
cAMP, which activates PKA to cause downstream opening of potassium channels (Cook 
et al., 1993; Johnson, 1998). However, it has been suggested that, in vagal sensory 
nerves, β2-adrenergic receptor agonists cause downstream activation of PKG rather than 
PKA (Freund-Michel et al., 2010). For this thesis however, the involvement of PKA/G was 
not investigated, rather certain critical steps in the classical β2-adrenergic receptor 
agonists pathway were examined – namely adenylyl cyclase and potassium channel 
involvement.  
 
Using genetic tools available in the mouse, it was shown that adenylyl cyclase sub-type 6 
is the predominant form of AC expressed in mouse vagal ganglia, and further, in mice 
adenylyl cyclase 5/6 KO mouse vagus nerve tissue, the β-adrenergic receptor agonists 
did not inhibit sensory nerve depolarisation. What is more, an activator of adenylyl 
cyclase (forskolin), which mimicked the inhibitory effect of β-adrenergic receptor agonists 
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in wild-type vagus nerve tissue also had no effect in AC5/6 KO mouse tissue, 
demonstrating the critical involvement of AC in this process. 
 
Finally the involvement of potassium channels was examined, with the result that only the 
BKCa channel blocker paxilline was effective at partially reversing the inhibitory effect on 
sensory nerves. This pharmacological assessment confirmed the involvement of the 
BKCa channel in the β-receptor effect on sensory nerves, however further work with a 
wider range of concentrations and/or mice lacking the BKCa channel would be required to 
conclusively demonstrate a role for this channel. However, a mechanism of action 
involving hyper-polarisation of sensory nerves via opening of potassium channels 
(reducing cellular excitability) concurs with the finding that β-receptor agonists have a 
general anti-tussive effect on multiple stimuli, rather than an effect on a specific 
‘upstream’ calcium channel such as TRPV1. Indeed, it has previously been shown that 
an opener of BKCa channels (NS1619) has similar effects to β-receptor agonists; both 
inhibiting vagus nerve firing to a range of tussive agents and inhibiting CA-evoked cough 
(Fox et al., 1997).  
 
These findings, taken together, indicate that β-receptor agonists, and specifically the 
LABA compounds olodaterol and formoterol, may be useful as general and clinically safe 
anti-tussives. 
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4.1 Introduction 
The methylxanthine theobromine has previously been shown to inhibit cough and 
sensory nerve activation in both pre-clinical and in clinical models (Usmani, 2004). This 
anti-tussive activity was suggested to be a property unique to theobromine, and not a 
function of its methylxanthine structure (Usmani, 2004). However recently it has been 
demonstrated that theophylline can also inhibit citric acid evoked cough in guinea pigs 
(Mokry & Nosalova, 2011), suggesting that methylxanthines as a drug class may have 
anti-tussive activity.  
 
Theophylline is widely known as a bronchodilator, which has been used for the treatment 
of respiratory diseases such as asthma and COPD for several decades, and yet its 
mechanism of action in this role has not been fully elucidated. Theophylline is a weak 
and non-specific inhibitor of phosphodiesterases (PDEs), causing cAMP and cGMP 
accumulation at higher concentrations, and this property is frequently associated with its 
bronchodilator activity (Rabe et al., 1995; Niewoehner et al., 2002). It is thought that this 
cAMP accumulation in airway smooth muscle initiates a signaling cascade which results 
in opening of large-conductance potassium channels to cause relaxation of smooth 
muscle (Miura et al., 1992b; Ise et al., 2003; Liu et al., 2003; Wu et al., 2004; Xin et al., 
2012). The signaling mechanisms by which theophylline, or methylxanthines more 
generally, exert their anti-tussive effects have not yet been investigated.  
 
The aim of this chapter was to study the effect of theophylline on sensory nerve 
depolarisation and cough to a range of different stimuli, to gauge its effectiveness as a 
general anti-tussive. The secondary aim of this chapter was to examine the mechanism 
of action of theophylline in sensory nerves and neurons. 
 
In order to fulfill these aims, the ability of theophylline to inhibit both citric acid- and 
capsaicin-evoked cough, as well as capsaicin-evoked in vivo sensory nerve firing and in 
vitro intracellular calcium movement in airway neurons was examined. Furthermore, the 
isolated vagus nerve preparation was used to examine the mechanism of action of 
theophylline, as a more pharmacologically amenable and cost-effective assay system. 
Using this system, the effect of theophylline was examined on depolarisation induced by 
a range of exogenous and endogenous tussive stimuli. Pharmacological blockers of 
potassium channels were used in the isolated vagus preparation to examine the role of 
potassium channels in the effects of theophylline. Furthermore, this preparation allowed 
the use of human donor vagal tissue to show that the effects observed in animal models 
may translate to the clinic.  
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Finally, the nature of the interaction between theophylline and specific potassium 
channels highlighted by experiments in the isolated vagus perparation was examined 
using whole cell perforated and inside-out single channel patch clamp techniques on 
primary guinea pig jugular ganglia neurons.  
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4.2 Methods 
4.2.1 Determining the effect of theophylline on capsaicin- and CA-evoked 
cough in the conscious guinea pig 
In order to examine the effect of theophylline, male Dunkin Hartley guinea pigs were 
administered vehicle (0.5%w/v methylcellulose, 0.2%v/v tween80 in PBS), or theophylline 
(0.3-100mg.kg-1, i.p.) 1h prior to challenge with tussive agent. For cough recordings, a 
guinea pig was placed into a Perspex chamber attached to a microphone where coughs 
could be observed and recorded as described previously (Methods 2.2). A baseline 
recording was taken for 5min, and then capsaicin (60µM) was administered by aerosol 
for 5min, during which time coughs were counted and Penh recorded, as well as for a 
further 5min post-exposure, using the Buxco Cough Analyser. Alternatively, citric acid 
(300mM) was administered by aerosol for 10min, during which time coughs were counted 
and Penh recorded using the Buxco Cough Analyser. The route of administration was 
selected from Mokry & Nosalova (2011), and the timings for assessment of cough 
response following treatment was selected from Freund-Michel et al. (2010). 
 
4.2.2 Determining the effect of theophylline on guinea pig airway-terminating 
C-fibre firing 
The general premise of this technique was to assess the effect of theophylline on the 
firing activity of a single afferent airway-terminating C-fibre in response to capsaicin. To 
that end, surgery and setup was performed as described in Methods 2.6 to allow 
assessment of action potentials generated by capsaicin aerosol in single afferent C-fibres 
of anaethetised and artificially ventilated guinea pigs.  After surgery and setup, the 
animals were allowed to stabilise for at least 30min. After a control baseline recording of 
at least 2min, capsaicin (100µM) was administered by aerosol for 15s and changes in 
fibre activity, intra-tracheal pressure and blood pressure were continuously recorded until 
baseline or a steady state was re-established. After 10min, the capsaicin aerosol (15s, 
100µM) was repeated. After a further 10min vehicle (0.1%v/v DMSO in PBS) or 
theophylline (100mg.kg-1) were administered i.v.. A final capsaicin aerosol (15s, 100µM) 
was administered 20min after vehicle/drug administration. In addition, in order to further 
separate the action of theophylline on sensory nerve firing from its known bronchodilator 
activity in an in vivo setting, the experiments above were repeated, except with PGE2 as 
the challenge agent instead of capsaicin. The protocol described above was therefore 
modified by evoking nerve firing with aerosolised PGE2 (100µg.ml-1, 1min) instead of 
aerosolised capsaicin. In addition, an application of aerosolised capsaicin was used prior 
at the start of the experiment to aid identification of a C-fibre.  
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4.2.3 Determining the effect of theophylline on capsaicin-induced responses 
in isolated airway jugular ganglia neurons 
Male Dunkin-Hartley guinea pigs were euthanised, jugular ganglia were removed, and 
individual jugular ganglia neurons were isolated as described in Methods 2.4. The jugular 
and nodose ganglia contain the majority of the cell bodies for airway terminating vagal 
sensory neurons. Previous data in our group indicated that a greater proportion of jugular 
ganglia neurons respond to capsaicin (Grace et al., 2012). For this reason only jugular 
neurons were used to examine the inhibitory effects of theophylline.  
 
As described previously (Methods 2.4.1) guinea pigs had been i.n. dosed with DiI, a 
retrograde tracer dye, and airway-terminating neurons isolated from these animals were 
identified by the DiI present in their plasma membranes. Isolated neurons were incubated 
(37°C, 5%CO2) overnight in complete F12 media (containing penicillin and streptavidin), 
in order to allow adherence to poly-D-lysine- and laminin-coated fluorodishes. 
Immediately prior to imaging experiments, cells were incubated with the calcium sensitive 
dye Fura-2AM.  
 
To test the effect of theophylline on the release of calcium in the ganglia, cells were 
acquired using a confocal epi-fluorescence microscope, and sensory neurons were 
identified by their body characteristics (20-30µM diameter) and light diffraction in phase 
contrast, whilst DiI emission was used to identify airway-terminating neurons. The 
fluorodish was connected to a pressurised perfusion system that allowed rapid change of 
the bath solutions as per the following protocol:  
 
An initial control response to application of K50 solution (50mM hyper-potassium solution 
containing; 50mM KCl; 91.4mM NaCl; 1mM MgCl2; 1.8mM CaCl2; 0.33mM NaH2PO4; 
10mM D-Glucose; 10mM HEPES; pH adjusted with NaOH to 7.4) was used to assess 
cell viability, and this response was used to normalise all subsequent responses within 
each cell. After perfusion with ECS to remove the K50 solution and allow recovery of 
calcium and voltage dye emissions back to baseline, cells were then stimulated twice 
with capsaicin (1µm) as control responses followed by a wash with ECS to recover 
baseline levels. The cells were then incubated with vehicle (0.1% DMSO in ECS), or 
theophylline (0.01, 0.1, 1 or 1µM) for 10min, and then re-stimulated with capsaicin in the 
presence of test compounds. ECS was then perfused for 10min to remove capsaicin and 
theophylline, following which a final capsaicin stimulation and K50 application were used 
to confirm that capsaicin responses recovered once the drug was removed, and that the 
cell(s) remained viable.  
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4.2.4 Determining the effect of theophylline on isolated vagus nerve 
depolarisation 
The following experimental protocol was used to examine the effects of theophylline on 
isolated vagus nerve depolarisation induced by tussive stimuli. Following sacrifice of the 
guinea pig and dissection of the vagus nerve as outlined previously (Methods 2.3), the 
isolated nerve was allowed to equilibrate for 10min in the grease-gap chamber, following 
which capsaicin (1µM) was perfused for 2min, causing depolarisation. The nerve was 
then ‘washed’ (perfusion of KH alone) until the signal returned to baseline. Two 
reproducible responses to capsaicin were recorded in this way, following which the vagus 
nerve was incubated with vehicle (0.1% DMSO) or theophylline (0.1-100µM) for 10min, 
according to a standard protocol for examining efficacy in this system (Freund-Michel et 
al., 2010). The vagus was then re-challenged with capsaicin, in the presence of test 
compound. Following a ‘wash’ period of 10min, a final stimulation of capsaicin was used 
to determine tissue viability. On each piece of nerve tissue, only one concentration of any 
vehicle or drug was examined. 
 
A single sub-maximal concentration of theophylline was selected for evaluation against, 
acrolein (300µM), PGE2 (10µM), or bradykinin (3µM). These compounds were used in 
place of capsaicin as described above.  
 
4.2.5 Determining the role of K+ channels in the action of theophylline on 
vagus nerve depolarisation 
The role of potassium channels in the action of theophylline on vagus nerves was 
investigated by examining the effect of the K+ channel blockers paxilline, clotrimazole, 
apamin or glibenclamide on inhibition of capsaicin by theophylline. The channel blockers 
were evaluated against a single sub-maximal concentration of theophylline on guinea pig 
vagus nerve. The protocol used here was modified from that described in Section 4.2.4, 
as follows: two control responses to capsaicin were generated, and then vehicle (0.1% 
v/v DMSO), paxilline (1µM), apamin (1µM), glibenclamide (10µM) or clotrimazole (10µM) 
were incubated for 10min alone, and then co-incubated for 10min with vehicle or 
theophylline (single sub-maximal concentration). The nerve was then stimulated with 
capsaicin in the presence of both vehicle/channel blocker and vehicle/theophylline, 
followed by a ‘wash’ period of 10min, and a final stimulation with capsaicin alone. 
Concentrations of potsassium channel blockers were selected from Freund-Michel et al. 
(2010).  
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4.2.6 Determining the mechanism of action of theophylline on K+ channels in 
guinea pig airway neurons  
The role of potassium channels in the action of theophylline on sensory nerves, and the 
nature of this interaction, was investigated using whole cell perforated, and also inside-
out single channel type patch clamping techniques. Primary guinea pig jugular ganglia 
were isolated and allowed to adhere to laminin and poly-D-lysine coated petri dishes as 
described in Methods 2.4. Isolated neurons were incubated (37°C, 5%CO2) overnight in 
complete F12 media (containing penicillin and streptavidin), in order to allow adherence 
to poly-D-lysine- and laminin-coated fluorodishes.  
 
Ganglia cells were acquired using a bright field microscope, and sensory neurons were 
identified by their body characteristics (20-30µM diameter) and light diffraction in phase 
contrast. The fluorodish was connected to a pressurised perfusion system that allowed 
rapid change of the bath solutions. Prior to experiments isolated neurons were bathed in 
ECS, and all experiments were performed in this media except where otherwise stated.  
 
For whole cell patch clamp recording, a 2-3MΩ micropipette (Borosilicate glass, Warner 
Instruments, UK), back filled with 325µg.ml-1 amphotericin-B, was sealed to the cell of 
interest using a 3-6gΩ seal. The cell membrane inside the micropipette was then 
perforated by the amphotericin B diffusing to the pipette tip within 20min. Potassium 
currents were elicited using 800ms depolarizing square pulses at 10mV increments 
between -100mV and 120mV with a holding potential of -70mV. Current amplitude was 
measured as the average of the current value during the last 50ms of the pulse. 
Immediately prior to each recording, ECS was replaced with a modified extracellular 
solution (mECS, in mM: KCl 5.4, Choline-Cl 143.5, MgCl2 1, NaH2PO4 0.33, D-Glucose 
10, HEPES 10. pH 7.4 using KOH at 37°C, 321.71mOsm.L-1) supplemented with 
tetrodotoxin (300 nM), nifedipine (1 µM), paxilline (1 µM) and glibenclamide (10 µM), to 
block the opening of sodium and calcium channels, as well as potassium channels apart 
from those of interest. The perfusion was reverted back to ECS between series of 
voltage-step recordings. Clotrimazole- and apamin-sensitive currents were calculated by 
the current difference between control recordings in mECS and currents recorded during 
perfusion of clotrimazole (10 µM) or apamin (1 µM) in mECS. 
 
For excised inside-out recording, a 5-8MΩ micropipette (Borosilicate glass, Warner 
instruments, UK) was sealed to the cell of interest using a seal of at least 10gΩ. The cell 
membrane patch held inside the micropipette was then ripped from the rest of the cell to 
leave an intact membrane sealed to the micropipette tip separated from the intracellular 
machinery. Potassium currents were recorded in iso-potassium conditions, using an 
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intra-cellular solution (ICS, in mM; K-Gluconate 120, KCl 30, HEPES 10 and EGTA 10; 
pH adjusted to 7.2 using KOH, 330mOsm.L-1) in the bath, and modified ICS (ICS + 
Sucrose 5mM, 335 mOsm.L-1) in the micropipette, supplemented with tetrodotoxin 
(300nM), nifedipine (1µM), clotrimazole (1µM), paxilline (1µM) and glibenclamide (10µM) 
to block the opening of sodium and calcium channels, as well as potassium channels, 
apart from those of interest. Clotrimazole- and apamin-sensitive currents were then 
assessed in the absence or presence of theophylline in ICS (500nM free Ca2+) and low 
calcium ICS (20nM free Ca2+). Free calcium concentrations of 20nM and 500nM were 
achieved by adding to the bath soultion calcium amounts calculated using the Stanford 
University software “Ca- EGTA Calculator v1.3” 
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4.3 Anti-tussive potential of theophylline 
4.3.1 Theophylline effect on naïve guinea pig cough 
The effect of theophylline on numbers of cough evoked by capsaicin or citric acid was 
examined. Conscious guinea pigs were treated with vehicle or theophylline (0.3-
100mg.kg-1 i.p.), and 1h later were challenged with an aerosol of capsaicin (60µM) or 
citric acid (300mM) to evoke cough, during which, and for 5 minutes post-aerosol, the 
number of coughs evoked was recorded. Theophylline at 30 and 100mg.kg-1 significantly 
attenuated the cough response to capsaicin, whereas coughs evoked by citric acid were 
also inhibited only at 100mg.kg-1 (Fig. 4.1).  
 
Figure 4.1 Dose response of theophylline effect on guinea pig capsaicin-or citric 
acid-evoked cough 
Guinea pigs were pre-treated with vehicle (0.5%w/v methylcellulose, 0.2%v/v tween80 in 
PBS) or theophylline (100mg.kg-1), administered i.p., 1h prior to [A] 5min aerosol of 
capsaicin (60µM) after which number of coughs was recorded for a 10min period 
(including 5min of aerosol plus 5min post-aerosol), or, [B] 10min aerosol of citric acid 
(0.3M) during which number of coughs was recorded. Data displayed as mean±SEM, 
n=12-15, θ p<0.05 as determined by Kruskal-Wallis with Dunn’s post-test, comparing all 
columns to vehicle control.  
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4.3.2 Theophylline effect on guinea pig airway-terminating C-fibre firing 
The effect of theophylline on capsaicin-evoked firing of airway-terminating, single vagal 
afferent chemosensitive C-fibres and capsaicin-evoked bronchoconstriction was 
examined, as shown in the example trace below (Fig. 4.2a). At the same dose 
(100mg.kg-1 i.v.) that inhibits the in vivo cough response, theophylline significantly 
reduced the peak firing rate (13.2±5.9 to 3.7±1.4 imp.s-1) and number of action potentials 
(210.3±44.3 to 37.7±20.2 impulses) evoked by intra-tracheal instillation of a capsaicin 
(100µM) aerosol (Fig. 4.2b&c). Baseline activity was recorded immediately prior to 
capsaicin aerosol, and there was little spontaneous activity in these fibres (data not 
shown). Theophylline also reduced capsaicin-evoked bronchoconstriction (Fig. 4.2d). 
 
Figure 4.2 Theophylline inhibition of capsaicin-evoked action potentials and 
bronchoconstriction in airway-terminating chemosensitive C-fibres  
[A] Example trace showing the effect of theophylline on capsaicin-evoked action potential 
firing of an airway-terminating, chemosensitive C-fibre. Lower panel shows action 
potential firing of the C-fibre, whilst upper panel shows tracheal pressure on same time-
scale, with arrows indicating time of drug applications. [B-D] All animals were firstly 
exposed to aerosolised capsaicin (15s, 100µM) alone, twice consecutively (internal 
control), and vehicle (0.5%w/v methylcellulose, 0.2%v/v tween80 in PBS) or theophylline 
(100mg.kg-1) was administered i.p. 1h prior to subsequent capsaicin application. Single 
C-fibre afferent nerve responses were assessed by recording [B] firing rate and [C] total 
impulses. Capsaicin evoked bronchoconstriction [D] was also assessed. Data displayed 
as mean±SEM, n=3 where * p<0.05 as determined by paired students t-test compared to 
respective internal control (caps). 
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Whilst it can be seen in the example trace (Fig. 4.2) above that capsaicin evoked firing 
prior to the bronchoconstriction (increase in tracheal pressure), it is unclear that the 
inhibitory effect of theophylline on C-fibres firing in this preparation is separate from its 
bronchodilator activity. Similarly to capsaicin, PGE2 evokes firing of C-fibres, but unlike 
capsaicin it does not cause bronchoconstriction. Theophylline was therefore evaluated 
against this tussive agent to determine if it was directly inhibiting C-fibre firing 
independently of any bronchodilator activity. Indeed, theophylline significantly reduced 
the peak firing rate (16.4±4.7 to 4.3±2.3 imp.s-1; Fig. 4.3a&b) and number of action 
potentials (180.3±23.6 to 20.4±5.8 impulses; Fig. 4.3c&d) evoked by PGE2 aerosol 
(100µg.ml-1, 1min). PGE2 did not, however, cause any bronchoconstriction (4.3e&f). 
 
Figure 4.3 Theophylline inhibition of PGE2-evoked action potentials in airway-
terminating chemosensitive C-fibres 
All animals were firstly exposed to aerosolised capsaicin (cap; 15s, 100µM) to identify 
chemosensitive fibres. For experiments animals were exposed to aerosolised PGE2 
(100µg.ml-1, 1min) alone, twice consecutively (internal control), and then vehicle 
(0.5%w/v methylcellulose, 0.2%v/v tween80 in PBS) or theophylline (100mg.kg-1) was 
administered 1h prior to subsequent administration of PGE2. Single afferent C-fibre 
responses were assessed by monitoring [A&B] firing rate, and [C&D] total impulses. 
[E&F] Bronchoconstriction was also assessed. Data displayed as mean±SEM, n=3 
where * p<0.05 as determined by paired students t-test compared to respective internal 
control (PGE2). 
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4.3.3 Theophylline effect on guinea pig airway isolated neurons 
The effect of theophylline on capsaicin-induced intracellular calcium levels was examined 
in single chemo-sensitive airway-terminating neurons of the jugular ganglia. Theophylline 
significantly inhibited the capsaicin-induced increase in intracellular calcium levels at all 
concentrations used, in a dose-dependent manner (Fig. 4.4). 
 
 
Figure 4.4 Theophylline inhibition of capsaicin-induced calcium influx in jugular 
airway-terminating neurons 
[A] Representative trace of theophylline effect on capsaicin-induced intracellular calcium 
levels. Open triangles indicate K50 (50mM KCl in ECS solution, 15s) application, closed 
triangles indicate capsaicin (caps; 0.1µM, 30s) application, line indicates theophylline 
(1nM, 5min) incubation. [B] Summary graph shows the effect of theophylline (0.1-100µM) 
on capsaicin(0.1µM)-induced increases in intracellular calcium. Data displayed as mean 
%inhibition of initial capsaicin stimulations (internal control) ±SEM, n=9-20 cells from 3-4 
guinea pigs, * p<0.05 as determined by paired students t-test compared to respective 
internal control. 
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4.4 Mechanism of action of theophylline 
4.4.1 Theophylline effect on guinea pig vagus 
The effect of theophylline on capsaicin-induced depolarisation of guinea pig isolated 
vagus nerves was examined. Theophylline (0.1-100µM) caused a concentration-
dependent inhibition of capsaicin-induced sensory nerve depolarisation, which was 
significant at concentrations of 1µM or higher (Fig. 4.5).  
 
Figure 4.5 Non-cumulative concentration-response of theophylline effect on 
capsaicin depolarisation of guinea pig isolated vagus nerve 
Isolated guinea pig vagus nerve was incubated with vehicle or theophylline (0.1-100µM) 
to examine the effect on subsequent capsaicin depolarisation. Data displayed as mean 
%inhibition of initial capsaicin stimulations (internal control) ±SEM, n=8-18, * p<0.05 as 
determined by paired students t-test compared to respective internal control. 
 
 
 
4.4.2 Theophylline effect on alternative tussive stimuli 
A sub-maximal concentration of theophylline, which was effective at inhibiting capsaicin-
induced vagus nerve depolarisation, was evaluated for its ability to inhibit depolarisation 
induced by sub-maximal concentrations of a range of alternative tussive stimuli – acrolein 
(300µM), a TRPA1 agonist, and the endogenous tussive stimuli PGE2 (10µM) and 
bradykinin (3µM). Theophylline was effective at inhibiting all of these alternative tussive 
stimuli by approximately 55-80% at the single concentration of 10µM used (Fig. 4.6), 
suggesting a general mechanism of action on sensory nerve depolarisation rather than 
activity at the capsaicin receptor TRPV1.  
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Figure 4.6 Effect of theophylline on tussive stimuli-induced depolarisation of 
guinea pig isolated vagus nerve  
Isolated guinea pig vagus nerve was incubated with theophylline (10µM) to examine the 
effect on subsequent depolarisations induced by either capsaicin (1µM), acrolein 
(300µM), PGE2 (10µM) or BK (3µM). Data displayed as mean %inhibition of initial 
stimulations (internal control) ±SEM, n=3-4, * p<0.05 as determined by paired students t-
test compared to respective internal control. 
 
4.4.3 Role of K+ channels in theophylline inhibition on guinea pig vagus 
The effect of blockers of BKCa, IKCa, SKCa, KATP type potassium channels (paxilline, 
clotrimazole, apamin and glibenclamide respectively) on theophylline inhibition of 
capsaicin-induced depolarisation of guinea pig vagus nerve was examined. The SKCa 
blocker apamin (1µM) significantly reduced the effect of theophylline on capsaicin-
induced depolarisation (Fig. 4.7), indicating the SKCa channel is involved in the inhibitory 
effects of theophylline on guinea pig vagus nerve. Whilst theophylline was still effective in 
the presence of blockers of the other K+ channels, in the case of the IKCa blocker 
clotrimazole (10µM), there did appear to be a small reduction in the effect of theophylline, 
although this did not reach significance. This data suggests that opening of potassium 
channels, and specifically SKCa type potassium channels, plays a role in the inhibitory 
effects of theophylline on sensory nerve depolarisation. 
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Figure 4.7 Effect of K+ channel blockers on theophylline inhibition of capsaicin-
induced vagus nerve depolarisation 
The effect of vehicle (0.1% DMSO), paxilline (BKCa blocker; 1µM), apamin (SKCa blocker; 
1µM), glibenclamide (KATP blocker; 10µM) or clotrimazole (IKCa blocker; 10µM) pre-
incubated for 10min, on theophylline (10µM) inhibition of capsaicin-induced (1µM; 2min) 
depolarisation of guinea pig vagus nerve. Data displayed as mean %inhibition of initial 
capsaicin stimulations (internal control) ±SEM, n=3-6, where * p<0.05 as determined by 
paired students t test compared to internal control, and θ p<0.05 as determined Mann-
Whitney U test compared to vehicle control. 
 
4.4.4 Theophylline effect on human vagus 
Key experiments performed on guinea pig vagus nerve were repeated on human vagus 
nerve tissue, in order to determine whether the anti-tussive effects observed in guinea 
pig would be likely to translate to humans. The effect of a single concentration of 
theophylline on capsaicin-induced depolarisation was examined in the presence of, and 
following pre-incubation (10min) with, vehicle, apamin or clotrimazole. Similarly to the 
results observed in guinea pig vagus nerve tissue, theophylline was effective at inhibiting 
capsaicin-induced depolarisation of human sensory nerves (Fig. 4.8). Again, similarly to 
the results obtained in guinea pig vagus, apamin significantly reduced the inhibitory effect 
of theophylline, whereas clotrimazole (IKCa) did not have a significant effect, 
demonstrating that at least the SKCa channel plays a role in the effect of theophylline on 
human vagus nerve.  
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Figure 4.8 Effect of theophylline ± K+ channel blockers on depolarisation of human 
vagus nerve 
 [A] Representative traces of theophylline effect on capsaicin (cap) depolarisation of 
human vagus nerves, in presence of vehicle (upper; 0.1% DMSO) OR apamin (lower; 
1µM). [B] The effect of vehicle (0.1% DMSO), apamin (SKCa blocker; 1µM), or 
clotrimazole (IKCa blocker; 10µM), pre-incubated for 10min, on theophylline (10µM) 
inhibition of capsaicin-induced (1µM; 2min) depolarisation of human vagus nerve. Data 
displayed as mean %inhibition of initial capsaicin stimulations (internal control) ±SEM, 
n=3-4, * p<0.05 as determined by paired students t-test compared to respective internal 
control, and θ p<0.05 as determined Mann-Whitney U test compared to vehicle control. 
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4.4.5 Effect of theophylline on K+ currents 
The effect of theophylline on resting membrane potential was examined using patch 
clamp on primary jugular neurons. In a perforated patch experiment, which preserves the 
intracellular content and [Ca2+]i, theophylline caused a significant hyperpolarisation of the 
cell membrane (Fig. 4.9 panel a). The effect of theophylline on SKCa and IKCa currents 
was then investigated. In the presence of theophylline, both apamin- and clotrimazole-
sensitive potassium currents over a series of voltage steps were increased, as shown in 
the representative traces in Figure 4.9, panels b & c, respectively. The apamin- and 
clotrimazole-sensitive currents evoked by the voltage steps were then normalised to the 
size of the cell they were recorded from to give the current density. Overall theophylline 
increased both apamin- and clotrimazole-sensitive potassium current density, indicating 
that theophylline increases opening of both SKCa and IKCa channels, respectively. The 
effect on the apamin-sensitive (SKCa) current (Fig. 4.9d) reached significance at lower 
voltages (-30mV, p<0.05) than that of the clotrimazole-sensitive (IKCa) current (Fig. 4.9e: 
60mV, p<0.05), indicating that theophylline is likely to have a greater effect on SKCa at 
voltages closer to the resting membrane potential of the cell (-70mV).    
 
The single-channel, or inside-out patch clamp technique was then used to investigate 
whether theophylline acts directly on SKCa, independent of second messengers. This 
technique allows examination of the activity of a small number of channels on a patch of 
membrane separated from the rest of the cell. Figure 4.10a shows an example trace of 
the current through the SKCa channels present on the cell membrane patch in the 
absence and presence of theophylline, from which the frequency and number of SKCa 
channels in an open state was determined. As can be seen in the summary amplitude 
frequency histograms theophylline increased the channel open probability of SKCa 
channels by 62±7% at -100 mV voltage and in the presence of 500nM free calcium (Fig. 
4.10c). In addition, the theophylline effect appeared to be calcium-dependent as when 
[Ca2+]i is reduced to 20nM (the calcium concentration at which the open probability falls 
near to zero in the control) theophylline failed to induce any further channel opening (Fig. 
4.10b).  
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Figure 4.9 Theophylline effect on K+ channels in whole cell perforated patch 
clamped guinea pig jugular ganglia neurons 
[A] Representative trace (left) and summary graph (right, n=4) of theophylline effect on 
membrane resting voltage. * p<0.05 as determined by Mann-Whitney U test. Example 
trace of [B] apamin(1µM)-sensitive current, and [C] clotrimazole(1µM)-sensitive current 
elicited by square depolarising pulses in normal conditions (ECS; left graph) and after 
incubation with theophylline (0.1 µM; right graph). [D] & [E] summary graphs of current 
density-voltage relationship for apamin and clotrimazole-sensitive currents, respectively; 
open circles=normal conditions (ECS), closed circles=in presence of theophylline 
(0.1µM), data displayed as mean±SEM, n=4, * p<0.05 as determined by two-way paired 
ANOVA with Bonferroni’s post-hoc test. 
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Figure 4.10 Theophylline effect on K+ channels in patch clamped isolated 
membrane from guinea pig jugular ganglia neurons 
[A] Traces of a single channel recorded from the same patch of membrane in the 
presence of the vehicle control (left) and in the presence of 0.1µM theophylline (right), 
acquired at a voltage of -100mV in ECS (500nM free-calcium). [B] Traces acquired as in 
A, except in a low free-calcium (20nM) solution. Channel closed state (i=0 pA) is 
indicated by black triangles. The different open states recorded from this patch are 
indicated with a bracket on the left and identified by a dotted line. Current and time scales 
are indicated top right. [C] Normalised amplitude histograms of the single channel traces 
recorded over 30s for 500nM free calcium from the patch displayed in A. Histograms 
were fitted using a Gaussian function. The current level corresponding to the closed state 
of channel (0pA) is indicated by a black triangle. Amplitude scale is indicated below the 
histograms on the X-axis.  
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4.5 Summary/Discussion 
The aim of this chapter was to study the effect of theophylline on sensory nerve 
depolarisation and cough. The anti-tussive activity of theophylline was demonstrated in 
conscious guinea pig models of evoked cough to both capsaicin and citric acid challenge, 
which are commonly used tussive stimuli in objective clinical cough studies (Laude et al., 
1993). Theophylline significantly inhibited both citric acid and capsaicin-evoked cough, 
although the dose (100mg.kg-1) required to significantly inhibit evoked cough here was 
greater than the reported 10mg.kg-1 reported in a similar study by Mokry & Nosalova 
(2011). It should be noted that in the latter study, despite a higher concentration of citric 
acid being nebulized (0.6M instead of 0.3M), the challenge period was only 2 minutes, 
compared to the challenge period of 5 minutes used here. This is reflected in the different 
numbers of coughs evoked in control groups of the two studies, with approximately 4-6 
coughs evoked by a 2 minute aerosol, and 14.47±2.26 coughs evoked by the 5 minute 
aerosol in the current study. Another difference between these studies is the use of a 
repeated-measures study design in the study performed by Mokry & Nosalova, enabling 
the use of a paired students t-test, which increased the statistical power to detect smaller 
differences between control and treatment challenges. In this study it did appear that 
there was some anti-tussive effect of theophylline on CA cough at 3 and 30mg.kg-1, 
although this effect was not statistically significant with the methodology used here.  
 
The same dose of theophylline that was effective at inhibiting cough (100mg.kg-1) was 
also effective at inhibiting capsaicin-evoked in vivo firing of airway C-fibres, which are 
thought to play a role in the dysregulation of the cough reflex in respiratory disease 
(Coleridge & Coleridge, 1984). In the same system, theophylline also inhibited capsaicin-
evoked bronchoconstriction as assessed by measuring pulmonary pressure, indicating 
that theophylline is effective at inhibiting cough and bronchoconstriction at this dose. In 
order to determine whether the inhibition of nerve firing by theophylline in this in vivo 
setting was distinct from its bronchodilator activity, the effect of theophylline on PGE2-
evoked firing was examined. Similarly to capsaicin, PGE2 evokes firing of C-fibres (via 
TRPV1 and TRPA1; Grace et al., 2012) but unlike capsaicin, PGE2 does not cause 
bronchoconstriction. The inhibition by theophylline of PGE2-evoked C-fibre firing shows 
that theophylline has a direct inhibitory effect in vivo which is independent of its 
bronchodilator activity. Additionally, the inhibition by theophylline of capsaicin-induced 
calcium influx in isolated jugular-origin, airway-terminating neurons shows that 
theophylline also has a direct inhibitory effect directly on sensory neurons in an in vitro 
setting. 
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A concentration-dependent inhibitory effect of theophylline was observed on capsaicin-
induced depolarisation of guinea pig isolated vagus nerve, and a sub-maximal 
concentration of theophylline inhibited depolarisation induced by acrolein, PGE2 and 
bradykinin. Inhibition of this range of agonists, comprising exogenous and endogenous 
activators of at least the TRPV1 and TRPA1 ion channels (Grace et al., 2012), suggests 
that theophylline exerts a general anti-excitatory effect on sensory nerve depolarisation, 
rather than being a specific antagonist of a particular ion channel such as TRPV1. This is 
further confirmed by the inhibition by theophylline of both capsaicin- and citric acid- 
evoked cough, as capsaicin causes cough via TRPV1 (Grace et al., 2012), whereas citric 
acid causes cough partially through TRPV1 and partially through an as yet unknown 
alternative mechanism (Lalloo et al., 1995; Kollarik & Undem, 2004; Canning, 2006b).  
 
Having thus confirmed that theophylline has a general inhibitory directly on sensory nerve 
depolarisation, the isolated vagus nerve system was further used to examine its 
mechanism of action. Currently the mechanism of action of theophylline, even in it’s 
traditional role as a bronchodilator, is not entirely clear. Bronchodilation by theophylline is 
often attributed to its activity as a weak, non-specific phosphodiesterase (PDE) inhibitor, 
as frequently bronchodilation by theophylline in airway smooth muscle is associated with 
cAMP accumulation (Rabe et al., 1995; Niewoehner et al., 2002; Hansel et al., 2004). 
Theophylline has greatest activity on PDE4, with a reported IC50 of approximately 400µM 
(Schudt et al., 1991), yet in the data presented here theophylline significantly inhibited 
capsaicin-induced vagus nerve depolarisation at concentrations of 1µM and above, with 
an approximate IC50 of approximately 2µM. That theophylline exerts its inhibitory effects 
on sensory nerve depolarisation at such concentrations, well below its reported IC50 for 
PDE inhibition, indicates that the effect of theophylline on depolarisation of isolated vagus 
nerve is extremely unlikely to be due to its activity as a PDE inhibitor.  
 
Aside from PDE inhibition, another well-known property of theophylline is it’s potent 
antagonism of adenosine receptors (Pauwels & Joos, 1995). In the context of isolated 
vagus depolarisation, adenosine receptor antagonism seems an unlikely mechanism of 
action for theophylline, as, in vagus nerve tissue isolated from the normal endogenous 
systems/mediators, there should not be adenosine receptor agonists present. Indeed, in 
the same isolated systems used here, it has been shown that capsaicin-induced sensory 
nerve and neuron responses are completely blocked by a specific TRPV1 antagonist 
(JNJ17203212) (Grace et al., 2012). Furthermore, capsaicin-evoked cough in vivo is also 
completely blocked by the same specific TRPV1 antagonist (Grace et al., 2012), and 
therefore antagonism of the adenosine receptor is not a feasible mechanism for inhibition 
of capsaicin-evoked cough by theophylline. 
4. Theophylline  
130 
There is however, some evidence that methylxanthines cause relaxation of airway 
smooth muscle via an activity on potassium channels, with several studies finding 
bronchodilation is partially reversed by blockers of large-conductance calcium-activated 
potassium channels (BKCa) (Miura et al., 1992a; Ise et al., 2003; Liu et al., 2003; Wu et 
al., 2004; Xin et al., 2012). Additionally, a study by Wu et al. (2004) found that small-
conductance calcium activated potassium channels (SKCa) and ATP-sensitive potassium 
channels (KATP) play a role in theophylline bronchorelaxation. In primary neurons, albeit 
not afferent peripheral neurons, methylxanthines have been suggested to affect 
potassium currents and potassium permeability with a requirement for calcium to be 
present, suggesting a role for calcium activated potassium channels (Munakata & Akaike, 
1993; Simasko & Yan, 1993). Additionally, it has also been demonstrated that 
theophylline can activate calcium activated intermediate-conductance (IKCa) type 
potassium channels in a heterologous HEK293 cell line which stably expresses the IKCa 
channel (Schrøder et al., 2000).  
 
The use of pharmacological blockers of these types of potassium channels in guinea pig 
vagus nerve revealed that SKCa, and to a lesser extent IKCa, channels are involved in the 
inhibitory effect of theophylline on guinea pig isolated vagus nerve. What is more, key 
experiments were repeated with similar results in human vagus nerve, demonstrating 
firstly that the anti-tussive effect of theophylline is likely to translate to the clinic, and 
secondly that the mechanism of theophylline inhibition of human sensory nerve 
depolarisation is likely to be the same as in guinea pig.  
 
Experiments with isolated patch clamped jugular ganglia neurons confirmed that 
theophylline opens IKCa and SKCa channels, causing a hyperpolarisation of the cell that 
would explain its inhibitory action on sensory nerves. Using an inside-out patch clamp 
technique, it was shown that there was a requirement for calcium to be present for 
theophylline to open IKCa and SKCa channels. However, theophylline did not cause an 
increase in calcium (at the concentrations used here) in primary guinea pig airway jugular 
neurons, as determined by calcium imaging. What is more, the increased current activity 
of IKCa and SKCa channels was maintained when intracellular calcium influx was inhibited 
in whole cell patch clamp of the same cell type. These findings are in agreement with 
Schrøder et al. (2000) that the effect of theophylline on potassium channels is 
independent of an increase in intracellular calcium. The reduced activity of theophylline 
on IKCa compared to SKCa channels, and the lack of an effect on BKCa, could be a 
function of the differing calcium-sensitivity and voltage-dependence of these channels. 
IKCa open probability is poorly dependent on voltage and is largely regulated by [Ca2+]i 
with an opening concentration threshold that can vary over a wide range of 
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concentrations depending on the conditions whereas BKCa open probability is voltage 
dependent and needs high [Ca2+]i (Cui et al., 1997; Dai et al., 2009). SKCa on the other 
hand is highly sensitive to calcium and voltage-insensitive. This gives SKCa the ability to 
open at low [Ca2+]i, independently from the membrane potential, and furthermore it has 
been shown to be important in controlling neuronal excitability and firing rate along axons 
(Weatherall et al., 2010). The higher threshold of calcium-induced activation for IKCa 
gating, and the need for both increased membrane potential and [Ca2+]i to open BKCa 
would suggest that the resting [Ca2+]i under these conditions would not be sufficient for 
theophylline to open these channels. However, the possible activation of IKCa and/or 
BKCa by theophylline, when the sensory neurons are activated, [Ca2+]i raised and the 
membrane depolarised, also remains a possibility.  
 
Hyperpolarisation of sensory neurons by theophylline, via opening IKCa and SKCa 
channels, would explain its mode of action as a general inhibitor of excitatory stimuli in 
vagus nerves. What is more, its effectiveness at inhibiting human vagus sensory nerve 
depolarisation indicates that theophylline may be useful as a general anti-tussive in the 
clinic. In patients theophylline is generally administered orally, and levels in plasma are 
monitored to maintain a concentration of 10-20µg.ml-1, which is considered to be the 
therapeutic window in which efficacy is achieved without excessive side-effects (Barnes, 
2005). Theophylline inhibits capsaicin-induced depolarisation of human isolated vagus 
nerve by approx. 80% at 10µM, whereas in human airway smooth muscle, theophylline is 
reported to inhibit acetylcholine and capsaicin-induced bronchoconstriction with IC50 
values of 150µM and 100µM (Guillot et al., 1984; Manzini et al., 1987; Finney et al., 
2006). This comparison of in vitro potency would suggest that theophylline could be 
expected to inhibit cough at or below plasma concentrations used to achieve 
bronchodilation. However, it has been highlighted that theophylline is actually a relatively 
poor bronchodilator, as, assuming 60% protein binding, plasma levels of 375µM, or 
67µg.ml-1 would be required for 50% of the maximum bronchodilator effect of 
theophylline in vivo (Barnes et al., 1998). If the same theoretical calculation (assuming 
60% protein binding as before) were to be performed using the in vitro data generated 
here, then given the approximate IC50 of 2µM in guinea pig vagus nerve, a plasma 
concentration of only 5µM, or 0.9µg.ml-1 of theophylline would be required for anti-tussive 
effects. Of course the only way to truly determine the efficacy of theophylline to inhibit 
cough at therapeutic doses would be to perform a suitably powered, double-blind 
crossover study with objective cough counting as a primary end-point. The anti-tussive 
properties of theophylline presented here argue for such a clinical study, as, given that 
theophylline is a known quantity in terms of clinical use/approval, re-labelling/re-
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purposing of theophylline for use as a cough therapy would be quicker and cheaper than 
developing and gaining clinical approval for an entirely novel class of compounds.  
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5.1 Introduction 
Agonists of cannabinoid receptors, for example the archetypal non-selective Δ9THC (the 
active constituent of marijuana/Cannabis Sativa), have been investigated as potential 
therapies for pain, migraine, glaucoma, and hypertension (Axelrod & Felder, 1998). Two 
types of cannabinoid receptor (CB) with differing expression patterns have so far been 
identified, with CB1 receptors highly expressed within the CNS, and CB2 receptors highly 
expressed in non-neuronal peripheral tissues (Regard et al., 2008). However this view is 
overly simplistic, as CB1 receptors are also expressed in the periphery (Kress & Kuner, 
2009), and CB2 receptors are also expressed in the CNS (Storr et al., 2002; Duncan et 
al., 2008) and the peripheral nervous system (Griffin et al., 1997; Atwood & Mackie, 
2010). Despite the relatively high expression of CB2 receptors in the lung 
(http://pdsp.med.unc.edu/ShaunCell/family.php, Regard et al., 2008), cannabinoids are 
relatively unexplored as respiratory therapeutics. Recently however, non-specific 
cannabinoid agonists and CB2 agonists were shown to inhibit CA-evoked cough and 
sensory nerve depolarisation to a range of agonists including capsaicin and PGE2 via the 
CB2, but not the CB1 receptor, indicating that the CB2 receptor may prove the better 
target for anti-tussive therapies (Patel et al., 2003; Belvisi et al., 2009). Selective agonism 
of CB2 should also avoid the side-effects of non-specific cannabinoid agonists, which can 
cause drowsiness, anxiety and panic via their activity on CB1 receptors, due to their 
predominant expression in the CNS (Moreira et al., 2009).  
 
The integral membrane protein Fatty Acid Amide Hydrolase (FAAH) is the primary 
catabolic enzyme responsible for the breakdown of the endocannabinoid fatty acid amide 
(FAA) N-arachidonoyl ethanolamine (anandamide, AEA), as well as other related FAA 
signaling lipids such as palmitoylethanolamine (PEA), N-oleoylethanolamide (OEA) and 
linoleoyl ethanolamide (LEA). Pharmacological inhibition or deletion of FAAH has been 
shown to be anti-hyperalgesic and anti-nociceptive in pre-clinical models of pain and 
inflammation and is associated with a concomitant elevation in levels of FAAs (Kinsey et 
al., 2009; Schlosburg et al., 2009; Meyers et al., 2011). FAAs are endogenously 
produced and cause activation of the cannabinoid CB1 and CB2 receptors (Mechoulam et 
al., 1998), and are also known to activate non-cannabinoid receptors such as TRPV1, 
protease proliferator-activated receptors (PPAR) and opioid receptors (LoVerme et al., 
2005a; Chang et al., 2006; Ahn et al., 2009). The effects of cannabinoid agonists are 
known to be mediated by various potassium channels (Felder et al., 1995). In particular, 
although in non-neuronal cell types, the effects of AEA have been found to be sensitive 
to a blocker of SKCa type potassium channels (Welch et al., 1995b), as well as general 
blockade of all Ca2+-activated potassium channels, including large (BKCa), intermediate 
IKCa), and small-conductance (SKCa) potassium channels  (Yang et al., 2007). 
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The aim of this chapter was to study the effect of a novel FAAH inhibitor (FAAHi), 
PF04862853 (Meyers et al., 2011; Huggins et al., 2012), on sensory nerve depolarisation 
and cough to gauge its effectiveness as an anti-tussive. Furthermore, the secondary aim 
of this chapter was to examine the mechanism of action of FAAHi inhibition in sensory 
nerves and neurons. 
 
In order to fulfill these aims, the ability of PF04862853 to inhibit citric acid-evoked cough 
was examined. In addition, the effect of in vivo administration of PF04862853 on plasma 
levels of the FAAs AEA, PEA, OEA, and LEA was examined.  
 
The isolated vagus nerve preparation was used to examine the mechanism of action of 
PF04862853, as a more pharmacologically amenable and cost-effective assay system. 
Using this system, the effect of PF04862853, was examined on low pH- and capsaicin-
induced depolarisation of guinea pig. The ability of PEA to inhibit low pH-induced calcium 
responses in guinea pig isolated vagal neurons was examined in order to determine the 
effect of a FAA specifically on airway-terminating neurons. Selective antagonists of CB1 
and CB2 receptors were then used to determine the cannabinoid receptor subtype 
involved in FAAHi/FAA activity on sensory nerve. PEA was then selected in order to 
further evaluate the role of potassium channels in its activity on isolated vagus nerve 
depolarisation using pharmacological blockers of potassium channels. Finally, key 
experiments were repeated using vagus nerve from human donor tissues to show that 
the effects observed in animal models would translate to the clinic.   
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5.2 Methods 
5.2.1 Determining the effect of a FAAH inhibitor on CA-induced cough and 
FAA plasma levels in the conscious guinea pig 
Cough experiments and plasma analysis of fatty acid amides described in this section 
were performed by researchers at Pfizer (Sandwich, UK). 
In order to examine the effect of FAAH inhibition, vehicle (0.5%w/v methylcellulose, 
0.1%v/v tween80), or PF04862853 (1mg.kg-1) were administered p.o. to male Dunkin 
Hartley guinea pigs 4h prior to challenge with tussive agent. For cough recordings, a 
guinea pig was placed into a Perspex chamber attached to a microphone where coughs 
could be observed and recorded, as described previously (Methods 2.2). A baseline 
recording was taken for 5min, and then citric acid (0.3M) was administered by aerosol for 
10min, during which time coughs were counted, as well as for a further 5min post-
exposure, using the Buxco Cough Analyser. Blood samples were taken from the 
saphenous vein immediately following cough challenge and euthanisation. The timing for 
these assessments was based on a preliminary time-course study performed by 
researchers at Pfizer (Sandwich, UK) of plasma levels of PF04862853 showing peak 
exposure at 4h following p.o. administration (data not shown). 
 
Levels of the FAAs AEA, PEA, OEA, and LEA in blood plasma were assessed by liquid 
chromatography mass-spectroscopy (LC-MS) as follows. Blood samples were 
centrifuged and whole plasma was decanted and stored at –20°C until assay. Plasma 
(100µl) was mixed with internal standard (30µl) in 50% MeOH (AEA, PEA, OEA and 
LEA), 1.5M Tris (pH 10, 100µL), and methyl t-butyl ether (700µL). The mixture was 
vigorously mixed in a shaker (45min) and then centrifuged (200 x g, 15min). The resulting 
supernatant was dried under a stream of N2 gas (room temperature), and re-suspended 
in Diluton buffer (100µL). Lipid measurements were performed by LC-MS using an 
Agilent (1100) instrument. Solvent A was composed of 95:5 v/v H2O:MeOH, solvent B 
was composed of 65:35:5 v/v/v isopropanol:MeOH:H2O, and 0.1% formic acid was 
added to each solvent to assist in ion formation. The flow rate for each run started at 0.1 
ml.min-1 with 0% B. At 5min, the solvent was immediately changed to 60% B with a flow 
rate of 0.4ml.min-1 and increased linearly to 100% B over 10 min. This was followed by 
an isocratic gradient of 100% B for 5 min at 0.5ml.min-1 before equilibrating for 3 min at 
0% B at 0.5 ml.min-1. The following parameters were used to measure the indicated 
metabolites (precursor ion, product ion, collision, energy in V): AEA (348, 62, 35), PEA 
(300, 62, 35), OEA (326, 62, 35), and LEA (324, 62, 35), and PF04862853 (392, 143, 
55). Analysis was performed with an electrospray ionization (ESI) source. The capillary 
was set to 4kV and the fragmentor was set to 100V. The drying gas temperature was 
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350°C, the drying gas flow rate was 11 l.min-1, and the nebulizer pressure was 35psi. The 
LC-MS/MS system consisted of Shimadzu SCL-10A VP pumps, CTC-PAL auto sampler, 
and Sciex API 4000 mass spectrometer. The LC separation conditions consisted of a 5-
min gradient from 0 to 80% (v/v) MeOH in water with 0.1% formic acid at 0.2ml.min-1 on a 
Phenomenex Gemini C6 Phenyl column (3µm, 2 x 50mm). Comparing the mass ion peak 
areas with those of the corresponding deuterated standards allowed quantification of 
AEA, PEA, OEA and LEA levels.  
5.2.2 Determining the effect of FAA on isolated vagus nerve depolarisation 
The following experimental protocol was used to examine the effects of the FAAs AEA, 
PEA, OEA and LEA on isolated vagus nerve depolarisation induced by tussive stimuli. 
Following sacrifice of the guinea pig and dissection of the vagus nerve as outlined 
previously (Methods 2.3), the isolated nerve was allowed to equilibrate for 10min in the 
grease-gap chamber, following which capsaicin (1µM) or low pH KH solution (pH 5) was 
perfused for 2min, causing depolarisation. The nerve was then ‘washed’ (perfusion of KH 
alone) until the signal returned to baseline. Two reproducible responses to the same 
tussive stimulus were recorded in this way, following which the vagus nerve was 
incubated with vehicle (0.1% DMSO), PF04862853 (0.1-100µM), PEA (0.001-1µM), AEA 
(0.1µM), OEA (0.1µM), or LEA (0.1µM) for 10min, according to a standard protocol for 
examining efficacy in this system (Freund-Michel et al., 2010). The vagus was then re-
challenged with the initial tussive stimulus in the presence of test compound. Following a 
‘wash’ period of 10min, a final stimulation of the tussive stimulus was used to determine 
tissue viability. On each piece of nerve tissue, only one concentration of any vehicle or 
drug was examined. 
 
Key experiments were repeated on human vagus nerve tissue dissected from whole 
lungs unsuitable for transplant, as outlined in Methods 2.3.1. 
 
5.2.3 Determining the effect of PEA on low pH-induced responses in isolated 
airway jugular ganglia neurons 
Male Dunkin Hartley guinea pigs were euthanised, jugular ganglia were removed, and 
individual jugular ganglia neurons were isolated as described previously (Methods 2.4). 
The jugular and nodose ganglia contain the majority of the cell bodies for airway 
terminating vagal neurons. Previous data in our group indicated that a greater proportion 
of jugular ganglia neurons respond to capsaicin (Grace et al., 2012). For this reason only 
jugular neurons were used to examine the inhibitory effects of PEA.  
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As described previously (Methods 2.4.1) guinea pigs had been i.n. dosed with DiI, a 
retrograde tracer dye, and airway-terminating neurons isolated from these animals were 
identified by the DiI present in their plasma membranes. Isolated neurons were incubated 
(37°C, 5%CO2) overnight in complete F12 media (containing penicillin and streptavidin), 
in order to allow adherence to poly-D-lysine- and laminin-coated fluorodishes. 
Immediately prior to imaging experiments, cells were incubated with the calcium sensitive 
dye Fura-2AM.  
To test the effect of PEA on the release of calcium in the ganglia, cells were acquired 
using a confocal epi-fluorescence microscope, and sensory neurons were identified by 
their body characteristics (20-30µM diameter) and light diffraction in phase contrast, 
whilst DiI emission was used to identify airway-terminating neurons. The fluorodish was 
connected to a pressurised perfusion system that allowed rapid change of the bath 
solutions as per the following protocol:  
 
An initial control response to application of K50 solution (50mM hyper-potassium solution 
containing; 50mM KCl; 91.4mM NaCl; 1mM MgCl2; 1.8mM CaCl2; 0.33mM NaH2PO4; 
10mM D-Glucose; 10mM HEPES; pH adjusted with NaOH to 7.4) was used to assess 
cell viability, and this response was used to normalise all subsequent responses within 
each cell. After perfusion with ECS to remove the K50 solution and allow recovery of 
calcium and voltage dye emissions back to baseline, cells were then stimulated twice 
with low pH ECS (pH 6) as control responses followed by a wash with ECS to recover 
baseline levels. The cells were then incubated with vehicle (0.1% DMSO in ECS), or PEA 
(1nM) for 5min, and then re-stimulated with low pH ECS in the presence of test 
compounds. ECS was then perfused to washout drugs for at least 10min, or until signal 
returned to baseline, following which final low pH, and then K50 applications were used to 
confirm that low pH responses recovered once the drug was removed, and that the 
cell(s) remained viable.  
 
5.2.4 Determining the role of cannabinoid receptors and K+ channels in the 
action of FAAH inhibitor and FAA on vagus nerve depolarisation 
The role of cannabinoid receptors in the action of the FAAs PEA, AEA, OEA and LEA on 
vagus nerves was investigated using selective antagonists of cannabinoid receptors 
types 1 and 2 (CB1 - SR141716A; CB2 - SR144528). The role of potassium channels was 
similarly examined using the K+ channel blockers paxilline, clotrimazole, apamin and 
glibenclamide. The antagonists and channel blockers were evaluated against a single 
sub-maximal concentration of PEA, AEA, OEA or LEA on guinea pig vagus nerve. The 
protocol used here was modified from that described in Section 5.2.3, as follows: two 
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control responses to capsaicin (1µM) or low pH KH solution (pH 5) were generated, and 
then vehicle (0.1% v/v DMSO), SR141716A (0.01µM), SR144528 (0.01µM), paxilline 
(1µM), apamin (1µM), glibenclamide (10µM) or clotrimazole (10µM) were incubated for 
10min alone, and then co-incubated for 10min with vehicle (0.1% v/v DMSO), PEA 
(0.1µM), AEA (0.1µM), OEA (0.1µM) or LEA (0.1µM). The nerve was then stimulated with 
tussive stimulus in the presence of both vehicle/CB antagonist/channel blocker and 
vehicle/FAA, followed by a ‘wash’ period of 10min, and a final stimulation with tussive 
stimulus alone. The concentration of the CB antagonists used here (0.01µM) is similar to 
that used previously (Belvisi et al., 2009), and were close to the pA2 values for the CB1 
(SR141716A; 7.9nM) and CB2 (SR144528; 6.3nM) antagonists (Rinaldi-Carmona et al., 
1994; 1998). The concentrations of potassium channel blockers were selected from 
Freund-Michel et al. (2010).  
 
Key experiments were repeated on human vagus nerve tissue dissected from whole 
lungs unsuitable for transplant, as outlined in Methods 2.3.1. 
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5.3 Anti-tussive potential of FAAHi 
5.3.1 FAAHi effect on naïve guinea pig cough and plasma FAA levels 
The effect of the FAAH inhibitor PF04862853 on numbers of cough evoked by capsaicin 
or citric acid was examined. Conscious guinea pigs were treated with vehicle or 
PF04862853 (1mg.kg-1 p.o.), and 4h later were challenged with an aerosol of citric acid 
(0.3mM) for 10min to evoke cough, during which, and for 5 minutes post-aerosol, the 
number of coughs evoked was recorded. PF04862853 at 1mg.kg-1 significantly reduced 
the number of coughs evoked to 8.40±2.24, from 16.10±2.84 in the vehicle control group 
(Fig. 5.1a).  
 
 
 
Figure 5.1 Effect of PF04862853 on citric acid-evoked cough and plasma FAA 
levels in guinea pigs 
Guinea pigs were pre-treated with vehicle (0.5%w/v methylcellulose, 0.2%v/v tween80 in 
PBS) or PF04862853 (1mg.kg-1 i.p.) 4h prior to [A] recording of coughs evoked over 
15min by 5min aerosol of citric acid (0.3M) (including 5min recording during aerosol plus 
10min post-aerosol), following which [B] blood samples were taken (i.v.) to determine 
plasma levels of AEA, PEA, OEA and LEA. Data displayed as mean±SEM, n=8, * p<0.05 
as determined by students t-test compared to respective controls.  
 
 
Plasma levels of AEA, PEA, OEA and LEA were also elevated variously by between ~6-9 
fold in the PF04862853-treated animals at this efficacious dose (Fig. 5.1b). These data 
indicate that inhibition of FAAH enzyme activity and sustained elevation of AEA, PEA, 
OEA and LEA are associated with the antitussive activity of PF04862853 in the guinea-
pig cough model.  
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5.4 Mechanism of action of FAAHi 
5.4.1 FAA effect on guinea pig vagus 
As PF04862853 was shown to increase FAA levels in vivo, the effect of a selected FAA, 
palmitoylethanolamide (PEA), on low pH- and capsaicin-induced depolarisation of guinea 
pig isolated vagus nerves was examined to determine if it had similar inhibitory activity. 
The selected concentration range for PEA in this assay was based on the plasma 
concentration (10ng.ml-1, or ~0.03µM) reached 4h after PF04862853 administration in 
vivo (Section 5.3.1). PEA (0.001-1µM) caused a concentration-dependent inhibition of 
both low pH- and capsaicin-induced sensory nerve depolarisation, which reached 
significance at concentrations of 0.01µM and higher (Fig. 5.2).  
 
 
 
Figure 5.2 Non-cumulative concentration-response of PEA effect on low pH- or 
capsaicin-depolarisation of guinea pig isolated vagus nerve 
Isolated guinea pig vagus nerve was incubated with either vehicle (0.1% DMSO) or PEA 
(Palmitoylethanolamide; 0.001-1µM) to examine the effect on subsequent [A] low pH(5) 
or [B] capsaicin induced depolarisation. Data displayed as mean %inhibition of initial low 
pH(5) or capsaicin stimulations (internal controls) ±SEM, n=3-4, * p<0.05 as determined 
by paired students t-test compared to respective internal control. 
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5.4.2 FAA effect on guinea pig airway isolated neurons 
The effect of PEA on low pH-induced intracellular calcium flux was examined in single 
chemo-sensitive airway-terminating neurons of the jugular ganglia. PEA (1nM) 
significantly inhibited the increase in intracellular calcium levels caused by low pH (6) 
solution (Fig. 5.3).  
 
Figure 5.3 Effect of PEA on low pH-induced intracellular calcium flux in jugular 
airway-terminating neurons 
[A] Representative trace of PEA effect on low pH(6)-induced intracellular calcium levels. 
Open triangles indicate K50 (50mM KCl in ECS solution, 15s) application, closed triangles 
indicate pH6 (0.1µM, 30s) application, line indicates PEA (1nM, 2min) incubation. Images 
above trace show false-coloured representation of calcium fluorescence at time-points 
indicated by grey arrows. [B] Summary graph shows the effect of vehicle (0.1% DMSO) 
or PEA (1nM) on low pH-induced increases in intracellular calcium. Data displayed as 
mean %inhibition of initial low pH stimulations (internal control) ±SEM, n=5-14 cells from 
3-5 guinea pigs, * p<0.05 as determined by paired students t-test compared to internal 
control. 
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5.4.3 Effect of CB antagonists on FAA inhibition of vagus nerve 
depolarisation 
PF04862853 increased plasma levels of FAAs (PEA, AEA, OEA and LEA) in vivo, and 
PF04862853 inhibited guinea pig vagus nerve depolarisation. One of these elevated 
FAAs, PEA, was shown to also concentration-dependently inhibit guinea pig vagus nerve 
depolarisation (Section 5.4.1). Therefore the effect of PEA (0.1µM) on low pH- and 
capsaicin-induced depolarisation was examined in the presence of vehicle (0.1% DMSO) 
or the CB2-receptor selective antagonist (SR144528; 0.01µM) in order to determine if this 
FAA also inhibited vagal nerve depolarisation through the same receptor as the FAAHi.  
 
Figure 5.4 Effect of a CB2 selective antagonist on PEA inhibition of guinea pig 
vagus nerve depolarisation 
The effect of vehicle (0.1% DMSO) or CB2 antagonist (SR144528; 0.01µM), pre-
incubated for 10min, on PEA, AEA, OEA or LEA (all 0.1µM; 10min) inhibition of [A] low 
pH (pH5; 2min) or [B] capsaicin (1µM; 2min) depolarisation of guinea pig vagus nerve. 
Data displayed as mean %inhibition of initial stimulations (internal controls) ±SEM, n=4,  
* p<0.05 as determined by paired students t-test to internal control, θ p<0.05 as 
determined by Mann-Whitney U test to relevant vehicle control group. 
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Furthermore, the effect of same concentration (0.1µM) of the related FAAs OEA, AEA 
and LEA (which were also elevated by PF04862853 in vivo) on low pH- and capsaicin-
induced depolarisation was examined in the presence of vehicle or CB2-receptor 
selective antagonist (SR144528; 0.01µM). Similar to PEA, OEA, AEA, and LEA all 
inhibited both low pH- and capsaicin-induced depolarisation of guinea pig vagus nerve, 
an effect that was blocked by the CB2-receptor antagonist SR144528 (Fig. 5.4). 
 
5.4.4 Effect of K+ channel blockers on FAA inhibition 
The effect of blockers of BKCa, IKCa, SKCa, and KATP type potassium channels (paxilline, 
clotrimazole, apamin and glibenclamide respectively) on PEA inhibition of low pH- and 
capsaicin-induced depolarisation of guinea pig vagus nerve was examined. The SKCa 
blocker apamin (1µM) significantly reduced the effect of PEA on both low pH- and 
capsaicin-induced depolarisation, whereas the other K+ channel blockers, at the 
concentrations tested here, did not have a significant effect on PEA-mediated inhibition 
(Fig. 5.5). This data suggests that opening of potassium channels, and specifically SKCa 
type potassium channels, plays a role in the inhibitory effects of PEA on sensory nerve 
depolarisation. 
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Figure 5.5 Effect of K+ channel blockers on PEA inhibition of guinea pig vagus 
nerve depolarisation 
The effect of vehicle (0.1% DMSO), paxilline (BKCa blocker; 1µM), apamin (SKCa blocker; 
1µM), clotrimazole (IKCa blocker; 10µM) or glibenclamide (KATP blocker; 10µM), pre-
incubated for 10min, on PEA (0.1µM; 10min) inhibition of [A] low pH (pH5) or [B] 
capsaicin (1µM; 2min) depolarisation of guinea pig vagus nerve. Data displayed as mean 
%inhibition of initial low pH or capsaicin stimulations (internal control) ±SEM, n=4-5, 
where * p<0.05 as determined by paired students t test compared to internal control, and 
θ p<0.05 as determined Mann-Whitney U test compared to vehicle control. 
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5.4.5 FAA effect in human vagus 
Key experiments with FAAs performed on guinea pig vagus nerve were repeated on 
human vagus nerve tissue, in order to determine whether the anti-tussive effects 
observed in guinea pig would be likely to translate to humans. The effect of a single 
concentration of PEA on low pH-induced depolarisation was examined in the presence 
of, and following pre-incubation with, vehicle, CB1 or CB2 antagonist, or SKCa channel 
blocker (drugs, timings and concentrations as per Sections 5.4.3 & 5.4.4). In 
concordance with the results observed in guinea pig vagus nerve tissue, PEA (0.1µM) 
was effective at inhibiting low pH-induced depolarisation of human sensory nerves (Fig. 
5.6). Furthermore, the inhibitory effect of PEA was significantly reversed by both the CB2 
antagonist and apamin, whereas the CB1 receptor antagonist had no effect.  
Figure 5.6 Effect of PEA ± apamin or CB1/2 antagonists on depolarisation of human 
vagus nerve 
 [A] Representative traces of PEA effect on pH 5 induced (pH) depolarisation of human 
vagus nerves, in presence of vehicle (upper; 0.1% DMSO) OR apamin (lower; 1µM). [B] 
The effect of vehicle (0.1% DMSO), apamin (SKCa blocker; 1µM), CB1 antagonist 
(SR141716A; 0.01µM) or CB2 antagonist (SR144528; 0.01µM), pre-incubated for 10min, 
on PEA (1nM; 10min) inhibition of low pH-induced (pH5; 2min) depolarisation of human 
vagus nerve. Data displayed as mean %inhibition of initial low pH stimulations (internal 
control) ±SEM, n=3, * p<0.05 as determined by paired students t-test compared to 
respective internal control, and θ p<0.05 as determined by Mann-Whitney U test 
compared to vehicle control. 
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5.5 Summary/Discussion 
The aim of this chapter was to study the effect of the novel FAAHi, PF04862853, on 
sensory nerve depolarisation and cough. The anti-tussive activity of PF04862853 was 
demonstrated by its ability to reduce the numbers of CA-evoked coughs in a conscious 
guinea pig model. In this study (performed at Pfizer, Sandwich, UK), the effect of this 
FAAHi on plasma concentrations of the FAAs PEA, AEA, OEA and LEA was examined in 
the same animals used for cough evaluation. Plasma concentrations of all of the FAAs 
examined were elevated at the same time-point (4h) that the inhibition of cough was 
demonstrated. PF048642853 is a recently developed compound, which is reported to be 
potent and selective for the FAAH enzyme (Meyers et al., 2011). In addition this 
compound displayed analgesic effects in vivo in a model of inflammatory pain (Meyers et 
al., 2011). The elevation of FAAs reported here following the administration of 
PF04862853 is consistent with previous studies demonstrating increased levels of the 
same FAAs caused by the same compound at similar doses to those that inhibited cough 
in the guinea pig (as shown here) (Meyers et al., 2011). It was additionally shown in the 
same study that the same doses of PF04862853 almost completely abolished the activity 
of the FAAH enzyme in the rat (Meyers et al., 2011).  
 
The endogenous FAAs AEA, PEA and OEA have each been implicated in the regulation 
of feeding and nociception (Mechoulam et al., 1998; Suardíaz et al., 2007). However, 
aside from being implicated with some anti-inflammatory activity, little is known about 
LEA and its potential role in nociceptive fibres (Ishida et al., 2013). In order to examine 
this phenomenon further, one of the elevated FAAs, PEA, was also evaluated in the 
same preparation. Exogenous PEA applied to the isolated vagus nerve also 
concentration-dependently inhibited low pH- and capsaicin-induced depolarisation, and 
furthermore, AEA, OEA and LEA at 0.1µM each had a similar inhibitory effect. The 
effectiveness of the FAAs against both of these stimuli suggests a general anti-excitatory 
effect on sensory nerve depolarisation, as although capsaicin is known to cause 
depolarisation through TRPV1 alone, low pH activates vagal afferents not just via TRPV1 
but also via additional mechanisms which have not yet been fully elucidated (Fox et al., 
1995; Kollarik & Undem, 2002). What is more, PEA (1nM) almost completely inhibited the 
[Ca2+]i influx induced by low pH in guinea pig airway-terminating jugular neurons; further 
indicating that FAAs have a direct inhibitory effect on the cell type which is likely to 
mediate the cough reflex.  
 
It is interesting to note that PEA caused significant inhibition of low pH- and capsaicin-
induced vagus nerve depolarisation at concentrations of 0.01µM, with approximate IC50 
values of 17 and 3nM respectively; these effective concentrations of exogenous PEA are 
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similar to the plasma levels of PEA (approximately 8ng.ml-1 or 25nM) reached following in 
vivo administration of PF04862853. It should be noted however that this does not imply 
that these concentrations of PEA would be reached at the vagus nerve termini in vivo 
(due to unknown plasma binding levels and distances of termini from blood vessels), 
more that the concentrations effective on vagus nerves are theoretically plausible in an in 
vivo setting.  
 
The mechanism by which the FAAs inhibit depolarisation was then examined; firstly by 
determining the receptor(s) they may act on. Interestingly, whilst the FAAs are known as 
‘endocannabinoids’, the receptor through which they act is not entirely clear. Of the FAAs 
examined here, AEA (anandamide) is the best examined, and the functions of AEA are 
mediated mostly by the CB1 receptor (Palmer et al., 2002), although it has also been 
shown to induce functional effects through the CB2 receptor (Palmer et al., 2002), PPAR 
(O'Sullivan, 2007), TRPV1 (Starowicz et al., 2007), and TRPM8 (De Petrocellis et al., 
2007) in various tissues. Generally it appears that AEA has greatest functional affinity for 
the CB receptors, with reported IC50 values of 0.5µM and 1.9µM against CB1 and CB2 
receptors, respectively, in functional assay systems (Felder et al., 1995), compared to 
10-30µM for PPARα (Sun et al., 2007), 5-8µM for TRPV1 (Smart et al., 2000; Ralevic et 
al., 2001; Tognetto et al., 2001; Oz, 2006), & 3µM for TRPM8 (De Petrocellis et al., 
2007). AEA has been shown to cause depolarisation of rat and guinea pig vagus nerves 
(Kagaya et al., 2002; Weller et al., 2011), [Ca2+]i influx in sensory neurons (Jia et al., 
2002), and cough (Jia et al., 2002) through the TRPV1 receptor. It should be noted of this 
apparently contradictory data that the stimulatory effects of AEA (anandamide) were 
observed at concentrations at least 100 times higher than those used here. No 
activation/depolarisation of vagus nerve or neurons was observed in any of the assay 
systems used here. Indeed, bearing in mind the reported efficacy of AEA at various 
receptors in cell- and tissue-based assays when considering the functional inhibition of 
depolarisation by AEA observed here at 0.1µM suggests that this effect is most likely 
mediated by cannabinoid receptors.  
 
In contrast to AEA, PEA is thought to act predominantly via CB2 receptors (Calignano et 
al., 1998; Jaggar et al., 1998; Calignano et al., 2000; Farquhar-Smith & Rice, 2001; Conti 
et al., 2002; Helyes et al., 2003), and not via CB1 receptors (Lambert & Di Marzo, 1999), 
despite one report of functional antagonism with the CB1 antagonist SR141716A (Costa 
et al., 2008). Intriguingly, despite one initial contrary report (Facci et al., 1995), PEA has 
been shown not to bind directly to the CB2 receptor (Griffin et al., 2000), but rather is 
thought to be a ‘functional agonist’ of the CB2 receptor, as many of the pharmacological 
(Calignano et al., 1998; Jaggar et al., 1998; Calignano et al., 2000; Conti et al., 2002), as 
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well as the analgesic (Calignano et al., 1998; Farquhar-Smith & Rice, 2001; 2003; Helyes 
et al., 2003) actions of PEA are inhibited by the specific CB2 antagonist/inverse agonist 
SR144528. In addition to cannabinoid receptors, and similarly to AEA, PEA has also 
been shown to activate TRPV1 channels (Ambrosino et al., 2013) and PPAR receptors 
(LoVerme et al., 2005a; b; Costa et al., 2008). However, PEA is reportedly more 
efficacious at CB2 receptors, with an IC50 value of 0.015µM (Yoshihara et al., 2005), 
compared to approximately 3µM at TRPV1 channels (Ambrosino et al., 2013) and 3µM at 
PPAR receptors (LoVerme et al., 2005a; b). In the data presented here, PEA appeared to 
reach a maximal effect on vagus depolarisation at 1µM, with approximate IC50 values in 
this system of 17nM and 3nM against low pH- and capsaicin-induced depolarisation, 
respectively.  
 
Given that FAAs have only been reported to activate TRP channels and PPAR receptors 
at much higher concentrations than those used here, the effect of selective CB1 and CB2 
receptor antagonists on inhibition by the FAAs was examined. Against both capsaicin- 
and low pH-induced depolarisation of guinea pig vagus nerve, the CB2, but not the CB1 
specific antagonist reversed the inhibition caused by each of the applied FAAs. This data 
is in agreement with previous studies of exogenous cannabinoid agonists in this 
preparation, where it was demonstrated that the non-specific CB agonist CP55940, as 
well as the CB2 selective agonists JWH133 and GW833972A each caused inhibition of 
vagus nerve depolarisation via the CB2 receptor (Patel et al., 2003; Belvisi et al., 2009). 
The concentration of the antagonists used here (0.01µM) is similar to that used 
previously (Belvisi et al., 2009), and was selected to be close to the pA2 values for the 
CB1 (SR141716A; 7.9nM) and CB2 (SR144528; 6.3nM) antagonists (Rinaldi-Carmona et 
al., 1994; 1998). It therefore seems clear that, in this tissue type, and at these 
concentrations, AEA, PEA, OEA and LEA cause inhibition of induced depolarisation 
through the CB2 receptor. Further investigation would be required to determine if the 
FAAs would cause depolarisation of sensory nerves at higher concentrations, as has 
been reported for AEA (Jia et al., 2002; Kagaya et al., 2002; Weller et al., 2011). 
Moreover further investigation would be required to determine whether such high local 
and circulating plasma concentrations of FAAs could be caused by inhibition of FAAH, 
which might contraindicate their potential use as an anti-tussive. Of pertinence to the 
latter point, PF04862853 at the same concentration used here (1mg.kg-1) was supra-
maximal in causing complete inhibition of the FAAH enzyme (Meyers et al., 2011), which 
resulted in plasma concentrations of only 3nM AEA, which would seem to preclude 
activity at receptors other than CB2, at least in vagus nerve.  
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Whilst the FAAs examined here certainly appear to be ‘functional agonists’ of the CB2 
receptor (assuming SR144528 specificity), future work would be required to determine if 
PEA, OEA and LEA bind directly to CB2 receptors. One hypothesis is that these FAAs 
have a so-called ‘entourage effect’, whereby they act as competitive substrates for 
FAAHi, indirectly allowing the elevation of AEA, which then binds to and activates 
cannabinoid receptors (Lambert & Di Marzo, 1999), although this theory has not been 
tested.  
 
In order to further examine the mechanism of action of the FAAs, and thereby of FAAH 
inhibition, on sensory nerve depolarisation, the effect of pharmacological blockers of 
potassium channel blockers was profiled against the inhibitory effect of PEA. The effects 
of cannabinoid agonists are known to be mediated by various potassium channels 
(Felder et al., 1995). In particular, although in non-neuronal cell types, the effects of AEA 
have been found to be sensitive to a blocker of SKCa type potassium channels (Welch et 
al., 1995b), as well as general blockade of all Ca2+-activated potassium channels, 
including large (BKCa), intermediate (IKCa), and small-conductance (SKCa) potassium 
channels  (Yang et al., 2007). In addition, the peripheral nociceptive effects of PEA were 
reversed using the ATP-activated potassium channel (KATP) channel blocker 
glibenclamide in a rat model of PGE2 induced hyperalgesia (Romero & Duarte, 2012). 
The inhibitory effect of PEA on isolated guinea pig vagus nerve was therefore examined 
against blockers of the various calcium-activated potassium channels as well as ATP-
activated potassium channels. PEA inhibition was found to be sensitive to apamin, 
suggesting that SKCa type potassium channels are involved in the CB2-mediated FAA 
inhibition of depolarisation in guinea pig sensory nerves.  
 
Key experiments were repeated in human isolated vagus nerve to examine if the 
mechanism of action of PF04862853 might be translatable to human tissue, and ergo the 
human cough reflex. Similar to guinea pig vagus nerve issue, PEA (0.1µM) caused a 
significant inhibition of low pH-induced human vagus nerve depolarisation. What is more, 
the CB2 receptor antagonist and the SKCa channel blocker, but not the CB1 receptor 
antagonist attenuated this inhibition. These results indicate that the functional effect of 
FAAH inhibition observed in animal models is likely to translate to the clinic, and that a 
similar mechanism of action in sensory nerve tissue may be expected.  
 
One of the advantages of FAAH inhibition over the administration of exogenous 
cannabinoid agonists is the avoidance of the undesirable CNS effects associated with 
exogenous cannabinoid agonists (Moreira et al., 2009). As demonstrated previously and 
in this study, the antinociceptive effect of FAAs such as PEA are peripherally mediated, 
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without the need for CNS involvement (Romero et al., 2013). The FAAH inhibitors 
examined in clinical trials thus far, including the closely related compound PF04457845, 
have proven to be free of adverse effects (Huggins et al., 2012; Li et al., 2012). Indeed, 
the endogenous FAAs are reported to have far fewer adverse effects than exogenous 
cannabinoid agonists (Huggins et al., 2012). In particular, PEA, given orally, appeared to 
have few adverse effects in a recent small clinical trial (Gagliano et al., 2011), as well as 
in two larger trials in the former Czechslovakia during the 1970s (Masek et al., 1974; 
Kahlich et al., 1979). The latter trials even led to the clinical use of PEA for the treatment 
of acute respiratory diseases including influenza infections for a period. Although its use 
was discontinued, for reasons that are not clear, these reasons were apparently not 
related to adverse effects or the safety of the drug (LoVerme et al., 2005b). There is also 
evidence that cannabinoid receptors, in particular CB2 receptors, are inducible, and are 
up-regulated in tissues at the site of inflammation/pain, suggesting that levels of locally 
produced and systemic FAAs increased by inhibition of FAAH may be more effective at 
the site of inflammatory insult/injury (Ashton & Glass, 2007; Benito et al., 2008; Pertwee, 
2009; Miller & Devi, 2011).  
 
In summary, inhibition of FAAH, thereby elevating endogenous levels of 
FAAs/endocannabinoids, would seem to be a promising strategy for the inhibition of 
cough. The FAAH inhibitor PF04862853 examined here was effective in a pre-clinical 
guinea pig model of evoked cough, apparently via a mechanism involving the elevation of 
local FAAs, causing inhibition of sensory nerve depolarisation via activation of CB2 
receptors, and downstream small-conductance potassium channels. A similar 
mechanism of action was demonstrated in human isolated vagus nerve. Future 
investigation would be required to determine whether these promising results would 
translate to an anti-tussive effect of FAAH inhibition on the in vivo cough reflex in 
humans.  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
6. Eff icacy of anti-tussives in 
a disease model 
 
 
 
 
6. Efficacy of anti-tussives in a disease model  
154 
6.1 Introduction 
In the preceding three chapters the anti-tussive efficacy of three different classes of 
compounds has been investigated using in vivo and ex vivo models of cough and 
sensory nerve activation evoked by clinically relevant stimuli. The long acting β2-
adrenoreceptor agonists formoterol and olodaterol, as well as the methylxanthine 
theophylline, were each effective at inhibiting cough and sensory nerve activation/firing 
evoked by capsaicin challenge in naïve guinea pigs. Similarly, the novel fatty acid amide 
hydrolase inhibitor (FAAHi) PF04862853 was shown to inhibit coughs evoked by CA 
challenge in naïve guinea pigs, and the fatty acid amides, including PEA, levels of which 
were elevated by PF04862853, inhibited sensory nerve activation induced by a low pH 
stimulus.  
 
Capsaicin and CA are frequently used as stimuli in animal models of cough to mimic their 
use as standard tussive stimuli in clinical studies. Both stimuli have been shown to evoke 
cough in a dose-dependent manner in both guinea pigs and in healthy humans (Laude et 
al., 1993; Doherty et al., 2000). It is generally accepted that in humans the ‘normal’ cough 
reflex sensitivity to these stimuli is modified in respiratory diseases where chronic 
persistent cough presents as a problematic symptom (Wong & Morice, 1999; Doherty et 
al., 2000; Blanc et al., 2009; McGarvey et al., 2009). For example the threshold for cough 
evoked by capsaicin and citric acid is lowered in patients with acute respiratory infections 
(Empey et al., 1976; O'Connell et al., 1994; Vestbo et al., 2013), asthma (Laude et al., 
1993; Doherty et al., 2000) or COPD (Wong & Morice, 1999; Doherty et al., 2000; Blanc 
et al., 2009; McGarvey et al., 2009). As the purpose of any anti-tussive medication is to 
inhibit cough in patients whom exhibit such an exagerated cough response, examining 
the effect of novel therapeutics in animal models which display a similarly enhanced 
cough response may be considered a more pertinent indicator of efficacy compared to 
such investigations in naïve animals. As the spontaneous development of diseases such 
as COPD are rare in laboratory animals, mechanistic models of disease are used, 
whereby a challenge agent induces a similar phenotype, or aspects thereof, to that 
observed in the disease state.  
 
The aim of this chapter was therefore to examine the efficacy of the anti-tussive 
compounds examined in the preceding chapters in a mechanistic disease model of 
enhanced cough and sensory nerve responses.  
 
To evaluate the effectiveness of the compounds which have been shown in the 
preceding chapters to inhibit naïve capsaicin- and/or CA-evoked cough, a guinea pig 
model of cigarette smoke (CS)-enhanced capsaicin- and CA-evoked cough was selected. 
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CS exposure is considered to be a relevant challenge agent to drive this ‘COPD-like’ 
modification of the cough reflex, as cigarette smoking is the primary risk factor associated 
with the development of COPD (Empey et al., 1976; O'Connell et al., 1994; Vestbo et al., 
2013). In this model, guinea pigs are exposed to CS for 8 days, inducing an enhanced 
cough response to subsequent capsaicin or CA challenge. This increased sensitivity to 
tussive-stimulus challenge therefore mimics the lowered threshold to capsaicin or CA 
challenge observed in human smokers and COPD patients (Wong & Morice, 1999; 
Doherty et al., 2000; Lewis et al., 2007; Blanc et al., 2009). What is more, it has 
previously been shown that vagus nerve depolarisation responses to capsaicin and low 
pH in tissues taken from CS-exposed guinea pigs are similarly enhanced compared to 
air-exposed comparator animals (Wortley et al., 2011). 
 
The two LABA compounds, formoterol and olodaterol, the methylxanthine theophylline, 
and the FAA PEA will be examined for their ability to inhibit the sensory nerve 
depolarisation observed following CS-exposure. Where possible, due to considerations of 
the costs involved in using in vivo models, the efficacious compounds were advanced to 
be examined for efficacy in the in vivo model of CS-enhanced capsaicin-evoked cough.  
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6.2 Methods 
6.2.1 In vivo cigarette smoke exposures 
Male Dunkin Hartley guinea pigs used for the purposes of this chapter were randomly 
assigned to be exposed to room air or CS for 1h periods, twice daily, for 8 days, as per 
the protocol described previously (Methods 2.6). 24h after the last exposure period, 
animals were either euthanised, and had vagus nerves dissected, or were used for the 
assessment of cough. The number of days exposure and time-point following exposure 
were selected from Lewis et al. (2007), where it was demonstrated that these parameters 
resulted in a significant and robust enhancement of capsaicin- and CA-evoked cough.  
 
6.2.1 Evaluation of drug effectiveness against CS-enhanced capsaicin-
induced isolated vagus nerve depolarisation 
The aim of this protocol was to determine the effectiveness of the compounds examined 
in the previous chapters in a pre-clinical model of CS-enhanced capsaicin- or low pH-
induced vagus nerve depolarisation. The protocol used here (described below) was the 
same as that used to examine agonist efficacy in vagus nerves from naïve guinea pigs. 
Sub-maximal concentrations of test compounds were selected from the preceding 
chapters as outlined in Table 6.1 below. Drug vehicles were as indicated in the relevant 
chapter.  
 
Table 6.1 Details of compounds evaluated against CS-enhanced vagus nerve 
responses 
 
Guinea pigs were sacrificed and vagus nerves were dissected as outlined previously 
(Methods 2.3) 24h after air/CS-exposure. The isolated nerve was allowed to equilibrate 
for 10min in the grease-gap chamber, following which capsaicin (1µM) or low pH KH 
solution (pH 5) was perfused for 2min, causing depolarisation. The nerve was then 
‘washed’ (perfusion of KH alone) until the signal returned to baseline. Two reproducible 
responses to the same tussive stimulus were recorded in this way, following which the 
vagus nerve was incubated with test compound (for incubation time/concentration see 
Table 6.1). The vagus was then re-challenged with the initial tussive stimulus in the 
Test drug Type Concentration Incubation time Chapter 
Olodaterol LABA 10nM 20min 3 
Theophylline Methylxanthine 10µM 10min 4 
PEA Fatty Acid Amide 100nM 10min 5 
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presence of test compound. Following a ‘wash’ with KH solution alone for a period of 
10min, a final stimulation of the tussive stimulus was used to determine tissue viability. 
On each piece of nerve tissue, only one concentration of any vehicle or drug was 
examined. 
 
6.2.1 Evaluation of drug effectiveness against CS-enhanced capsaicin-
evoked guinea pig cough  
The aim of this protocol was to determine the effectiveness of the compounds examined 
in the previous chapters in a pre-clinical in vivo model of CS-enhanced capsaicin-evoked 
cough. The protocol used here (described below) was the same as that used to examine 
agonist efficacy against capsaicin-evoked cough in naïve guinea pigs. The only 
adaptation was to select a lower concentration of capsaicin (30µM) to be aerosolised as 
the challenge agent, in order to allow any CS-driven enhancement of the responses to be 
observed, and also to reduce the stress caused to the animals. Effective anti-tussive 
doses of test compounds were selected from the preceding chapters as outlined in Table 
6.2 below.  
 
Table 6.2 Details of compounds evaluated against CS-enhanced cough responses 
 
In order to examine the effect of the LABA compounds, 24h after the last exposure period 
guinea pigs were place in a Perspex chamber to receive vehicle (0.1% DMSO in PBS), 
olodaterol or formoterol (3µg.ml-1), aerosolised for 10min (approx. volume 10ml), 50min 
prior to cough challenge. In order to examine the effect of the theophylline, 24h after the 
last exposure period guinea pigs were administered vehicle (0.5%w/v methylcellulose, 
0.2%v/v tween80 in PBS) or theophylline 1h prior to cough challenge. 
 
For cough recordings, a guinea pig was placed into a Perspex chamber attached to a 
microphone where coughs could be observed and recorded, as described previously 
(Methods 2.2). A baseline recording of was taken for 5min, and then capsaicin (30µM) or 
citric acid (0.3M) were administered by aerosol for 5min, during which time coughs were 
counted and Penh recorded, as well as for a further 5min post-exposure, using the Buxco 
Cough Analyser. 
Test drug Type Dose Route of administration Chapter 
Formoterol LABA 3 µg.ml-1 aerosol 3 
Olodaterol LABA 3µg.ml-1 aerosol 3 
Theophylline Methyxanthine 100mg.kg-1 intra-peritoneal 4 
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6.3 Effect of anti-tussives on CS-enhanced vagus responses 
6.3.1 β-agonists effect on CS-enhanced vagus responses 
 Depolarisation induced by capsaicin was significantly increased in vagus nerves from 
guinea pigs exposed to CS for 8 days (0.41±0.05mV) compared to air-exposed 
comparators (0.23±0.03mV) (Fig. 6.1a). The novel LABA compound olodaterol 
significantly inhibited both the ‘normal’ and CS-enhanced capsaicin-induced sensory 
nerve depolarisation (Fig. 6.1b). There was no significant difference in the level of 
inhibition of depolarisation as determined by comparison of the percentage inhibition in 
the treatment groups by Mann-Whitney U test.   
 
Figure 6.1 Effect of olodaterol on CS-enhanced capsaicin responses in guinea pig 
isolated vagus nerves 
[A] Magnitude of capsaicin-induced (1µM; 2min) depolarisation of vagus nerve tissue 
from air- and CS-exposed guinea pigs. [B] Effect of olodaterol (10nM; 20min) on 
capsaicin-induced depolarisation of vagus nerve tissue from air- or CS-exposed guinea 
pigs. Data displayed as mean±SEM, n=4, ⊥ p<0.05 as determined by unpaired students 
t-test * p<0.05 as determined by paired students t-test.  
 
 
 
 
A B 
0.0
0.1
0.2
0.3
0.4
0.5
D
ep
ol
ar
is
at
io
n 
(m
V)
Air Smoke
⊥
0
20
40
60
80
100
%
 In
hi
bi
tio
n
Air Smoke
*
*
6.3 Effect of anti-tussives on CS-enhanced vagus responses  
159 
6.3.2 Theophylline effect on CS-enhanced vagus responses 
Depolarisation induced by capsaicin was significantly increased in vagus nerves from 
guinea pigs exposed to CS for 8 days (0.33±0.04mV) compared to air-exposed 
comparators (0.19±0.04mV) (Fig. 6.2a). The methylxanthine theophylline significantly 
inhibited both the ‘normal’ and CS-enhanced capsaicin-induced sensory nerve 
depolarisation (Fig. 6.2b). There was no significant difference in the level of inhibition of 
depolarisation as determined by comparison of the percentage inhibition in the treatment 
groups by Mann-Whitney U test.   
 
Figure 6.2 Effect of theophylline on CS-enhanced capsaicin responses in guinea 
pig isolated vagus nerves 
[A] Magnitude of capsaicin-induced (1µM; 2min) depolarisation of vagus nerve tissue 
from air- and CS-exposed guinea pigs. [B] Effect of theophylline (10µM; 10min) on 
capsaicin-induced depolarisation of vagus nerve tissue from air- or CS-exposed guinea 
pigs. Data displayed as mean±SEM, n=5, ⊥ p<0.05 as determined by unpaired students 
t-test * p<0.05 as determined by paired students t-test.  
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6.3.3 PEA effect on CS-enhanced vagus responses 
 Depolarisation induced by capsaicin was significantly increased in vagus nerves from 
guinea pigs exposed to CS for 8 days (0.20±0.02mV) compared to air-exposed 
comparators (0.10±0.02mV) (Fig. 6.3a). The fatty acid amide PEA significantly inhibited 
both the ‘normal’ and CS-enhanced low pH-induced sensory nerve depolarisation (Fig. 
6.3b). There was no significant difference in the level of inhibition of depolarisation as 
determined by comparison of the percentage inhibition in the treatment groups by Mann-
Whitney U test.   
 
 
Figure 6.3 Effect of PEA on CS-enhanced low pH responses in guinea pig isolated 
vagus nerves 
[A] Magnitude of low pH-induced (pH5; 2min) depolarisation of vagus nerve tissue from 
air- and CS-exposed guinea pigs. [B] Effect of PEA (1nM; 10min) on low pH-induced 
depolarisation of vagus nerve tissue from air- or CS-exposed guinea pigs. Data displayed 
as mean±SEM, n=5, ⊥ p<0.05 as determined by unpaired students t-test * p<0.05 as 
determined by paired students t-test.  
 
A B 
0.0
0.1
0.2
0.3
De
po
la
ris
at
io
n 
(m
V)
Air Smoke
⊥
0
20
40
60
80
100
%
 In
hi
bi
tio
n
Air Smoke
* *
6.4 Effect of anti-tussives on CS-enhanced cough responses  
161 
6.4 Effect of anti-tussives on CS-enhanced cough responses 
6.4.1 β-agonists effect on CS-enhanced cough responses 
The number of coughs evoked by capsaicin was increased by approximately 100% in 
guinea pigs exposed to CS for 8 days (11.4±2.5 coughs; mean±SEM) compared to air-
exposed comparators (6.0±1.3 coughs; mean±SEM) (Fig. 6.4). At the same dose that 
completely abolished capsaicin-evoked coughs in naïve animals (Section 3.3.1), the 
LABA compounds formoterol and olodaterol reduced the number of capsaicin-evoked 
coughs in CS-exposed guinea pigs to 1.8±1.2 and 0.3±0.2 coughs, respectively (Fig. 
6.4). 
 
 
Figure 6.4 Effect of LABA compounds on CS-enhanced capsaicin-evoked guinea 
pig cough 
 Guinea pigs, which had been exposed to room air or CS, twice daily, for 8 days, were 
pre-treated with an aerosol of vehicle (0.1% DMSO in PBS), formoterol (3µg.ml-1), or 
olodaterol (3µg.ml-1) for 10min, 1h prior to challenge with an aerosol of capsaicin (30µM; 
5min). Numbers of coughs were recorded for a 10min period, including 5min of aerosol 
plus 5min post-aerosol. Data displayed as mean±SEM, n=8, * p<0.05 as determined by 
Mann-Whitney U test compared to air/vehicle control, θ p<0.05 as determined by 
Kruskal-Wallis test with Dunn’s post-hoc test, compared to CS/vehicle control. 
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6.4.2 Theophylline effect on CS-enhanced cough responses 
 The number of coughs evoked by capsaicin was increased by approximately 100% in 
guinea pigs exposed to CS for 8 days (12.0±1.9 coughs; mean±SEM) compared to air-
exposed comparators (5.4±1.6 coughs; mean±SEM) (Fig. 6.5). At the same dose that 
significantly reduced capsaicin-evoked coughs in naïve animals (Section 4.3.1), 
theophylline reduced the number of capsaicin-evoked coughs in CS-exposed guinea pigs 
to 0.4±0.26 coughs (Fig. 6.5). 
 
 
Figure 6.5 Effect of theophylline on CS-enhanced capsaicin-evoked guinea pig 
cough 
Guinea pigs, which had been exposed to room air or CS, twice daily, for 8 days, were 
pre-treated with vehicle (0.5%w/v methylcellulose, 0.2%v/v tween80 in PBS) or 
theophylline (100mg.kg-1), administered i.p., 1h prior to challenge with capsaicin aerosol 
(30µM; 5min). Numbers of coughs were recorded for a 10min period, including 5min of 
aerosol plus 5min post-aerosol. Data displayed as mean±SEM, n=12, * p<0.05 as 
determined by Mann-Whitney U test compared to air/vehicle control, θ p<0.05 as 
determined by Mann-Whitney U test compared to CS/vehicle control. 
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6.5 Summary/Discussion 
The aim of this chapter was to examine the efficacy of the anti-tussive compounds, which 
have been shown (in the preceding chapters) to inhibit capsaicin- and/or CA-evoked 
cough in healthy animals, in a mechanistic disease model of CS-enhanced cough and 
sensory nerve responses.  
 
It should be noted that the experimental data obtained in this chapter were obtained in a 
series of studies. In each set of experimental data the number of coughs and the 
magnitude of vagus nerve depolarisation responses evoked by capsaicin, CA or low pH 
was significantly increased in CS-exposed guinea pigs, compared to those exposed in 
parallel to room air. The reproducibility of these enhanced responses is indicative of the 
robustness of this mechanistic model in mimicking the enhanced cough responsiveness 
observed in smokers and COPD patients in clinical studies (Wong & Morice, 1999; 
Doherty et al., 2000; Lewis et al., 2007; Blanc et al., 2009).  
 
Each of the compounds was first examined for their ability to inhibit the enhanced tussive 
stimulus-induced sensory nerve depolarisation observed following CS-exposure. The 
recently developed β-agonist olodaterol, and the methyxanthine theophylline both 
significantly inhibited the CS-enhanced capsaicin-induced vagus nerve responses to a 
similar proportion to the inhibition observed in vagus nerves from air-exposed 
comparators. Likewise, the FAA PEA inhibited the CS-enhanced low pH-induced 
responses, again to a similar proportion as in air-exposed comparator tissues.   
 
Following confirmation of the efficacy of these compounds in the ex vivo vagus nerve 
model of enhanced responsiveness, the effectiveness of the different classes of 
compound were examined in the in vivo model of CS-enhanced, capsaicin-evoked cough 
responses. Both of the LABA compounds, olodaterol and formoterol, inhibited the CS-
enhanced cough response by greater than 90%. Furthermore, the methylxanthine 
theophylline also displayed significant inhibition of the CS-enhanced cough response. 
Unfortunately, due to the closure of the Sandwich UK Pfizer site and re-structuring of the 
company resulted in a lack of financial provision and adequate amounts of the compound 
with which to examine the effect of the FAAH inhibitor (PF04862853) in the CS-enhanced 
cough model at this time. The efficacy of PEA against CS-enhanced vagus nerve 
responses, as one of the downstream mediators of the anti-tussive effects of 
PF04862853, suggests that this FAAH inhibitor would be effective in vivo at inhibiting 
evoked cough in the CS-enhanced model, however future research would be required to 
affirm this supposition.   
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The data presented here shows that each of the classes of compound evaluated in this 
thesis can effectively inhibit the enhanced cough responses observed in the guinea pig 
CS-exposure model. As mentioned in the introduction to this chapter, examining the 
effect of a drug in an animal model which displays a disease-like phenotype is 
considered to be more indicative of the likely effectiveness in human disease than such 
investigations in naïve animals. However, as the mechanisms by which the cough 
response is altered in human disease have not been determined, the relevance of the 
model to the clinic may be questioned.  
 
The primary consideration of a pre-clinical model of human disease, in order that it be 
useful and relevant, is that it displays an end-point resembling a relevant aspect of the 
clinical phenotype. It is difficult to compare objective clinical cough studies and objective 
animal cough studies directly, as they are typically not performed using the same 
methodology (see Introduction 1.5.3). Despite this, the lowered threshold concentration 
of capsaicin and CA required to evoke 5 coughs (C5) in smokers and COPD patients 
(Wong & Morice, 1999; Doherty et al., 2000; Lewis et al., 2007; Blanc et al., 2009), and 
the increased numbers of coughs evoked by a single concentration of the same stimuli in 
CS-exposed guinea pigs do both seem to indicate an increased sensitivity to the same 
tussive stimuli. This model was selected for its similar phenotype to the increased 
sensitivity to tussive stimuli observed in COPD patients, and in that specific sense, the 
model does appear to be clinically relevant. 
 
It is worth mentioning here that whilst it is generally accepted that the cough reflex can be 
sensitised to agents such as capsaicin and CA in COPD patients, some studies do not 
find a modification of cough in COPD (Wong & Morice, 1999). When attempting to 
understand this discrepancy, it should be considered that COPD is a diagnostic label 
covering a wide range of disease manifestations; indeed the term ‘COPD’ was coined as 
an umbrella term for what used to be considered as separate obstructive lung diseases 
(Barnes, 2001). Chronic cough is only one symptom of COPD, and not all COPD patients 
exhibit chronic cough. Whether cough as a symptom is associated with a certain sub-
population of COPD patients whom may have a common underlying cause is unclear. 
What is clear is that the heterogeneity of cough as a symptom in COPD may explain the 
disparity between the findings of various cough studies in COPD patients mentioned 
above. This heterogeneity of cough as a COPD symptom is reflected in the diagnostic 
criteria outlined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
(Vestbo et al., 2013). To paraphrase the original document; "A clinical diagnosis of COPD 
should be considered in any patient who has… chronic cough… and a history of 
exposure to risk factors [including cigarette smoking]… [although] spirometry is required 
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to make the diagnosis in this clinical context… and conversely significant airflow limitation 
may develop without chronic cough and sputum production." It may be considered then 
that the CS-enhanced cough model is relevant to those COPD patients presenting with 
chronic cough who also have a lowered threshold/increased sensitivity to chemically 
(capsaicin/CA) evoked cough. The proportion of COPD chronic coughers whom fit into 
this category is unclear, as to date no large scale clinical studies have been performed 
evaluating the cough reflex sensitivity of COPD patients. However, clinical trials 
examining anti-tussive compounds would be likely to use objective cough monitoring 
initially, due to the advantages of such study design in determining efficacy. Furthermore 
it may be supposed that such clinical studies would seek to screen for chronic coughers 
who have a heightened sensitivity to capsaicin as part of their study design. It follows 
therefore that the CS-enhanced capsaicin-evoked cough model used here should be 
representative of the type of COPD patients (those with chronic cough and enhanced 
capsaicin sensitivity) who would be selected for clinical trials of novel anti-tussives.  
 
Another key factor in the translatability of a disease model to the clinic is the clinical 
relevance of the challenge stimulus. Globally, the prevelant risk factor for developing 
COPD is cigarette smoking (Vestbo et al., 2013). However, the development of COPD is 
not due to cigarette smoking alone, as whilst CS exposure is a prominent risk factor for 
COPD, only approximately 25% of smokers develop COPD (Løkke et al., 2006). Genetic 
susceptibility, old age, exposure to other inhaled particles, asthma hyperreactivity and 
infections are some of the other risk factors indicated in COPD development (Vestbo, 
others). However, the interaction between these various factors in the development and 
progression of the disease is not currently fully understood, and therefore cigarette 
smoke exposure seems to be the most relevant and feasible challenge stimulus to use in 
a mechanistic animal model of COPD such as the one described in this chapter.  
 
Given that the challenge stimulus used is relevant, and that the model represents a 
relevant phenotypic end-point, the remaining key question would be whether the 
mechanisms by which cough is enhanced in this model are the same as the mechanisms 
involved in the pathogenesis of chronic cough in COPD patients. Unfortunately the 
mechanisms underlying chronic cough in disease are currently not completely elucidated, 
and as such no definitive answer can be asserted to this question. What can be said, 
however, is that multiple clinical features and biomarkers associated with disease 
progression/severity of COPD are replicated in CS-exposure models in guinea pigs, as 
discussed more fully in the conclusion (see Section 7.1.2) to this thesis. These include 
structural changes such as fibrosis (Domínguez-Fandos et al., 2012) and emphysema 
(Wright & Churg, 1990; Domínguez-Fandos et al., 2012), as well as inflammatory cell 
6. Efficacy of anti-tussives in a disease model  
166 
(predominantly neutrophilic) infiltration into the lungs (Domínguez-Fandos et al., 2012). 
However it is generally considered that inflammatory mediators play an important role in 
the sensitisation of sensory nerve responses to capsaicin (Lee & Pisarri, 2001; Mazzone 
& McGovern, 2007). A number of mediators implicated with a role in sensory 
sensitisation, such as tumour necrosis factor (TNF)-α, interleukin-1β (IL-1β), interleukin-8 
(IL-8), prostaglandin E2 (PGE2) and neurokinins have been shown to be upregulated in 
CS-exposed guinea pigs (Kuo & Lu, 1995; Hong & Lee, 1996; Kwong et al., 2001; Churg 
et al., 2002; Wortley et al., 2011; Luo et al., 2012), again similarly to observations in 
human COPD patients (Keatings et al., 1996; Chung, 2005; Miotto et al., 2007; Chen et 
al., 2008; Profita et al., 2010; Vatrella et al., 2010). As this model replicates many 
features of the human disease, investigating the mechanisms underlying enhanced 
cough in the CS-exposure model would be an interesting direction for future research, 
that might provide insights into the human condition (Bolser, 2004; Lewis et al., 2007; 
Stevenson & Belvisi, 2008; Lee et al., 2009).  
 
In summary, both the long acting β2-agonists, as well as theophylline were effective at 
inhibiting both the in vivo enhanced capsaicin cough and ex vivo enhanced isolated 
vagus capsaicin responses in CS-exposed guinea pigs. Whilst it is not possible to 
examine the FAAH inhibitor (PF04862853) in vivo, the FAA PEA, one of the downstream 
effectors of PF04862853 on vagus nerve, was effective at inhibiting the CS-enhanced 
isolated vagus low pH responses, hinting that PF04862853 would be effective in the in 
vivo enhanced cough model. As the CS-exposure model used appeared to replicate the 
disease condition of the cough reflex in COPD patients, these results suggest 
advancement to clinical research is warranted for all three classes of compound 
examined here, in order to confirm their usefulness as peripherally acting and efficacious 
anti-tussive therapies in man.  
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7.1 Summary of thesis 
Excessive cough is one of the most common reasons that patients seek ambulatory care 
(Schappert & Rechtsteiner, 2011), and in a survey as much as 12% of the general 
population self-reported suffering with chronic cough and phlegm on most days for at 
least 3 months of the year (Cerveri et al., 2003). Cough is a common symptom of upper 
respiratory tract infections, and in the majority of these cases cough resolves upon 
successful clearance of the infection, being considered an acute symptom where cough 
persists for less than 3 weeks (Pratter, 2006a). By contrast, chronic cough is defined as 
cough of a duration greater than 8 weeks, and the non-resolving, non-productive 
persistent cough which afflicts chronic cough patients can persist for many years 
(Dicpinigaitis, 2012). Chronic cough can be a distressing symptom with multiple physical 
and psycho-social consequences that can severely reduce sufferers quality of life (Irwin, 
2006c), and this condition is commonly associated with PNDS, GERD, asthma and 
COPD (Pratter, 2006b). Whilst it has been suggested that successful diagnosis and 
treatment of PNDS and GERD may resolve cough (Irwin, 2006b), more recent evidence 
suggests, at least in the case of GERD, that the clinical picture may be less clear cut, as 
a recent Cochrane review of GERD treatments failed to find sufficient high quality 
evidence to support this claim (Chang et al., 2011). Indeed, the view that acidic reflux is 
one of the major causes of chronic cough has been challenged by studies finding a lack 
of correlation between reflux events and cough in many chronic cough subjects, and also 
the lack of efficacy in appropriately designed clinical trials of acid suppression therapies 
(Smith & Houghton, 2013). Moreover, cough is often persistent in patients with chronic 
respiratory conditions, particularly in severe asthma and COPD, which are poorly 
controlled by standard treatments (Irwin & Curley, 1991). Therefore, where the underlying 
condition is not sufficiently controlled by medication, successful treatment fails to restore 
a normal cough reflex, or where a cause of cough cannot be identified (unexplained 
cough), direct cough suppressants are required.  
 
Existing cough therapies, however, are either ineffective, or are associated with adverse 
effects (Yancy et al., 2013). In general, centrally acting antitussives are the only 
moderately effective type of antitussive, but are commonly associated with adverse 
effects, including sedation and nausea (Bolser, 2006b). By contrast, peripherally acting 
antitussives are associated with far fewer adverse effects, but evidence for the efficacy of 
these therapies is less clear. For example, a meta-analysis of clinical studies of existing 
cough therapies found that moguisteine, a peripherally acting antitussive, provides a 
significant but highly variable improvement over placebo in terms of cough severity 
(assessed by subjective measures), but did not reduce cough frequency (Yancy et al., 
2013). Considering the ineffectiveness or risk of adverse effects associated with current 
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therapies, the high prevalence of chronic cough in the general population, and the impact 
of chronic cough on patients lives, new cough medications are urgently needed.  
7.1.1 Summary of findings 
This thesis therefore examined three classes of compound which have been implicated 
as potential antitussives; long-acting β2-adrenergic receptor agonists (LABA), 
methylxanthines, and fatty acid amide hydrolase (FAAH) inhibitors. Short acting β2-
adrenergic receptor agonists (fenoterol, terbutaline) have previously been demonstrated 
to have a direct antitussive effect via an action on vagal sensory nerves; inhibiting 
capsaicin-induced cough in guinea pigs, and also depolarisation of guinea pig and 
human vagus nerve (Freund-Michel et al., 2010). By contrast, LABA type bronchodilators 
are more commonly used clinically, but have not been investigated for any antitussive 
properties. The methylxanthine compound theophylline has been shown to inhibit 
capsaicin-evoked cough in subjects with angiotensin-converting enzyme inhibitor related 
cough (Cazzola et al., 1993), but this potential has not been further investigated, despite 
another methylxanthine, theobromine, being shown to inhibit evoked cough and sensory 
nerve activation in both pre-clinical and human subjects (Usmani, 2004). In small clinical 
trials, FAAH inhibitors have been shown to causes elevation of endocannibinoid fatty acid 
amides (Li et al., 2012). Whilst cannabinoid receptor agonists generally are associated 
with multiple adverse effects, a recent clinical trial found the FAAH inhibitor PF-04457845 
was not associated with adverse effects in healthy volunteers. It therefore appears that 
increasing the levels of endogenously produced fatty acid amides is comparatively safer 
than exogenously administering cannabinoids (Li et al., 2012). Cannabinoid receptor 
agonists have been shown to exert an antitussive effect via the CB2 receptor on vagal 
afferent sensory nerves (Belvisi et al., 2009).  
 
To bring a newly discovered compound through lead testing and clinical trials can take 
around a decade and US$1 billion (DiMasi et al., 2003). Therefore the compounds 
selected for evaluation in this thesis include the LABA formoterol, as well as the 
methylxanthine theophylline, both of which are clinically approved and indicated for use 
as bronchodilators in patients with asthma and COPD. The repurposing, or ‘repositioning’ 
of these existing bronchodilators as antitussives is an attractive prospect, given that 
repurposing of existing drugs can bring benefits to patients faster, and reduce the costs 
and failure risk to pharmaceutical companies compared to the full drug development 
cycle for a new compound (Novac, 2013). In addition, olodaterol, a novel LABA which 
has entered phase III clinical trials for use as a bronchodilator 
(http://www.clinicaltrials.gov/ct2/results?term=olodaterol&phase=2; accessed 20.08.13), 
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and PF04862853, a FAAH inhibitor in pre-clinical testing (Meyers et al., 2011), were also 
evaluated for their antitussive potential.  
 
Initially, it was shown that formoterol, olodaterol, theophylline, and PF04862853 were 
each able to inhibit either capsaicin-, CA-evoked cough, or both, in conscious guinea 
pigs. Once efficacy had been confirmed in this in vivo model, appropriate lines of 
investigation were undertaken for each compound in order to examine their activity on 
sensory nerve activation by tussive agents, and their mechanism of action in this context.  
 
Formoterol, olodaterol and theophylline inhibited the capsaicin-evoked firing of C-fibres in 
vivo, demonstrating that these compounds are effective at inhibiting activation of the 
fibres thought to mediate the cough response to capsaicin (see Introduction 1.2; 
Canning, 2011). Theophylline was also shown to inhibit PGE2-evoked firing of C-fibres in 
vivo, demonstrating an antitussive mechanism of action for theophylline independent of 
its bronchodilator activity. Furthermore, theophylline, as well as formoterol and olodaterol, 
were shown to inhibit capsaicin-induced calcium flux in isolated airway-terminating 
jugular neurons; demonstrating that each of these compounds can directly inhibit 
activation of the airway neurons likely involved in the cough reflex, independent of their 
bronchodilator activity. The FAAH inhibitor PF04862853 was shown to cause elevation of 
plasma levels of the fatty acid amides PEA, AEA, OEA and LEA. PEA was demonstrated 
to inhibit low pH-induced calcium flux in isolated airway-terminating jugular neurons – 
suggesting that the FAAs elevated by PF04862853 administration may exert an 
antitussive activity via an action on the sensory nerves involved in evoking cough.  
 
The mechanism of action on sensory nerves of β-adrenergic receptor agonists, 
theophylline and the endocannibinoids elevated by PF04862853 (PEA, AEA, OEA and 
LEA) was then investigated, as summarised below (Fig. 7.1, 7.2, and 7.3 respectively).  
 
Using selective antagonists and β2- and β3-adrenergic receptor KO mouse vagus nerve 
tissue it was shown that formoterol and olodaterol exert their inhibitory effects on sensory 
nerves via the β2-adrenergic receptor. A novel finding was that β1- and β3-adrenergic 
receptor agonists had a similar effect; whilst β1-receptor agonists are unlikely to have 
utility as antitussives due to their adverse effects on the cardiovascular system, β3-
receptor agonists are not as abundant in cardiac tissue, and therefore may be an 
interesting target for future drug development. Downstream of the receptors, the 
inhibitory activity of these agonists was investigated. Previously, the inhibitory action of 
SABA on vagal sensory nerves has been shown be via elevation of cyclic AMP (cAMP), 
activating Protein Kinase G (PKG) and downstream large conductance calcium-activated 
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Figure 7.1 Schematic illustration of mechanism of action of LABA drugs 
Simplified cartoon schematic of mechanism of action of formoterol, olodaterol (LABAs), 
denopamine (β1-agonist) and BRL37344 (β3-agonist) on sensory nerves. Denopamine, 
formoterol, olodaterol and BRL37344 were shown to cause inhibition of vagus nerve 
depolarisation through the β1-, β2- and β3-adrenoreceptors (respectively), effects that 
were respectively blocked by the specific β1-, β2- and β3-adrenoreceptor antagonists 
CGP20712A, ICI118551 and L748337. Downstream of the receptor, agonism of any of 
the β-adrenoreceptors caused opening of the BKCa potassium channels, as their 
inhibitory effects were blocked by paxilline. It is thought that the influx of potassium 
reduces the excitability of the cell, thereby causing the observed functional inhibition of 
depolarisation by TRPV1 and TRPA1 agonists. The AC activator forskolin mimicked this 
functional inhibition of the same agonists, and the effect of the β-adrenoreceptor agonists 
was lost in AC KO mice, suggesting a Gs/AC/PKA or PKG pathway is involved in the 
opening of the BKCa channel. Key - arrow=activating interaction, blocked line=inhibiting 
interaction, grey blocked line=functional inhibition, ?=unconfirmed pathway.  
Abbreviations; β1AR/β2AR/β3AR; β-adrenergic receptors type 1/2/3, CGP20712A; β1AR 
antagonist, ICI118551; β2AR antagonist, L748337; β3AR antagonist, AC; adenylyl 
cyclase, cAMP; cyclic adenosine monophosphate, PKA/G; protein kinase type A/G, BKCa; 
large-conductance calcium-activated potassium channel, TRPV1; transient receptor 
potential vanilloid type 1 receptor, TRPA1; TRP ankyrin type 1 receptor.  
 
potassium channels (BKCa) (Freund-Michel et al., 2010). In this thesis it was 
demonstrated that AC activation plays a key role in the inhibitory activity of LABA and β1- 
and β3-adrenergic receptor agonists. Firstly forskolin, an activator of AC (the enzyme 
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regulating cAMP production) was shown to mimic the inhibitory activity of the β-
adrenergic receptor agonists in mouse vagus nerve. Then, after observing that 
expression of AC6 was the highest of the 10 AC isoforms in mouse vagal ganglia, the 
inhibitory action of each of the β-adrenergic receptor agonists tested, as well as forskolin, 
was shown to be lost in AC5/6 KO mouse vagus tissue. Downstream of AC activation, a 
role for BKCa, but not of other calcium-activated potassium channels, was demonstrated 
in the inhibitory action of the β-adrenergic receptor agonists on guinea pig vagus nerve 
tissue. The activation of BKCa by β-adrenergic receptor agonists suggests a mechanism 
of action involving the efflux of potassium ions, causing hyperpolarisation of sensory 
neurons, and decreasing the general ‘excitability’ to future stimuli. Formoterol, olodaterol, 
and the β1- and β3-adrenergic receptor agonists were each shown to inhibit 
depolarisation evoked by exogenous and endogenous agonists of TRPV1 and TRPA1, a 
finding suggestive of such a general inhibition of sensory nerve activity. In addition, the 
LABA compounds and β1-/β3- agonists were shown to inhibit capsaicin-induced  
depolarisation of human vagus nerve tissue through their respective receptors, 
demonstrating the translational potential of this work to humans.    
 
In contrast to the LABA compounds, theophylline is not thought to activate a 
metabotropic receptor, but is known to be a weak non-specific PDE inhibitor. Whilst PDE 
inhibitors have been shown to inhibit cough in guinea pigs (Mokry & Nosalova, 2011), in 
the current context this mechanism was considered unlikely due to the observed potency 
of theophylline on vagus nerves being far lower than its reported potency as a PDE 
inhibitor. Using pharmacological antagonists, the SKCa and IKCa channels were shown to 
be involved in the inhibitory action of theophylline on guinea pig vagus nerve 
depolarisation. Experiments with isolated patch clamped jugular ganglia neurons 
confirmed that theophylline opens SKCa and IKCa channels, causing a hyperpolarisation of 
the cell that would explain its inhibitory action on sensory nerves. Furthermore, 
theophylline increased the open potential of the SKCa channel in inside-out patch clamp 
experiments, demonstrating a mechanism of action independent of intracellular second 
messengers such as cAMP. The inhibitory activity of theophylline and the involvement of 
SKCa and IKCa was observed in human vagus nerve tissue, demonstrating the 
translational potential of this work to humans. 
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Figure 7.2 Schematic illustration of mechanism of action of theophylline 
Simplified cartoon schematic of mechanism of action of theophylline (methylxanthine) on 
sensory nerves. Theophylline was shown to cause inhibition of vagus nerve 
depolarisation to a variety of tussive stimuli, including capsaicin, acrolein and low pH. 
This effect was shown to be via opening of SKCa and IKCa potassium channels, as the 
inhibitory effects of theophylline were reversed by blockers of these channels (apamin 
and coltrimazole). Using the inside-out patch clamp technique it was shown that 
theophylline directly opens these channels independently of intracellular second 
messengers. It was shown that the influx of potassium ions into the cell lowers the resting 
membrane potential voltage, and it is therefore thought that this reduces the excitability of 
vagal neurons, causing functional inhibition to a range of pro-tussive stimuli. Key - 
arrow=activating interaction, blocked line=inhibiting interaction, grey blocked 
line=functional inhibition.  Abbreviations; SKCa; small-conductance calcium-activated 
potassium channel, IKCa; intermediate-conductance calcium-activated potassium 
channel, TRPV1; transient receptor potential vanilloid type 1 receptor, TRPA1; TRP 
ankyrin type 1 receptor.  
 
 
Levels of the endogenous fatty acid amides PEA, AEA, OEA and LEA were shown to 
elevated by administration of PF04862853. Each of these FAAs was shown to exert 
inhibitory activity on capsaicin- and low pH-induced guinea pig vagus nerve 
depolarisation. As they are known to be endocannibinoids, the effect of CB1 and CB2 
receptor antagonists was examined; showing that PEA-, AEA-, OEA- and LEA- mediated 
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inhibition of guinea pig vagus nerve depolarisation is via the CB2, but not the CB1 
receptor. Whilst the intracellular signaling pathways downstream of CB2 receptor 
activation have not been fully elucidated (Demuth & Molleman, 2006), cannabinoid 
receptor activation is known to cause downstream calcium-activated potassium channel  
 
 
Figure 7.3 Illustration of mechanism of action of PF04862853 
Simplified schematic of mechanism of action of PF04862853 (FAAHi), via fatty acid 
amides, on sensory nerves. PF-04862853 was shown to inhibit cough, and to elevate 
plasma levels of the endogenous FAAs PEA, AEA, OEA and LEA, an effect thought to be 
caused by inhibition of the FAAH enzyme. PEA, AEA, OEA and LEA were shown to 
inhibit vagus nerve depolarisation via the CB2 receptor, an effect that was blocked by a 
specific CB2 receptor antagonist. PEA was also shown to inhibit depolarisation via BKCa 
potassium channels, as the inhibitory effects of PEA were reversed by a blocker of this 
channel (apamin). It is thought that the influx of potassium reduces the excitability of the 
cell, thereby causing the observed functional inhibition of depolarisation by TRPV1 and 
TRPA1 agonists. The G protein receptor mediated pathway between CB2 activation and 
BKCa channel opening is unknown, and may be a Gi- or Gs-coupled cascade. In other 
systems it has been suggested that cannabinoid effects may be dependent on opioid 
pathway signaling. Key: arrow=activating interaction, blocked line=inhibiting interaction, 
grey blocked line=functional inhibition, ?=unconfirmed pathway.  Abbreviations; FAAH; 
fatty acid amide hydrolase, PEA; palmitoylethanolamide, AEA; anandamide, OEA; 
oleoylethanolamide, LEA; linoleoylethanolamide, CB2; cannabinoid type 2 receptor, SKCa; 
small-conductance calcium-activated potassium channel, TRPV1; transient receptor 
potential vanilloid type 1 receptor, TRPA1; TRP ankyrin type 1 receptor. 
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opening (Welch et al., 1995a; Yang et al., 2007). Using pharmacological antagonists, 
SKCa type potassium channels were implicated with a role in the inhibitory action of PEA 
on guinea pig vagus nerve depolarisation. Furthermore, PEA also inhibited low pH-
induced depolarisation of human vagus nerve tissue, an effect reversed by both a CB2 
receptor antagonist or SKCa channel blocker, demonstrating that the mechanism of 
endocannibinoid action on sensory nerves may translate to humans. 
 
Finally, as the purpose of any anti-tussive medication is to inhibit cough in patients whom 
exhibit such an exaggerated cough response, the effect of LABA, theophylline and 
PF04862853 were examined in an animal model of CS-enhanced cough and responses. 
Both LABA compounds, formoterol and olodaterol, as well as theophylline, were effective 
at inhibiting both the in vivo enhanced capsaicin cough and ex vivo enhanced, capsaicin-
induced isolated vagus depolarisation observed in CS-exposed guinea pigs. Whilst it was 
not possible to examine the FAAH inhibitor (PF04862853) in vivo, the FAA PEA, one of 
the downstream effectors of PF04862853 on vagus nerve, was effective at inhibiting CS-
enhanced, low pH-induced isolated vagus nerve depolarisation.  
 
Importantly, both LABA compounds, as well as theophylline, were shown to inhibit 
capsaicin-evoked firing of C-fibres in vivo. Whilst the anti-tussive effects of LABAs have 
not been previously demonstrated, the LABA compound indacaterol has been shown to 
cause single fibre firing in a preparation similar to the one used in this thesis (Sladen et 
al., 2009). However, it was not established whether this was an effect of the drug 
vehicle/delivery route, of indacaterol itself, or a drug effect common to the LABA class of 
drugs. Therefore the finding here that formoterol, as well as the novel LABA compound 
olodaterol, do not cause activation of airway single C-fibres suggests that LABA 
compounds as a class do not possess pro-tussive effects of themselves.  
 
Collectively, these results suggest that each of the three classes of compound evaluated 
in this thesis possess efficacy as peripherally acting antitussives. Each of the compounds 
had a direct inhibitory effect on sensory nerve activation, mediated by distinct 
mechanisms, a common element of which is an effect on calcium-activated potassium 
channels.  
 
7.1.2 Limitations of studies 
The in vivo models of objective cough to capsaicin and CA were selected for use in this 
thesis due to the clinical relevance of these stimuli. In addition, it has been shown that 
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cough reflex sensitivity to both of these stimuli is similar between human subjects and 
guinea pigs (Laude et al., 1993).  
 
The examination of signaling pathways and activity of drugs on sensory nerve activation 
was also primarily completed in guinea pig and mouse tissue. Whilst the expression of 
various receptors and signaling proteins may differ between species, key experiments 
were repeated in human vagus nerve tissue, to demonstrate the effects observed in 
animal models translate to a relevant tissue.  
 
Each of the techniques detailed in this thesis have different advantages and limitations. 
Therefore, where possible, the techniques used were selected to complement each other 
by mitigating these limitations. For example, the isolated vagus nerve recording 
technique allows relatively cost-effective pharmacological evaluation of sensory nerve 
activity in guinea pig, human and knock-out mouse tissues. However the technique 
cannot be used to examine the activity of only airway-terminating nerves. By contrast, the 
isolated neuron calcium imaging and single fibre nerve recording techniques do allow 
discrimination between airway and non-airway neurons/nerves. However, the single fibre 
technique is relatively labour-intensive and costly, as only one nerve fibre can be 
examined in a single animal. In addition, translational data cannot be obtained in either 
the isolated neuron calcium imaging or single fibre nerve recording techniques.  
 
Whilst the above techniques were useful in demonstrating the antitussive efficacy of 
these compounds against the normal capsaicin-evoked cough reflex, in the clinic any 
antitussive medication would be expected to inhibit the exaggerated cough response 
observed in patients with chronic cough. The model of CS-enhanced cough and sensory 
nerve responses described in chapter 6 was therefore designed to mimic the enhanced 
sensitivity to capsaicin and CA observed in COPD patients with chronic cough (Wong & 
Morice, 1999; Doherty et al., 2000; Blanc et al., 2009). As cigarette smoking is the 
primary risk factor associated with the development of COPD, CS exposure was used as 
a relevant challenge agent to drive this ‘COPD-like’ modification of the cough reflex 
(Vestbo et al., 2013). However, only approximately 25% of smokers develop COPD, 
indicating that other factors (genetic, alternate environmental exposures) likely play a role 
in the development of COPD (Løkke et al., 2006; Vestbo et al., 2013). As the model 
described here is one of only CS-exposure, and does not take into account such factors 
that may influence the susceptibility of individuals to COPD, the validity of the model may 
reasonably be questioned. Indeed, due to the shorter duration over which smoke 
exposures take place (8 days), it could be argued that the model employed here is more 
one of cigarette smoking than of COPD per se. 
7.1 Summary of thesis  
177 
 
The exposure periods and duration of CS-exposures in the guinea pig model were 
selected following the validation studies previously completed, as described in Lewis et 
al. (2007). In the validation of this model, bronchoalveolar lavage (BAL) was taken from 
guinea pigs exposed to either room air or CS in parallel. The numbers of neutrophils in 
the BAL fluid were increased in CS-exposed guinea pigs (see Appendix; Fig. A1). 
Additionally, as described previously (see Chapter 6), enhanced cough and vagus nerve 
responses to capsaicin and low pH were observed in this model. The enhanced cough 
responses in these guinea pigs are suggestive of the enhanced sensitivity to the same 
tussive stimuli seen in chronic cough subjects with COPD (Wong & Morice, 1999; 
Doherty et al., 2000; Blanc et al., 2009). Furthermore, preliminary data obtained in the 
isolated vagus nerve preparation suggests that capsaicin and low pH evoked greater 
depolarisation in human smokers compared to non-smokers (see Appendix; Fig. A2). 
However, this data is limited due to the small population size, and the lack of information 
about the prevalence of cough in the sample subjects (see Appendix; Table A1). Beyond 
comparing these characteristics of the CS-exposure model to the clinical manifestations 
of chronic cough and COPD, it is not possible to affirmatively state that the mechanisms 
underlying the modification of the cough reflex are the same, as most of the hypotheses 
on mechanisms of modified human cough reflex come from animal studies.  
 
However, investigating the mechanisms underlying enhanced cough in the CS- exposure 
model would be an interesting direction for future research, that might provide further 
insights into the human condition (Bolser, 2004; Lewis et al., 2007; Stevenson & Belvisi, 
2008; Lee et al., 2009). 
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7.3 Future directions 
In this section the potential direction of future research into the antitussive potential of the 
compounds examined in this thesis will be explored. Additionally, ideas for the future 
direction of research into the mechanisms of CS-enhanced cough will be considered.  
 
7.3.1 Further studies examining antitussive activity & mechanisms 
Formoterol, olodaterol, theophylline and PF04862853 have each been shown to inhibit 
either capsaicin- and/or CA-evoked cough. In addition, formoterol, olodaterol and 
theophylline have each been shown to inhibit capsaicin-evoked firing of C-fibres in vivo. 
Demonstrating that PF04862853 has a similar action on C-fibres would therefore likewise 
confirm that this compound inhibits activation of the fibres thought to mediate the cough 
response to capsaicin (Canning, 2011). 
 
Further, the effect of repeated aerosol dosing of LABA compounds over time on their 
subsequent efficacy against cough could be investigated. β2-adrenoreceptor agonists are 
known to cause agonist-induced desensitisation of the β2-adrenoreceptor. Both SABA 
and LABA have been shown to induce desensitisation of the β2-adrenoreceptor, leading 
to a clear loss of their bronchoprotection and bronchodilation function, as demonstrated 
in some studies (Newnham et al., 1995; Aziz et al., 1998; Giannini et al., 2001; Tsagaraki 
et al., 2006). Whilst it has been suggested that LABA cause more downregulation of the 
β2-adrenoreceptor than SABA (January et al., 1997; Clark et al., 1999; Moore et al., 
2007), it has also been argued that the reverse may be true, as LABA achieve an 
equivalent functional efficacy with less receptor occupancy, which may reduce 
downregulation of the receptor at equi-effective doses relative to SABA (Charlton, 2009). 
Obviously, however, given the novelty of the findings presented here, the effect of long-
term dosing of LABA on their anti-tussive efficacy has not been investigated. It would 
therefore be worthwhile to establish the possible effects any such desensitisation would 
have on the ability of the LABA compounds to inhibit cough.  
 
It would also be interesting to examine the activity of each of the different classes of 
compound on other fibre types thought to be involved in the cough reflex. RARs and 
cough receptors have also been suggested to be key nerve fibres involved in regulating 
the cough reflex (Canning, 2004). This may provide more detailed information about the 
type of cough these drugs may be expected to inhibit. RARs and cough receptors are 
particularly implicated with a role in mediating cough evoked by mechanical stimuli. As 
discussed previously (Introduction 1.3.4), one hypothesis is that increased 
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responsiveness of nerve fibres to chemical stimuli is responsible for the unproductive 
cough observed in chronic cough subjects (Nasra & Belvisi, 2009). Therefore drugs that 
block chemically-evoked cough but not mechanically-evoked cough may inhibit the 
unproductive cough whilst leaving the defensive cough reflex intact. Should the drugs 
examined in this thesis have no effect on mechanically evoked RAR/cough receptor 
firing, they may thus prove to be ideal candidate antitussive compounds. If, on the other 
hand, they were to inhibit mechanical activation of airway afferent nerve fibres, an 
alternative clinical strategy would be titration of drug dosage to a level that alleviates the 
burden of excessive cough whilst leaving some level of defensive cough reflex intact.    
 
Further to examining the effect of these drugs on mechanical pro-tussive stimuli, future 
work is required to further elucidate portions of the signalling pathways mediating 
inhibition of sensory nerve activation. 
  
 
Several components of the signalling pathway downstream of β-adrenergic receptor 
activation remain to be investigated: 
• Examine the activation of AC by β-adrenergic receptor agonists in guinea pig and human 
nerve tissues. Future studies may therefore examine the effect of AC activation on 
depolarisation, and also the effect of an AC inhibitor on the inhibitory activity of β-
adrenergic receptor agonists in these tissues. 
• Downstream of AC, the elevation of cAMP in response to LABA activation of the β2-
adrenergic receptor has not been confirmed. This could be achieved in guinea pig 
ganglia cells using a fluorescence energy resonance transfer (FRET) assay, using 
commercially available kits. 
• Whilst it has been shown previously a PKG inhibitor blocks the activity of SABA, it has 
not been demonstrated that LABA and β1- and β3-adrenergic receptor agonists act in the 
same way.  
• The effect of LABA in mouse vagus nerve tissue from BKCa knock-out mice (Slo-/-) could 
be examined to confirm the role of the BKCa channel in LABA inhibition of capsaicin 
depolarisation.  
• Furthermore, the effect of the BKCa blocker, paxilline, could be examined on the LABA 
inhibition of human vagus nerve depolarisation to confirm that the proposed mechanism 
translates to human subjects. 
 
In addition to the above experiments to confirm and further probe elements of β-
adrenergic receptor signaling in guinea pig ganglia, it would be interesting to repeat key 
experiments in human jugular ganglia neurons to confirm that the mechanism of action of 
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these compounds translates to human sensory nerves. Obtaining such cells would be 
invaluable as a translational research tool.  
 
In contrast to β-adrenergic receptor, relatively few pathways remain to be elucidated for 
the mechanism of action of theophylline on sensory nerves. Inside-out patch clamping of 
guinea pig vagal ganglia demonstrated that theophylline acts on potassium channels 
independently of intracellular 2nd messenger activity. However, if human primary jugular 
ganglia cells could be obtained, it would be useful to confirm (using patch clamp 
techniques) that theophylline exerts the same effect on IKCa and SKCa channels in a 
relevant human cell type.  
 
In guinea pigs, the FAAH inhibitor PF04862853 has been shown to cause elevation of 
plasma levels of the FAAs AEA, PEA, OEA and LEA. It was subsequently demonstrated 
that FAAs cause inhibition of sensory nerve depolarisation via CB2 receptors and 
downstream IKCa channels. However, the intracellular signalling pathways between the 
receptor and ion channel have not yet been elucidated.  
 
Initially, determining the type of G protein the CB2 receptor is coupled to following 
activation by the FAAs may give an indication of the likely pathways involved in the 
downstream inhibition of capsaicin and low pH depolarisation (Fig. 7.3). Classically, 
cannabinoid receptors are thought to be coupled to Gi, which activate intracellular 
signalling cascades which result in the activation of potassium channels (Demuth & 
Molleman, 2006). If the inhibitory effects of PEA, AEA, OEA or LEA are blocked by the 
application of pertussis toxin, this may indicate a Gi mediated downstream effect. 
Alternatively, the inhibitory effects of the FAAs could be profiled in vagus tissue from 
AC5/6-/- mouse tissue, similarly to the methods described to examine the effects of the 
LABA compounds (see Section 3.4.6). However, whilst it has been shown that CB2 can 
couple to Gs subunits (Demuth & Molleman, 2006), in the context of the findings of this 
thesis, a Gs-AC-cAMP-PKA pathway seems unlikely, given that the LABA compounds 
were shown to act via BKCa, whereas the inhibitory effect of the FAAs were found to act 
via SKCa. 
 
Downstream of G protein coupling, it has been suggested that CB2 receptor activation 
may stimulate the release of endogenous opioids, including β-endorphin (see Fig. 7.3; 
Ibrahim, 2005). Opiate-based drugs are some of the most efficacious antitussives, and 
whilst they are thought to act predominantly in the central nervous system, it is thought 
that activation of peripheral opioid receptors on sensory nerves may play a role in the 
inhibition of cough (Karlsson et al., 1990; Adcock, 1991). Furthermore, it has been shown 
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that the antinociceptive effects induced by administration of AEA following FAAH 
inhibition can be blocked by opioid receptor antagonists (Haller et al., 2008). It would 
therefore be interesting to examine the involvement of opioid receptors in the inhibitory 
effects of the FAAs on cough and sensory nerve responses.  
 
Finally, it would also be interesting to examine the effect of combining LABA compounds 
and either theophylline or PF04862853 on sensory nerve depolarisation and cough. 
These drugs appear to act via the opening of different calcium-activated potassium 
channels, therefore may be expected to have additive antitussive effects. Clinically, 
administration of two antitussives that act via different pathways could provide more 
effective inhibition of cough than either alone, and may be beneficial in reducing any 
adverse effects. 
 
7.3.2 Further studies examining CS-enhanced cough mechanisms 
Investigating the mechanisms underlying enhanced cough in the CS- exposure model 
would be an interesting direction for future research. Indeed, some preliminary 
investigations have already been begun, using the CS-exposure model described 
previously (see Chapter 6) to examine the responses of isolated airway neurons to CS-
exposure. This section will describe some of these initial findings, and suggest some 
future avenues of research. 
 
Thus far, the capsaicin responsiveness of airway-terminating neurons isolated from the 
jugular and nodose ganglia of air- and CS-exposed guinea pigs has been examined. 
These investigations have shown that in CS-exposed animals, airway-terminating jugular 
neurons show an enhanced responsiveness to capsaicin, with the same concentration of 
capsaicin apparently causing a greater elevation of intracellular calcium influx (see 
Appendix; Fig. A3a). Additionally, whilst the majority of airway-terminating nodose 
neurons from air-exposed guinea pigs do not respond to capsaicin, in CS-exposed 
guinea pigs these cells become responsive to capsaicin (see Appendix; Fig. A3b).  
 
Currently the mechanisms underlying these changes have not been elucidated, but these 
results are suggestive that two mechanisms may be involved in the CS-enhancement of 
the cough reflex evoked by capsaicin.  
 
Firstly, the enhanced responsiveness of jugular origin neurons is suggestive of the 
‘sensitisation’ of TRPV1 by inflammatory mediators, as has been previously described in 
vitro (see Introduction 1.3.4; Ma & Quirion, 2007; Petrus et al., 2007; Zhang et al., 2008b; 
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Adcock, 2009). This hypothesis could be examined by exposing primary guinea pig 
airway terminating jugular ganglia neurons to CS in vitro. Should it be possible to induce 
similar enhanced responsiveness to capsaicin in vitro, this would provide an ideal assay 
system to examine the mediators and pathways involved in such a process.  
 
In addition, it is possible that a change in the phenotype of nodose-originating neurons is 
induced by CS-exposure, inducing the expression of proteins (such as TRPV1) that are 
normally only expressed by chemosensitive neurons. Such a phenotypic switch has been 
demonstrated in models of allergic airway inflammation, where nodose neurons have 
been shown to begin expressing TRPV1 and neuropeptides (SP, CGRP and NKA) which 
they do not express under normal conditions (Fischer et al., 1996; Undem et al., 1999; 
Myers et al., 2002; Lieu et al., 2012). Speculatively, this could indicate that mechanically 
sensitive Aδ-type fibres, such as RARs and cough receptors, which are normally non-
chemosensitive, change phenotype following CS exposure. The first step in testing this 
hypothesis will be to examine the expression of TRPV1 in nodose neurons, using a 
single cell q-PCR technique as described by Lieu et al. (2012).  
 
Additionally, it would be interesting to use the single fibre technique to examine whether 
the changes observed in the jugular and nodose cells in vitro equate to functional 
changes in vivo, by examining the responsiveness of C-fibres, and the sensitivity of 
mechanically sensitive fibres (RARs and cough receptors) to capsaicin. Previously, 
Bergren et al. (2001b) have demonstrated modulation of C-fibre and RAR activity in a 
similar preparation, although their model of enhanced responsiveness to capsaicin differs 
significantly from the model of CS-exposure used here, and is perhaps more a model of 
severe asthma than COPD. Guinea pigs were treated with either vehicle (saline) or 
ovalbumin (OVA), and then exposed to either air or CS for 120 days. The authors found 
that OVA/CS exposure enhanced the responsiveness of C-fibres to capsaicin, compared 
to all other treatment groups. Interestingly, no difference was observed in the 
responsiveness of C-fibres to capsaicin in saline/air-exposed animals compared to 
saline/CS-exposed animals. However, in a previous publication by the same author, 
using the same treatment protocol but with cough as an endpoint, capsaicin evoked a 
greater number of coughs in saline/CS-exposed animals compared to saline/air-exposed 
animals (Bergren, 2001a). This suggests that the CS-enhancement of capsaicin-evoked 
cough is due to an enhanced responsiveness of fibres other than C-fibres. Therefore, 
examining the responsiveness of Aδ-nociceptors, RARs, and cough receptors capsaicin 
may reveal the contribution of these fibres to the enhanced capsaicin-evoked cough 
observed following CS exposure, and potentially provide further insights into the 
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mechanisms by which the cough reflex is modified in chronic cough patients (Bolser, 
2004; Lewis et al., 2007; Stevenson & Belvisi, 2008; Lee et al., 2009).   
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7.3.3 Concluding remarks 
The data presented here shows that the related compound PF04862853 possesses 
antitussive efficacy in guinea pigs via elevation of endocannibinoids, which inhibit 
activation of airway sensory nerves via the CB2 receptor. However, the signaling 
pathways activated by endocannibinoids downstream of the CB2 receptor remain to be 
really investigated. Recent trials of the related FAAH inhibitor PF-04457845 have 
demonstrated the safety of this compound in humans (Huggins et al., 2012; Li et al., 
2012). However, whilst inhibition of FAAH and elevation of endocannibinoids was 
demonstrated in these studies, PF-04457845 did not show analgesic efficacy against 
osteoarthritic knee pain. Therefore, whilst the data presented here would suggest that 
PF04862853 has potential as an antitussive, questions over the efficacy of FAAH 
inhibition as analgesics in pain would somewhat temper this optimistic statement.  
 
LABAs and theophylline have previously been observed to have some antitussive 
activity, but the mechanism of this activity was either attributed to their bronchodilator 
activity (Pounsford et al., 1985), or not elucidated (Cazzola et al., 1993). Hopefully the 
data provided in this thesis goes some way further to demonstrating an antitussive effect 
for LABAs and theophylline via an action on sensory nerves, independent of their 
bronchodilator activity. The repositioning of existing therapies such as formoterol and 
theophylline could potentially be a relatively quick and cost-effective route to getting a 
safe and effective antitussive to the clinic. It would therefore be interesting to further 
determine the utility of these compounds as antitussives in humans by examining the 
effect of formoterol, olodaterol or theophylline on capsaicin- and PGE2-evoked cough in a 
small clinical trial of healthy human volunteers.  
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Figure A1 Neutrophil levels in BAL fluid of air- or CS-exposed guinea pigs 
Graph shows the numbers of neutrophils in BAL fluid taken from guinea pigs exposed to 
either room air or CS for 1h periods, twice daily, for 8 days (see Methods 2.6). 
Bronchoalveolar lavage was recovered 24h after the last CS-exposure, and neutrophil 
numbers in the BAL were counted as described in McCluskie et al. (2004). Data 
displayed as mean±SEM, n=6, * p<0.05 as determined by Mann-Whitney U test.  
 
 
 
Figure A2 Capsaicin depolarisation of isolated vagus nerves from human non-
smokers and smokers 
 Magnitude of capsaicin-induced (1µM) depolarisation of vagus nerve tissue from human 
non-smoker or smoker subjects. The non-smoker and smoker subjects criteria 
(age/sex/smoking history) are given in Tables A1 and A2 respectively. Data displayed as 
mean±SEM, n=6-14, * p<0.05 as determined by Mann-Whitney U test.  
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Age	   Sex	   COD	   Smoking	  history	   Other	  information	  
61	   M	   ICH/Stroke	   None	   Hypertension	  
45	   F	   Unknown	   None	   Normal	  lung	  function	  
58	   F	   Asphyxiation/Anoxia	   None	   -­‐	  
60	   F	   Cerebovascular/Anoxia	   None	   -­‐	  
48	   M	   Cerebovascular/Stroke	   None	   -­‐	  
23	   M	   Asphyxiation/Anoxia	   None	   -­‐	  
Mean	  
Age	  
M:F	  
ratio	  
	   	   	  
46.2	   1:1	   	   	   	  
	   	  
Age	   Sex	   COD	   Smoking	  history	   Other	  information	  
	   	   	   PPD	   Years	   	  
72	   F	   Unknown	   n/a	   30	   	  
58	   F	   ICH/Stroke	   n/a	   30	   	  Hypertension	  
21	   M	   ICH/Stroke	   0.5	   40	   	  Hypertension	  
28	   M	   Cardiovasc/Anoxia	   n/a	   13	   -­‐	  
54	   M	   Unknown	   n/a	   27	   Cystic	  Fibrosis	  
51	   M	   ICH/Stroke	   1.5	   40	   	  Alcohol	  abuse	  
43	   M	   Asphyxiation	   1	   15	   	  Marijuana	  abuse	  
35	   F	   Head	  trauma	   n/a	   15	   -­‐	  
48	   M	   Head	  trauma	   0.5	   34	   	  Crack	  cocaine	  abuse	  
51	   F	   ICH/CVA	   1	   37	   Crack	  cocaine	  abuse	  
45	   F	   Stroke	   1	   27	   	  Hypertension,	  marijuana	  abuse	  
45	   M	   ICH/Stroke	   2	   30	   	  Marijuana	  abuse	  
39	   F	   Overdose/Anoxia	   1	   23	   	  Asthmatic	  (unknown	  meds)	  
57	   M	   ICH/Stroke	   1	   20	   Hypertension	  
Mean	  
Age	  
M:F	  
ratio	  
	   	   	  
46.2	   8-­‐6	  
 
Table A1 Criteria for non-smoker and smokers subjects from whom isolated vagal 
tissue was obtained 
Table shows the age, sex, cause of death (COD), smoking history (packs per day [PPD] 
and years), and other relevant information for [top] smoker and [bottom] non-smoker 
subjects from whom vagal tissue was obtained for isolated vagus nerve depolarisation 
experiments presented in Figure A2.   
 
 
 
 
 
 
Appendix  
210 
 
 
Figure A3 Effect of CS-exposures on capsaicin-induced intracellular calcium flux 
in jugular or nodose airway-terminating neurons 
Jugular and nodose neurons were isolated from guinea pigs (see Methods 2.4.2) that 
had been exposed to air or CS for 1h, twice daily, for 8 days (see Methods 2.6). Airway 
terminating neurons were identified by the presence of DiI stain, which had been 
administered 12 days before experiment end-point (see Methods 2.4.1). Capsaicin (1µM, 
30s) was applied to either [A] jugular or [B] nodose airway-terminating neurons, and the 
resultant increase in intracellular calcium was monitored via the fluorescence of the 
Fura2 calcium fluorophore (see Methods 2.4.3). The capsaicin response was recorded 
either until baseline was recovered, or for 10min (whichever was sooner), and the 
resultant area under the curve for the increased fluorescence (see Methods 2.4.6) was 
normalised to an initial response to K50 (50mM potassium solution; 15s) recorded in the 
same cell. Data displayed as mean±SEM, bold number indicates number of animals, 
italics number indicates number of cells, percentage indicates proportion of cells 
responding to capsaicin (with arbitrary cut-off of 10% of K50 response), * p<0.05 as 
determined by Mann-Whitney U test comparing CS-exposed to air-exposed groups.  
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